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ABSTRACT 
 
MicroRNAs (miRNAs) are short, non-protein coding RNAs.  These small-RNAs can regulate 
gene expression by either inhibiting translation or promoting mRNA degradation, they are 
also involved in diverse physiological and pathological events.  Previous data from our group, 
showed that phenobarbital (PB, a CAR activator), induces dysregulation of the hepatic 
miRNAome in rat livers.  In this study, we aim to determine if non-genotoxic rodent 
carcinogens can deregulate miRNA expression.  Thus, the liver miRNAome associated with a 
novel chemical (SYN) and the non-genotoxic rodent carcinogen PB was explored at different 
doses and time points using high-throughput sequencing of small-RNAs (miRNA-seq), a 
powerful tool for discovery and profiling of miRNA expression, providing a deeper 
understanding of molecular toxicology.  Male Han Wistar rats were treated with PB (50 or 
1000 ppm) or SYN (50, 500, and 3000 ppm) in the diet for up to 28 days.  Control animals were 
fed regular diet.  Rats were sacrificed after 1, 3, and 28 days.  Total RNA was isolated from 
frozen livers and library constructs were generated with the Illumina platform.  The 
miRanalyzer algorithm and DESeq were used for bioinformatics (for known and novel 
miRNAs) and statistical analysis.  Around 200 known miRNAs were detected per sample.  
Three key miRNAs related to the epithelial-to-mesenchymal transition (EMT), were detected 
at the 3rd day –miR-200s, miR-30b, and miR-21.  Consequently downregulation of targets 
related to these RNAs and EMT (ZEB1/2, Snail-1, PTEN, and E-cadherin) was seen.  These 
findings suggest activation of a homeostatic response in EMT control in response to PB/SYN 
treatment, presumably in order to preserve the epithelial nature of hepatocytes.  Analysis of 
putative novel miRNAs sequences determined three candidates homologous to miR-4488 and 
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a putative isomiRNA of miR-6215.  The miRNA-seq approach enables a more detailed 
exploration of miRNAs and their response to hepatotoxicants, such as PB, helping elucidate 
underlying pathway perturbations. 
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1.1  Carcinogenesis 
Carcinogenesis can be defined as the process by which cancer develops (Oliveira et al. 2007).  
Cancer has been defined as a large group of diseases, all of them characterized by a multistep 
process that involves cells growing outside of the normal regulatory mechanisms of cell 
division (Shaw and Jones 1994), that could lead to the formation of a tumour.  This 
uncontrolled proliferation and accompanying genetic change can give cells the ability to 
invade surrounding and distant tissues.  A key event in cancer development is the 
accumulation of multiple genetic alterations in cancer causing genes, such as oncogenes and 
tumour suppressor genes.  This occurs over a period of time, often several years (Croce 2009).  
In normal cells, proto-oncogenes are positive regulators of cell differentiation, proliferation 
and inhibitors of cell death; as such they play an important role in embryogenesis.  An 
oncogene is the mutated version of a proto-oncogene and usually has gain-of-function-
mutations leading to the subsequent aberrant regulation of its activity.  In contrast, tumour 
suppressor genes are negative regulators of cell proliferation and loss of its functions 
contribute to cancer development (Lodish et al. 2000; Hodgson 2004).  Examples of 
oncogenes are myc and Ras, and tumour suppressor genes include p53, BRCA-1.  Mutations 
in these cancer causing genes also help cells to avoid apoptosis or programed cell death giving 
them a selective advantage over the cell population (Cox and Der 2003). 
 
1.1.1  Chemical Carcinogens 
A carcinogen is any agent that can cause irreversible changes to the normal cellular 
physiology, resulting in cell transformation and uncontrolled proliferation; if a chemical 
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compound is responsible for these changes, it is named a chemical carcinogen and the process 
is known as chemical carcinogenesis (Plant 2008). 
Based on their ability to react with DNA (Cohen and Arnold 2011) chemical carcinogens are 
divided into two main groups: genotoxic (GTX) and non-genotoxic (NGTX) carcinogens  (Chen 
et al. 2008; Weisburger and Williams 1981). 
 
GTX carcinogens interact physically with DNA, by either binding covalently to it or 
intercalating with the double helix, leading to the initiation of a tumour.  This type of chemical 
carcinogen can be subdivided in two groups (Klaassen 2008; Hodgson 2004): 
1) Direct-acting compounds.  These are very reactive molecules (electrophiles) that do not 
need metabolic activation or chemical alterations to interact with DNA.  Most direct-acting 
compounds are positive to the Ames test, without biotransformation, for example with the 
S9 fraction (Klaassen 2008).  The Ames test is a bacteria based mutagenic assay used to 
identify potential carcinogens, by their ability to cause DNA mutations with or without 
metabolic activation  e.g. by cytochrome P450s (CYP). (Mortelmans and Zeiger 2000). 
2) Indirect-acting compounds.  These carcinogens need metabolic activation, usually via 
CYPs, of the parent compound in order to react with DNA.  Because of this, these molecules 
do not usually affect the site of exposure but are damaging to the tissue/organ where the 
metabolic activation is taking place or at sites that are exposed to the metabolically activated 
products. 
Ionizing radiation and oxidative stress can also cause direct/indirect damage to the DNA 
(Hodgson 2004; Klaassen 2008). 
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NGTX carcinogens –also referred to as epigenetic carcinogens, do not react directly with DNA 
but are still able to induce tumour formation through different mechanisms.  Several modes 
of action have been proposed for these types of carcinogens: 
1) Cytotoxicity.  It is thought that these compounds may have a direct mitogenic effect or 
might stimulate regenerative cell growth after cytotoxic effects.  The increase in cell 
proliferation represents a pre-neoplastic step that is very important for the final development 
of tumours (Cohen and Ellwein 1990; van Delft et al. 2004). 
2) Receptor mediated.  Many epigenetic carcinogens are known to bind or activate different 
cellular receptors, like the Constitutive Androstane Receptor –CAR (Whysner, Ross, and 
Williams 1996) , the Aryl Hydrocarbon Receptor –AhR (Moennikes et al. 2004) or the 
Peroxisome Proliferator Activated Receptor α –PPARα (Lake 1995),  as a consequence of this 
activation they induce metabolic enzymes (e.g. CYPs), cell proliferation, hyperplasia, tumour 
promotion, and inhibition of apoptosis. 
3) Hormonal.  NGTX carcinogens can also induce hormonal imbalance via receptor-mediated 
activation, for example, to the Estrogen Receptor –ER,  the Progesterone Receptor, and the 
Thyroid Hormone Receptor  (Hernández et al. 2009).  For example, estrogenic agents that 
bind to the ER, can promote tumour development in estrogen dependent tissues, and when 
17β-estradiol was given orally to female mice it increased the rate of mammary tumours 
(Welsch et al. 1977).  Estrogens can regulate transcription factors related to cell proliferation, 
differentiation, cell motility, and apoptosis (G. G. Chen, Zeng, and Tse 2008; Hernández et al. 
2009).  Some types of cancer are estrogen-responsive, such as breast and endometrial 
(Hernández et al. 2009).  However, it is not always necessary to activate a receptor to cause 
hormonal perturbations, in rats and mice some anti-thyroid drugs may alter the biosynthesis 
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and secretion of thyroid hormones causing an increase in thyroid tumours (Hernández et al. 
2009). 
4) Altered Methylation.  DNA methylation is an important regulator of gene expression; when 
a gene is highly methylated its expression is usually repressed.  DNA cytosines can be 
methylated in the 5 position generating 5-methylcytosine (5mC).  In carcinogenesis,  both 
hypermethylation and hypomethylation can occur (Counts and Goodman 1995; Baylin 1997), 
the latter has been related to an increase in mutation rates.  Also, many oncogenes have an 
amplified expression due to hypomethylation, for example c-myc, c-fos, and c-H-ras  (Wainfan 
and Poirier 1992). 
5) Oxidative stress inducers.  Generation of Reactive Oxygen Species (ROS) and Reactive 
Nitrogen Species (RNS) can contribute to carcinogenesis.  ROS/RNS are generated in the cell 
as a defence mechanism during the respiratory burst in macrophages (inflammatory cell 
activation) or as an intracellular messenger (Sauer, Wartenberg, and Hescheler 2001).  
Metabolism of chemical carcinogens via CYPs, peroxisomes or in the mitochondria are other 
sources of ROS.  Antioxidants counteract oxidative species, but when the generation of 
reactive species is greater than the antioxidant capacity, damage to macromolecules may 
occur –oxidizing DNA, and causing lipid peroxidation.  Imbalanced ROS can also affect cell 
proliferation and apoptosis by altering different signalling pathways and transcription factors 
(e.g. NF-κB) (Klaassen 2008). 
6) Inhibition of gap-junction Intracellular communications (GJIC).  Gap junctions are 
intracellular channels of connexin proteins that help with cell-to-cell communication allowing 
the exchange of small molecules and ions (< 1 kDa).  Communication between cells is very 
important to maintain cell homeostasis by controlling cell growth and death (Hernández et 
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al. 2009; Klaassen 2008).  The loss or inhibition of GJIC has been observed with different NGTX 
compounds, for example 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been reported to 
inhibit GJIC in breast cancer cells (MCF-7) (Gakhar, Schrempp, and Nguyen 2009; Hernández 
et al. 2009). 
These las two modes of action (oxidative stress inducers and inhibition of GJIC) may also occur 
during the development of the other modes of action (cytotoxicity, hormonal, receptor 
mediated, and altered methylation). 
Because the effects of GTX and NGTX compounds on gene expression profiles are likely to be 
very different from each other, gene expression profiling might be applicable for mechanism 
based-classification of chemical carcinogens as GTX or NGTX (van Delft et al. 2004). 
Examples of GTX carcinogens are: benzo[a]pyrene, dibenz[a,h]anthracene, 
dimethylnitrosamine, and mitomycin-C;  and NGTX carcinogens include: phenobarbital, TCDD, 
among others  (Figure 1.1). 
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Figure 1.1  Examples of genotoxic (A) and non-genotoxic (B) carcinogens. 
 
 
1.1.2  A prototype NGTX carcinogen –Phenobarbital. 
For over 100 years Phenobarbital (PB) has been used in the treatment of epilepsy as an 
antiepileptic drug (Brodie and Kwan 2012).  Furthermore in toxicology, PB is a prototype 
rodent NGTX carcinogen.  Different studies with rats and mice have shown that this 
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compound can cause hyperplasia and liver enlargement.  Chronic and dose-dependent 
exposure to PB can increase the number of tumours in the liver of mice (Jones, Orton, and 
Lake 2009); other effects on this organ include increased tissue weight, hyperplasia and 
neoplastic nodule formation.  Also, PB is an important inducer of hepatic Cytochrome P450 
2B (Cyp2b) family, (e.g. cyp2b1 and cyp2b2) in the rat (Lake 2009; Whysner, Ross, and 
Williams 1996) via activation of the Constitutive Androstane Receptor  (CAR). 
CAR is part of the nuclear receptor superfamily;  it is primarily located in the liver and kidney 
but can also be localised in other tissues, such as brain, heart, and intestine, although to a 
lesser extent (Timsit and Negishi 2007).  This receptor can modulate a wide variety of genes, 
from lipid and glucose metabolism/homeostasis (Kassam et al. 2000) to xenobiotics 
metabolism and elimination of endogenous compounds like bile acids and bilirubin (Kachaylo 
et al. 2011).  Until its activation, phosphorylated CAR is located in the cytoplasm forming a 
complex with different chaperon proteins  –the heat shock protein 90 (HSP90), cytoplasmic 
CAR-retaining protein (CCRP), and the protein phosphatase 1β membrane bound subunit 
(PP1R16A), to prevent its translocation into the nucleus (Figure 1.2).  After cells are exposed 
to PB,  CAR is dephosphorylated by protein phosphatase 2A (PP2A) and moved from the 
cytoplasm to the nucleus, where it interacts and associates with the Retinoid X Receptor (RXR) 
to form a heterodimer (Yang and Wang 2014).  This heterodimer then binds to the PB –
responsive enhancer module (PBREM) (Honkakoski et al. 1998) to promote gene expression.  
Thus in the rat, PB induces Cyp enzymes via CAR activation (Czekaj 2000).  However this is an 
indirect activation, PB does not bind directly to this nuclear receptor, as it was seen by (Mutoh 
et al. 2013), where in mice, PB indirectly activates CAR by inhibiting the signalling pathway of 
the Epidermal Growth Factor Receptor;  this promotes the dephosphorylation of RACK1 
(Tyr52), which in result induces CAR dephosphorylation and activation. 
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Additionally, there is no reported evidence of PB induced hepatocellular carcinoma tumours 
in the rat, in contrast to the mouse where PB is a clear liver carcinogen. The biochemical 
mechanisms involved in this PB toxicity in the rat are not fully understood. 
 
 
Figure 1.2  Mechanism of CAR activation 
 
 
CAR is a promiscuous receptor that can be activated, either directly or indirectly, by a wide 
variety of compounds with different chemical structures (Timsit and Negishi 2007);  examples 
of this are TCPOBOP, [1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene] (Tzameli et al. 2000) and 
CITCO [6-(4-chlorophenyl) imidazo (2,1b)(1,3)thiazole-5-carbaldehyde  O-(3,4-dichlorobenzyl) 
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oxime]  (Maglich et al. 2003),  both compounds bind to CAR in mouse and human respectively, 
and also are able to modulate the expression of CYP enzymes.  Just like these chemical 
entities, there are many new compounds generated by chemical companies that may also 
have a PB-like mode of action; it is important to study and understand their toxicological 
mechanism to design more effective and less toxic chemical compounds.  The SYN 546 
compound tested in this thesis and generated by the agrochemical company Syngenta, is an 
example of these new chemical entities.  Although its hepatotoxic mode of action is not 
completely known, it is thought to behave as a PB-like compound. (Personal communication 
with Syngenta) 
 
1.1.3  Chemical Carcinogenesis as a multi-step process 
The use of animal models and the analysis of epidemiological data have helped us understand 
how the process of carcinogenesis evolves.  Traditionally this process has been divided into 
three stages: initiation, promotion, and progression (Klaassen 2008; Oliveira et al. 2007). 
Initiation is the first step in the carcinogenesis development process, it is a stable and 
irreversible event that starts when an initiator, mainly an indirect-acting carcinogen (after 
metabolic activation), causes DNA damage such as mutations or deletions.  At this stage, DNA 
repair mechanisms in the cell, in a proliferative phase, have failed and damaged DNA is not 
repaired before DNA synthesis.  This allows the newly synthesized DNA to carry the damage 
(deletions/mutations) which is then inherited by daughter cells.  Once cells are initiated they 
can take different outcomes: 1)  they can arrest in a non-dividing state, despite the presence 
of growth factors, 2)  DNA damage can compromise cell viability leading initiated cells to 
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apoptose or 3)  they can proliferate.  Phenotypically these cells look very similar to healthy 
(non-initiated) cells but they carry damaged or mutated DNA. 
Promotion occurs when latent initiated cells are exposed to an 
agent  -endogenous/exogenous, that can induce cell differentiation and proliferation, alter 
gene expression, and thus contribute to mutation fixation, and inhibition of apoptosis.  These 
agents are best known as tumour promoters and are mostly NGTX carcinogens, their effects 
are mainly organ/tissue specific.  In order to continue towards tumour formation, initiated 
cells need a prolonged exposure to the chemical promoter to encourage proliferation.  If the 
tumour promoter is removed the cell should return to the initiated state or move towards 
apoptosis, making the promotion phase a reversible event.  Lesions identified at this stage 
can be identified by histopathology analysis and are often known as pre-neoplastic lesions or 
benign neoplasia. 
Progression is the final events of this multi-stage process.  In this moment, benign 
pre-neoplastic lesions change to neoplastic cancer.  Cells exposed to GTX carcinogens have 
shown an increase in DNA synthesis and proliferation, however chromosomal damage 
(aberrations and deletions), and epigenetic changes can also take place in this stage.  
Progression is an irreversible event due to neoplasm formation under the lack of growth 
control; invasion, metastization, and metabolic/morphological changes are also characteristic 
of this stage. 
 
Although this classical approach to defining chemical carcinogenesis is now dated, it still 
describes many of the important steps involved in this process.  Currently, there are at least 
seven perspectives of the carcinogenesis event (reviewed by (Bogen 2013)), including 
Chapter 1 
[ 32 ] 
 
multistage mutation and clonal proliferation (MMP), chronic oxidative stress (COS), chronic 
inflammation/infection and its associated microenvironment (CIM), defective wound healing 
(DWH), aberrant DNA methylation (ADM), aneuploidy and consequent genomic instability 
(AGI), and miRNA dysregulation (MRD).  All of these theories may overlap to some extent, 
MMP seems to be the most general one, it includes elements from the other theories such as 
oxidative stress, inflammation, wound healing, chromosomal damage, amongst others.  
However of particular interest in this thesis is the involvement of miRNAs in the 
carcinogenesis process.  An important feature of the MRD theory is that a single miRNA can 
regulate the inhibition of a number of target mRNAs and thus affect several pathways in an 
organized manner.  It is thought that in MRD, miRNAs are involved in deregulating the 
hyperplasia process that in healthy condition repairs and protects the tissue. 
 
1.2  microRNAs 
In 1993, microRNAs (miRNAs) were described for the first time by two different groups, (Lee, 
Feinbaum, and Ambros 1993) and (Wightman, Ha, and Ruvkun 1993) in Caenorhabditis 
elegans.  They identified lin-4, a 22 nt non-coding RNA derived from the lin-4 gene, which is 
related to developmental timing in the worm, from larval to adult stages.  They reported that 
lin-4 could repress the translation of lin-14 by binding to the mRNA 3’ untranslated region 
(UTR), suggesting an antisense RNA-RNA interaction.  Since this initial discovery, research on 
the role of miRNA in mediating post-transcriptional gene regulation has grown exponentially. 
MiRNAs are a class of small non-coding RNAs (~22 nt in length) (Ambros 2004), found in 
animal and plant cells (Sato et al. 2011).  They are involved in most biological process such as, 
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cellular differentiation, proliferation, and death; metabolic control, transposon silencing, and 
antiviral defence (Kim, Han, and Siomi 2009). 
These small-RNAs target mRNA by inhibiting its translation or promoting its degradation 
through base pairing of the 3’ UTR of mRNA (J. Liu 2008; S. K. Singh et al. 2008) to the miRNAs 
seed region (nucleotides 2-8, 5’end) (Moreno-Moya, Vilella, and Simón 2014).  MiRNAs 
sharing seed region homology can be organized into families (S. K. Singh et al. 2008).  Some 
miRNAs are found as single genes that encode a specific miRNA; others are arranged into 
clusters, which are transcribed together as a polycystronic unit (Lagos-Quintana et al. 2001) 
and could target the same mRNA or regulate different targets, often in the same 
biochemical/biological pathway (S. K. Singh et al. 2008; Rodriguez et al. 2004).  Due to the 
reduced size of the recognition elements (3’UTR/seed region), one miRNA can target a wide 
variety of mRNAs and a single mRNA target can also be susceptible to a large number of 
miRNAs (Moreno-Moya, Vilella, and Simón 2014).  Compared with other mechanisms of gene 
expression, miRNAs act before the process of protein synthesis and are therefore involved in 
fine-tuning gene expression or quantitative regulation (Bartel and Chen 2004; Ying et al. 
2006).  Computational predictions of miRNAs targets suggest that up to 30% human protein 
coding genes may be regulated by miRNAs (Lewis, Burge, and Bartel 2005; Rajewsky 2006). 
 
1.2.1  miRNAs Biogenesis 
MiRNA biogenesis starts in the nucleus (Figure 1.3), where an RNA polymerase II (Pol II) 
transcribes miRNAs into long segments (70-100 nt) of RNA named primary-miRNAs 
(pri-miRNAs)  These pri-miRNAs have a stem-loop shape, where the sequence of the miRNA 
is embedded, and usually contain a 7-methylguanosine cap (5’ end) and a poly(A) tail (3’ end) 
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(Cai, Hagedorn, and Cullen 2004);  later they are captured by a complex containing Drosha 
(RNase type III) and Pasha (DGCR8-microprocessor complex) (Sato et al. 2011; Kim, Han, and 
Siomi 2009) and the stem-loop is extracted (cropped), leaving a 2 nt overhang in the 3’end 
that is recognised by Exportin-5 and Dicer (Kim 2005; Köhler and Hurt 2007).  These short 
loop-shaped RNAs (60-70 nt) are known as precursor-miRNAs (pre-miRNAs) and are exported 
from the nucleus to the cytoplasm by an export carrier called Exportin-5 (Exp5), in a Ran-GTP 
dependant manner (Bohnsack, Czaplinski, and Gorlich 2004; Köhler and Hurt 2007).  Once in 
the cytoplasm, pre-miRNAs are further processed to a double stranded miRNA duplex by Dicer 
(dsRNase type III), then it is unwound and one strand, the guide strand or mature miRNA is 
incorporated into a RNA-induced silencer complex (RISC)-loading complex (RLC) and serves as 
a template for capturing target mRNAs (Sato et al. 2011; Orban and Izaurralde 2005; Yoda et 
al. 2010) by base complementarity to the 3’ UTR.  The remaining strand or passenger strand 
(miRNA*) (Figure 1.3) is degraded in the cell (Kim, Han, and Siomi 2009).   Mature miRNA-RISC 
complex target mRNA by binding to the 3’UTR of the mRNA target, if the level of homology 
and complementarity between the miRNA-mRNA duplex is high, the mRNA is degraded.  In 
contrast, the presence of mismatches leads to inhibition of mRNA translation (R. W. Carthew 
and Sontheimer 2009).  (Alemán, Doench, and Sharp 2007) reported that the number and 
location of mismatches is important to determine if there would be mRNA degradation or 
inhibition of translation. 
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Figure 1.3  miRNAs biogenesis and the mechanism of mRNA regulation. 
 
 
1.2.2  miRNA Nomenclature 
The miRBase is the main online miRNA repository for sequences and annotations (Kozomara 
and Griffiths-Jones 2014), it was established in 2002 as the miRNA Registry (Griffiths-Jones 
2004) and the main goal is to assign names to newly described miRNAs (Kozomara and 
Griffiths-Jones 2014).  As such the authors have set nomenclature rules for naming miRNAs, 
as described in different papers (Moreno-Moya, Vilella, and Simón 2014; Kozomara and 
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Griffiths-Jones 2014; Griffiths-Jones et al. 2006; Kozomara and Griffiths-Jones 2011) and the 
miRBase website (www.mirbase.org).  Below, there are three examples of how miRNA 
nomenclature rules are used to name and identify different miRNAs. 
 
 
a—All species are designated by a three-letter prefix, e.g. rno-Rattus norvegicus, hsa-Homo 
sapiens, mmu-Mus musculus.  b—miR, indicates the mature form of the miRNA, when the 
prefix mir is used, it refers to the pre-miRNA sequence or the miRNA gene.  c—All miRNAs are 
numbered sequentially indicating the order of their naming, miR-100 was described and 
annotated before miR-101.  d—miRNAs can be generated from opposite arms of the same 
pre-miRNA, -5p arm and -3p arm.  When there is not enough data to determine which strand 
is more abundant these suffixes are also used to differentiate between both miRNAs. 
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e—When different pre-miRNAs produce the same mature sequence each stem-loop 
sequence is identified with a number.  f—A lowercase letter suffix differentiates between 
miRNAs that have very similar mature sequences, with changes in 1-2 positions, that are 
generated by different precursors.  g— When  differential expression data is available, an 
asterisk is used to indicate the less abundant strand.  MiR-100b is more predominant than 
miR-100*, although both share the same pre-miRNA. 
 
1.2.3  miRNA in Cancer 
MiRNAs are also involved in cancer development.  First described by (Calin et al. 2002) when 
they discovered that a cluster of miRNAs were frequently down regulated or deleted in 
chronic lymphocytic leukaemia (CLL), suggesting that miRNAs could play an important role 
contributing to  disease development.  In their study, miRNA expression profiles were shown 
to have a unique and distinct pattern (Almeida, Reis, and Calin 2011) that could be used as a 
guide for tumour classification (J. Lu et al. 2005), to take treatment decisions or for a prognosis 
approach (Lujambio and Lowe 2012). 
MiRNAs can play opposite roles in cancer depending on their cellular environment, they can 
either act as oncogenes –oncomirs- or as tumour suppressors (Garzon, Calin, and Croce 2009);  
the miR-17-92 cluster, miR-155, and miR-21 are examples of oncomirs.  These miRNAs target 
tumour suppressor gene (TSG) mRNA and by regulating the TSG target expression, they can 
act as oncogenes.  MiR-15a/16-1, the let-7 family, the miR-34 family, and the miR-29 family 
are tumour suppressor miRNAs (Lujambio and Lowe 2012), and by targeting oncogenic 
mRNAs they can have TSG activity. 
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MiRNAs can act as both an oncomir or as a tumour suppressor in different types of cells; for 
example, in lung tumours the miR-29 family can have a tumour suppression effect, while 
being an oncogenic gene in breast cancer (Fabbri et al. 2007; Gebeshuber, Zatloukal, and 
Martinez 2009).  This pattern can also occur in metastasis, where the miR-200 family 
promotes the metastatic colonization in breast cancer and yet inhibits the epithelial–to–
mesenchymal transition  (Amparo Cano and Nieto 2008; Korpal et al. 2011). 
It has been thought that miRNAs could be used as biomarkers for cancer diagnosis.  Although 
this area is still under investigation, there are some miRNAs that show potential as possible 
biomarkers, for example in non-small lung cancer where poor prognosis, correlates with an 
increase of miR-155 (Yanaihara et al. 2006) and decrease of let-7, and a 13 miRNA signature 
is related to CLL progression (Calin et al. 2005). 
 
1.2.4  Circulating miRNAs 
MiRNAs can also be found in different types of body fluids, such as saliva, blood, and urine 
(Weber et al. 2010).  Initially, circulating miRNAs were thought to be unstable molecules, but 
they are now known to be very stable in serum and plasma.  They are resistant to RNase 
activity, extreme pH levels (1-3), and changes of temperature (Chen et al. 2008; Mitchell et 
al. 2008; Zen and Zhang 2010).  These circulating miRNAs can reside in microvesicles 
(exosomes, microparticles, and apoptotic bodies) (Chen et al. 2008; Zampetaki et al. 2011) 
that can offer protection against degradation from RNase activity (Zampetaki et al. 2011).  
Some miRNAs were reported to be detectable in the plasma fraction devoid of microvesicles, 
suggesting the existence of non-vesicle associated miRNA-protein/lipoprotein complexes in 
extracellular fluids (Zampetaki et al. 2011; K. Wang et al. 2010).  Studies by (Arroyo et al. 2011) 
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have shown that a portion of circulating miRNAs are associated with ribonucleoproteins, such 
as argonaute protein 2 (Ago2). 
Despite all the evidence for the presence of miRNAs in body fluids, the function of these 
circulating miRNAs remains still poorly understood.  The discovery of these miRNAs is perhaps 
one of the most interesting applications of small-RNAs as diagnostic tools, since taking a blood 
or urine sample is less invasive than a biopsy or other type of procedures (Tiberio et al. 2015).  
An example of the potential use of circulating miRNAs as diagnostic tools is miR-141, whose 
serum levels are higher in prostate cancer patients than in healthy subjects (Catto et al. 2011). 
Although detection and analysis of circulating miRNAs still represents  a challenge because of 
their low concentration, there are several technologies available for this purpose, such as 
quantitative real time PCR, miRNA microarray, and next generation sequencing analysis 
(RNA-seq)  (Pritchard, Cheng, and Tewari 2012). 
 
1.3  RNA-seq as a tool for miRNA expression analysis 
Due to the low number of copies of miRNAs that are expressed (Hackenberg et al. 2009) in 
the cell, RNA-seq analysis is considered a valuable approach for miRNA expression profiling 
(Pritchard, Cheng, and Tewari 2012). In this method, a cDNA library is prepared from 
small-RNAs harvested from total RNA samples, followed by massive parallel sequencing of 
individual cDNA molecules within the library (Pritchard, Cheng, and Tewari 2012).  Then, 
bioinformatics analysis of the sequence reads is needed for three purposes: 1)  to identify 
known miRNAs, aligning to the miRBase datasets, 2)  additionally novel miRNAs can be 
identified (which is the major advantage of this technique), and 3) to provide a relative 
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quantification of the individual miRNA species.  This means that the number of sequence 
reads of a miRNA in relation to the total number of reads in the sample is an estimate of the 
relative abundance of the miRNA (Pritchard, Cheng, and Tewari 2012; Creighton, Reid, and 
Gunaratne 2009).  Sequencing analysis is able to detect changes between miRNAs of one 
nucleotide, as well as variants in length, also known as isomiRs. 
Even though RNA-seq can identify a large number of small-RNA sequences or putative 
miRNAs, not all of these may be defined as miRNAs (Chiang et al. 2010), a guideline (Ambros 
et al. 2003; Kozomara and Griffiths-Jones 2011) has been developed to help identify and 
annotate putative miRNAs into the appropriate repository.  This topic will be further discussed 
in Chapter 3 –miRNA-seq Analysis: Library Preparation and Data Analysis. 
Due to the impact that miRNA-seq analyses have had, several bioinformatics tools have been 
developed to analyse these type of data, some of these include miRDeep (Friedländer et al. 
2008), miRanalyzer (Hackenberg et al. 2009; Hackenberg, Rodríguez-Ezpeleta, and Aransay 
2011), miRExpress (W.-C. Wang et al. 2009), miRTRAP (Hendrix, Levine, and Shi 2010), 
DSAP (Huang et al. 2010), mirTools (Wu et al. 2013), MIReNA (Mathelier and Carbone 2010), 
and miRNAkey (Ronen et al. 2010).  It is important to notice that the most appropriate 
software depends on the input and output requirements of the analysis (Li et al. 2012). 
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1.4  Hypothesis 
The aim of this project is to examine the following hypotheses, 1) Phenobarbital –a 
non-genotoxic chemical carcinogens, and a novel chemical compound from Syngenta have a 
similar mode of action;  2) these compounds dysregulate miRNA expression similarly in liver 
tissue and body fluids;  3) dysregulated miRNAs are biomarkers of non-genotoxic 
carcinogenesis and help to the preservation of the homeostasis in the rat liver tissue. 
 
1.5  Objectives 
1. To investigate the effect of the treatment with Phenobarbital –an epigenetic liver tumour 
promoter, or the SYN 546 compound on the liver pathology and the expression of drug 
metabolizing enzymes such as Cytochrome P450. 
2. To characterize the miRNA expression profiles in the liver from rats treated with 
Phenobarbital. 
3. To characterize the miRNA expression profiles in the liver from rats treated with SYN 546 
and compare them to PB miRNA profiles. 
4. To investigate whether blood miRNA expression levels reflect tissue miRNA changes in 
treated rats. 
5. To use bioinformatics and in silico analysis to predict targets of dysregulated known 
miRNAs and to determine the presence of putative novel miRNAs. 
6. To investigate the effect that altered miRNA expression has on different targets, both 
mRNA and proteins, involved in the epithelial-to-mesenchymal transition. 
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2.1  INTRODUCTION 
This work was undertaken in collaboration with the agricultural chemical company Syngenta. 
A number of the chemicals developed by Syngenta for agricultural use have inherent toxicity 
when tested in rodents and it is important to understand the mechanisms of this toxicity in 
order to design more effective and less toxic active ingredient chemicals.  A number of these 
potential active ingredient chemicals have an hepatotoxicity profile similar to the rodent 
hepatotoxin PB.  Therefore in collaboration with Syngenta, a toxicology study was designed 
to investigate the hepatotoxicity of PB in parallel with the Syngenta 546 compound.  This 
chapter investigates the effect of dose and time-dependent treatment with PB or the 
Syngenta 546 compound for up to 28 days on liver tissue and expression of drug metabolizing 
enzymes such as Cytochrome P450 in male rats.  As expected PB treatment induced cyp2b1 
and cyp2b2 expression levels in a dose and time-dependent manner.  SYN treatment also 
showed dose and time-dependent effects on cyp2b1 and cyp2b2, although the response was 
not as strong as with PB. 
 
2.1.1  Tested compounds 
2.1.1.1  Phenobarbital 
As mentioned in Chapter 1 –Introduction,  PB (purchased from Sigma-Aldrich with a purity of 
99%) is a prototype rodent NGTX carcinogen that can cause hyperplasia and liver enlargement 
in rats and mice, and an increase in the number of tumours in the liver of mice after long term 
exposure (P. Carthew, Edwards, and Nolan 1998).  Furthermore, PB is a strong inducer of 
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hepatic Cyp2b family, (e.g. cyp2b1 and cyp2b2)  in the rat (Lake 2009; Whysner, Ross, and 
Williams 1996) via indirect CAR activation. 
Two-year bioassay studies in Fischer F344 rats treated with (PB 1000 ppm) (Butler 1978) in 
the diet showed an increase in the number of neoplastic nodules, but no changes were 
observed when treated with 500 ppm (Saito et al. 1990), although a reversible increase in the 
liver weight after 1-2 week of treatment was recorded (Isenberg et al. 2001).  When Wistar 
rats were also treated with 500 ppm of PB in drinking water for three years an increase in 
adenomas was observed (Rossi et al. 1977).  Additionally, (Waterman et al. 2010) reported 
that feeding with a non-carcinogenic dose of PB (50 ppm) induced hepatic metabolism 
activity, that a 500 ppm dose can cause changes in the liver weight and hepatic drug 
metabolizing activity, and that 1000 ppm, increases the liver weight, drug metabolizing 
activity, and causes hyperplasia.  Thus in the rat, PB induces Cyp enzymes via indirect CAR 
activation and there are dose and time-dependent toxic effects on the liver that include 
increased liver weight, hyperplasia and neoplastic nodule formation.  Although there is no 
reported evidence of hepatocellular carcinoma tumours in the rat, in contrast to the mouse 
where PB is a clear hepato-carcinogen (IARC- International Agency for Research on Cancer 
2001), the biochemical mechanisms involved in this toxicity in the rat are not fully 
understood. 
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Figure 2.1  Phenobarbital chemical structure. 
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2.1.1.2  Syngenta 546 compound 
The Syngenta 546 (SYN) is a novel compound synthesized by Syngenta to be used as an 
herbicide, its structure is shown in Figure 2.2.  SYN induces drug metabolizing enzymes, like 
CYP2B, causes hyperplasia, and hypertrophy.  Its mechanism of action is not yet fully 
understood,  but it is thought to include CAR activation, like PB  (Personal communication 
with Syngenta). 
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Figure 2.2  Syngenta 546 compound chemical structure 
 
 
The Syngenta 546 compound was synthesized and given to us by Syngenta (Syngenta Crop 
Protection, Munchwilen AG)  with a purity of 98.4%  (Syngenta Certificate of Analysis, May 
2010). 
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2.2  MATERIAL AND METHODS 
2.2.1  Experimental design, animal treatment, and sample collection 
Animal experiments were carried out for Syngenta at Charles River (Edinburgh, UK). 
Ten-week old male Han Wistar rats were kept in polycarbonate cages –2 or 3 per cage and 
divided by treatment (5 rats per treatment), all animals had access to water and food (diet) 
ad libitum.  For the experiment, rats were treated, in the diet, with a non-carcinogenic and a 
hepatotoxic dose of PB –50 ppm or 1000 ppm, or with SYN –50, 500, and 3000 ppm, during 
28 days.  Doses of the SYN compound were selected by Syngenta from previous studies 
performed with this chemical entity (Personal communication with Syngenta).  Control rats 
were feed with regular diet.   Animals were sacrificed at different time points:  1, 3, 7, 14, and 
28 days of treatment  (Figure 2.3). 
After treatment, different tissue samples (liver, kidney, and bladder) were harvested.  Liver 
tissue samples were cut into pieces (  ̴100 mg) and submerged in RNAlater (Ambion, Life 
Technologies, USA) for their preservation and then snap frozen in liquid nitrogen.  Body fluid 
samples (plasma and urine) were also collected, at each time point.  All samples were stored 
at -80°C until use. 
 
Chapter 2 
[ 47 ] 
 
 
 
Figure 2.3  Timeline of rat treatment with PB (50 and 1000 ppm) or SYN (50, 500, and 3000 ppm)  and 
tissue sample collection at 1, 3, 7, 14, and 28 days of treatment. 
 
2.2.2  RNA Extraction 
After tissue harvest, liver samples were stored at -80°C until used.  Prior to RNA extraction 
working benches and pipettes were cleaned with RNase Zap (Ambion, Life Technologies, USA) 
to avoid contamination and RNA degradation by RNases.  Total RNA (days 1st, 3rd and 28th)1 
was isolated from small pieces of frozen tissue (  ̴100 mg) using the mirVana PARIS kit 
(Ambion, Life Technologies, USA), without allowing any thaw.  This kit combines an organic 
extraction and a final RNA purification/concentration over a glass-fibre filter.  Briefly, tissue 
was homogenised on ice using a polytron homogenizer (Labortechnik, Germany) with ice-cold 
Cell Disruption Buffer and left on ice for a 10-minute incubation.  For lysis, homogenate was 
mixed at room temperature with 2X Denaturing Solution and incubated on ice for 10 minutes, 
then RNA was isolated by an Acid-Phenol:Chloroform extraction.  One mL of room 
temperature Acid-Phenol:Chloroform, was added to the lysate and shaken vigorously for 
                                                          
1 Samples from days 7 and 14 were not examined or used for further analysis. 
   1       3               7                             14                                            28 days   
                         post-treatment 
 
  
 
 
 
 
Tissue and body fluid samples at 1, 3, 7, 14, and 28 
post-treatment 
Chapter 2 
[ 48 ] 
 
1 minute; the mixture was centrifuged for 5 minutes at 12,000 r.p.m. to fully separate both 
aqueous and organic phases.  The aqueous (upper) phase, containing the RNA fraction, was 
removed to a fresh tube and 100% Ethanol was added for RNA precipitation, this mixture was 
passed through a glass-fibre filter into a collection tube by centrifugation (10 seconds, 
1,000 r.p.m.).  The glass-fibre filter, where the RNA is immobilized, was washed once with 
miRNA Washing Solution 1 and twice with Washing Solution 2/3; after all the washes the filter 
was centrifuged for 1 minute at 1,000 r.p.m. to remove all residues and to prepare it for a 
final elution with pre-heated Nuclease-free water (100 µL).  Total RNA samples were stored 
at -80°C until use. 
 
2.2.3  Real-Time Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative Polymerase Chain Reaction (qPCR) was developed by (Higuchi et al. 1992), who 
added Ethidium Bromide (EtBr) to the PCR master mix to visualize and quantify the 
concentration of the PCR product, or amplicon, by fluorescence in an agarose gel.  EtBr 
intercalates into double-stranded DNA making it easier to detect when exposed to UV light. 
Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR or qPCR) (Fraga, Meulia, and 
Fenster 2008) is a modification of the qPCR technology that enables researchers to monitor 
and assess, in “real time”, gene expression of specific targets in a complex sample.  This PCR 
variant uses a set of fluorescent-labelled probes that are incorporated into the PCR product 
generating a fluorescence detected by the equipment.  The level of fluorescent signal is 
proportional to the concentration of the PCR product over the exponential phase of the PCR 
cycle, when there is less variability. 
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qPCR is a two-step methodology; in the first step RNA samples are reverse transcribed (RT) to 
complementary DNA (cDNA), then cDNA is used for the PCR amplification 
cycle  -denaturation, annealing, and extension. 
qPCR was used to determine the expression of cyp2b1/2 –-mRNA, in samples from the 1st, 3rd, 
and 28th days of treatment with either PB or SYN. 
For RT reaction, 500 ng of total RNA were used mixed with 300 ng Random Primers 
(Sigma-Aldrich, Germany) and Nuclease-free water, for a final volume of 15 µL.  This mixture 
was incubated for 10 minutes at 65°C and immediately placed on ice.  PCR amplification 
master mix consisted of: 10 mM dNTPs (Sigma Aldrich, Germany) and 5x First Strand Buffer, 
0.1 mM DTT, and SuperScript II enzyme –from the SuperScript II Reverse Transcriptase kit 
(Invitrogen, Paisley, UK).  Master Mix (8.5 µL) was added to each sample after incubation and 
amplified in a MJ Research PTC-200 Thermocycler (GMI Inc. USA), amplification conditions 
were: 10 minutes at 25°C, 90 minutes at 42°C and 15 minutes at 70°C.  cDNA was stored 
at -20°C until use for qPCR. 
Later, RT product (cDNA) was mixed with 2x TaqMan Universal Master Mix II –no UNG 
(Applied Biosystems, Foster City, CA, USA), TaqMan Gene Expression Assay probes (20x) for 
cyp2b1, cyp2b1 and GAPDH as housekeeping control, and Nuclease-free water for a final 
volume of 10 µL, details of the primers used are mentioned in Appendix 1.  qPCR reactions 
were ran by triplicate in 96-well plates (Thermo Scientific) on the StepOne Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA).  The following conditions were used:  
10 minutes at 95°C;  40 cycles of 15 seconds at 95°C and  60 seconds at 60°C.   
Analysis of mRNA expression was done using StepOne Software v2.3 (Applied Biosystems, 
Foster City, CA, USA).  For quantification the 2-ΔCt comparative method was used, normalizing 
Chapter 2 
[ 50 ] 
 
to GAPDH as endogenous reference.  A mRNA was considered significant when the value 
calculated by 2-ΔCt  method was higher than 1.5 SD or less expressed when the value was 
below 0.5 SD.  When appropriate, statistical analysis using the Student’s unpaired t-test or 
One-way ANOVA with Dunnett’s comparison to Control samples was used. 
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2.3  RESULTS 
2.3.1  Effect of treatments on the animals. 
Both compounds and all doses were generally well tolerated.  However, at the beginning of 
the treatment, the SYN 3000 ppm dose caused a loss of body weight, although not significant 
the weight was not fully recovered to the level noted in other groups by the end of the 
treatment.  There was also a decrease in food intake for animals treated with the 3000 ppm 
dose, but this was not considered to be related to the reduction of body weight.  Only this 
dose of the SYN compound showed an effect on body weight (Syngenta Pathology Report). 
There were no gross histological findings for any of the treatments and any of the time points 
examined.  There was evidence of hepatic centrilobular hypertrophy at the highest dose of 
PB (1000 ppm) (5/5) and SYN (3000 ppm) (5/5) that persisted up to the end of the study  
(Syngenta Pathology Report). 
 
2.3.2  Effect of treatment on Liver weight  
PB treatment of rats exerts a variety of effects in hepatocytes and liver tissue, including cell 
proliferation and liver enlargement.  The latter is due to hyperplasia and hypertrophy in the 
centrilobular region (Gooding et al. 1978) and includes proliferation of the smooth 
endoplasmic reticulum (Lake 2009; Whysner, Ross, and Williams 1996; Elcombe et al. 2014). 
Relative Liver weights were significantly higher in rats treated with PB 1000 ppm at the 3rd 
and 28th days of treatment, as shown in Figure 2.4, the 50 ppm dose did not show any 
significant changes when compared to Control.  Histopathological examination confirmed 
centrilobular hypertrophy, particularly at the high dose of PB treatment. 
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Treatment with SYN did not give such a pronounced effect on liver weight. Although there 
was a slight increase in liver weight over the course of the study, there was no obvious 
dose-dependent trend (Figure 2.5).  There was evidence of centrilobular hypertrophy in the 
liver of animals given SYN 3000 ppm after 28 days  (Syngenta Pathology Report). 
 
R e la tiv e  L iv e r  w e ig h t -P B
L
iv
e
r
 (
g
/1
0
0
 g
 B
W
)
D a y 1 D a y 3 D a y 2 8
0
1
2
3
4
5
C o n tro l P B  5 0  p p mP B  1 0 0 0  p p m
** *
 
Figure 2.4  Relative Liver weight (RLW) after PB (50 and 1000ppm) treatment during 1 (left), 3 (centre), 
and 28 (right) days.  Mean RLW changes compared to Control ± S.D. from each day of treatment.  
One-way ANOVA  *p<0.05, **p<0.001.  n=5 rats per data point.  BW –Body weight. 
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Figure 2.5  Relative Liver weight (RLW) after SYN (50, 500, and 3000ppm) treatment during 1 (left), 
3 (centre), and 28 (right) days.  Mean RLW changes compared to Control ± S.D. from each day of 
treatment.  One-way ANOVA  *p<0.05, **p<0.001.  n=5 rats per data point.  BW –Body weight. 
 
 
2.3.3  PB and SYN induce Cyp2b subfamily 
The Cytochrome P450 (CYP) is a superfamily of well-conserved enzymes that play an 
important role in oxidative metabolism of a great variety of chemical compounds, both 
endogenous and exogenous.  They are also responsible for biotransformation of drugs and 
other xenobiotics, and are important in the detoxication process in the cell (Boobis et al. 1990; 
Ortiz de Montellano 2005; Tompkins and Wallace 2007). 
In the liver, PB is a well-known inducer of these Phase I-Drug metabolizing enzymes, especially 
the cyp2b subfamily –cyp2b1 and cyp2b2.  It has been proposed that in the rat cyp2b 
induction, by PB treatment, occurs mainly in the centrilobular region of this organ (Lake 2009; 
Gooding et al. 1978). 
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To determine the effect of the PB treatment, the level of cyp2b1 and cyp2b2 mRNA from liver 
samples from the 1st, 3rd, and 28th days of treatment, were measured by qPCR (as described 
in section 2.2.3). 
As expected both doses of PB induced cyp2b1 and cyp2b2 gene expression.  cyp2b1 
(Figure 2.6) was strongly induced by PB 1000 ppm at all time points examined (821, 422, and 
1,535 –fold induction at days 1st, 3rd, and 28th respectively, compared to Control); as expected, 
PB 50 ppm induced less strongly (41, 37, and 60 –fold induction at days 1st, 3rd, and 28th 
respectively, when compared to Control) and again the highest level of induction was also 
detected on day 28th. 
Regarding cyp2b2, PB again strongly induced the expression of this enzyme, particularly at 
the highest dose and again induction was most profound at day 28th (385 –fold induction 
compared to Control). However, induction of cyp2b2 was not as high as for cyp2b1. 
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Figure 2.6  Cyp2b1 mRNA expression with PB (50 and 1000 ppm) after 1 (left), 3 (centre), and 28 (right) 
days of treatment.  Mean fold Change relative to Control ± S.D.  t-test  *p<0.05, **p<0.001, 
***p<0.0001.  n=5 rats per treatment. 
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Figure 2.7  Cyp2b2 mRNA expression with PB (50 and 1000 ppm) after 1 (left), 3 (centre), and 28 (right) 
days of treatment.  Mean fold Change relative to Control ± S.D.  t-test  *p<0.05, **p<0.001, 
***p<0.0001.  n=5 rats per treatment. 
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Although not as powerful an inducer as PB, SYN also induced the expression of the cyp2b 
subfamily.  In this case cyp2b1 (Figure 2.8) and cyp2b2 (Figure 2.9) were significantly induced 
with doses 500 and 3000 ppm from the 1st day onwards, with maximal effect at day 1 with 
the higher dose (3000 ppm).  As with PB treatment, cyp2b1 was the most induced isoform 
(1000 –fold versus 300 –fold induction compared to the Control on Day 1).  SYN treatment, 
also showed a similar dose-dependent effect for each day of treatment, although the 
response declined after Day 1. 
 
 
c y p 2 b 1  m R N A  in d u c tio n  b y  S Y N
F
o
ld
 c
h
a
n
g
e
D a y 1 D a y 3 D a y 2 8
0
5
1 0
5 0
2 0 0
3 5 0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
C o n tro l S Y N  5 0  p p m S Y N  5 0 0  p p m S Y N  3 0 0 0  p p m
****
****
***
****
***
****
 
Figure 2.8  Cyp2b1 mRNA expression with SYN (50, 500, and 3000 ppm) after 1 (left), 3 (centre), and 
28 (right) days of treatment.  Mean fold Change relative to Control ± S.D.  t-test  *p<0.05, **p<0.001, 
***p<0.0001.  n=5 rats per treatment group. 
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Figure 2.9  Cyp2b2 mRNA expression with SYN (50, 500, and 3000 ppm) after 1 (left), 3 (centre), and 
28 (right) days of treatment.  Mean fold Change relative to Control ± S.D.  t-test  *p<0.05, **p<0.001, 
***p<0.0001.  n=5 rats per treatment group. 
 
 
2.4  DISCUSSION 
Animals tolerated, both PB and SYN, treatments well.  In the case of PB there was a dose and 
time-dependent increase in liver weight (Figure 2.4) and centrilobular hypertrophy.  These 
results are consistent with previous reports, from our group (Koufaris et al. 2012) and others 
(Whysner, Ross, and Williams 1996; Waterman et al. 2010; P. Carthew, Edwards, and Nolan 
1998), on treatment with PB, where high doses of this NGTX carcinogen showed an effect on 
liver weight and on the incidence of liver lesions, such as centrilobular hypertrophy.  However, 
in the case of SYN there were less pronounced effects on the liver weight, but there was also 
evidence of centrilobular hypertrophy at the highest dose (3000 ppm), particularly at the later 
time point. 
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As expected, PB treatment had a profound effect on cyp2b1 and cyp2b2 expression levels and 
again a dose and time-dependent induction.  SYN treatment also had a strong dose and 
time-dependent induction effect on cyp2b1 and cyp2b2, although it was not as potent as PB.  
Cyp2b enzyme induction is a characteristic effect of PB treatment (Lake 2009; Czekaj 2000), 
which is also an indicator of CAR activation (IARC- International Agency for Research on 
Cancer 2001; Whysner, Ross, and Williams 1996; Lake 2009; Elcombe et al. 2014).  It is thought 
that these PB-inducible CYPs might be related to oxidative stress in the cell, due to the 
continuous presence of ROS  (Imaoka et al. 2004; Whysner, Ross, and Williams 1996). 
Collectively, these results are consistent with the known mode of action and toxicity of PB 
(Elcombe et al. 2014);  i.e. activation of CAR receptor leading to proliferation and hypertrophy 
and induction of cyp2b enzymes.  In the case of SYN, the effects on liver size and induction of 
cyp2b enzymes were less pronounced compared to PB, but again are consistent with SYN 
being an activator of CAR receptor. 
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3.1  INTRODUCTION 
Since their discovery and due to their involvement in the regulation of different cellular 
processes and diseases, the study of miRNAs has been of great interest to many research 
groups.  Profiling of miRNAs, to detect key miRNAs as possible biomarkers of diseases or 
cellular mechanisms, has become an important area of research.  The term miRNA profiling 
refers to the assessment of the abundance of a group of miRNAs present in a certain type of 
sample  (Pritchard, Cheng, and Tewari 2012) to determine possible miRNA deregulation. 
MiRNA profiling can be performed using different approaches.  The most often used are 
qPCR-methods, hybridization-methods, and next generation sequencing analysis. (Pritchard, 
Cheng, and Tewari 2012; Baker 2010; Git et al. 2010). 
qPCR-based methods are one of the principal techniques used for small-RNA profiling.  They 
are based on miRNA reverse transcription to cDNA, then real-time qPCR, by either using a 
stem-loop primer to create a reverse transcription binding site or by enzymatically adding a 
poly-(A) tail as a primer for RT reactions.  The qPCR-based approach is sensitive and specific, 
and easy to incorporate into research laboratories who are familiar with qPCR.  For miRNA 
profiling, many qPCR reactions can be performed in parallel, as with microfluidic cards, which 
can be used to measure miRNAs expression in different samples or could be customized to 
analyse a specific group of miRNAs.  Multi-well plates that contain pre-loaded PCR primers 
are also available, these can partake hundreds of reactions at nano-litre scale.  Disadvantages 
of qPCR-methods are that microfluidic cards or multi-well plates are not available for all 
organisms,  they could be very expensive and time consuming if a large number of samples 
are analysed, and possible new miRNAs cannot be detected by this method. 
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Hybridization methods, such as microarrays are a well-known and established techniques for 
parallel analysis of miRNAs, that are often less expensive than other profiling methods.  They 
are based on the enzymatic fluorescent-labelling of miRNAs followed by hybridization to a 
DNA-based array  (Pritchard, Cheng, and Tewari 2012),  that contains the antisense sequences 
of the miRNAs of interest (Esquela-Kerscher and Slack 2004).  MiRNA labelling is performed 
by using a T4 RNA ligase to attach fluorophore-conjugated oligonucleotides to the miRNA 
3’-OH end.  The relative abundance of a miRNA is determined by measuring its fluorescence 
in the array.  Drawbacks of this technique are background signal, cross-hybridization between 
similar miRNA probes or labelling bias due to sequence similarities (Esquela-Kerscher and 
Slack 2004; C.-G. Liu et al. 2008). 
Next generation sequencing (NGS) of small-RNAs such as miRNAs (miRNA-seq), is considered 
one of the first successes of the application of NGS to RNA-seq (Vigneault, Sismour, and 
Church 2008).  As mentioned in Chapter 1 –Introduction, generally for NGS analysis a cDNA 
library is prepared from total RNA samples by attaching an adapter on each side of the RNA 
sequences (3’ and 5’ ends) and a tag to identify each sample in a multiplex analysis, then the 
library is massive parallel sequenced in a flow cell.  MiRNA-seq is one of the best approaches 
for miRNA profiling analysis due to the low copy number of these molecules present in the 
cell (Hackenberg et al. 2009).  Although usually perceived as an expensive tool, NGS has the 
advantage that multiple samples can be pooled and sequenced in one sequencer lane, 
reducing the costs per sample without risking the expression analysis on each sample 
(Eminaga et al. 2013).  The main advantage of miRNA sequencing analysis, over qPCR and 
hybridization profiling methods, is that it is possible to detect miRNAs variants, from changes 
in one nucleotide, to length differences, and identification of potential new miRNAs.  
However, not all the sequences predicted as novel miRNAs by a bioinformatics analysis after 
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NGS profiling are true miRNAs (Pritchard, Cheng, and Tewari 2012),  it is necessary to study 
more in depth those sequences to classify them as miRNAs . 
This chapter focuses on miRNA profiling using NGS analysis for small-RNAs –miRNA-seq on 
liver tissue samples from rats treated with either PB (50 or 1000 ppm) or SYN (50, 500, and 
3000 ppm) during 1, 3 or 28th days.  First, total RNA was extracted from tissue samples; both 
purity and integrity analysis were performed for all samples.  A miRNA-seq protocol was then 
optimised for library construction using two different T4 RNA ligases, different amounts of 
RNA, and testing different numbers of PCR cycles.  Once the protocol was optimised, library 
constructs from RNA samples were prepared and sequencing run was performed.  
Bioinformatics analysis of the reads was completed to determine the number of known 
miRNAs and the presence of possible new miRNA sequences in the samples after PB/SYN 
treatment at different time points. 
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3.2  MATERIAL AND METHODS 
3.2.1.  Rat liver Samples 
Ten-week old male Han Wistar rats were treated with PB (50 and 1000 ppm) or SYN (50, 500, 
and 3000 ppm) for up to 28 days as described in Chapter 2 –2.2.1  Experimental design, animal 
treatment, and sample collection.  Liver tissue samples were harvested at different time 
points and kept at -80°C until used.  Treated liver samples from Days 1, 3, and 28 were 
processed for RNA extraction. 
 
3.2.2  RNA Extraction 
RNA extraction from liver tissue samples (1st, 3rd, and 28th days) was performed following the 
protocol described in Chapter 2 –2.2.2 RNA Extraction, using the mirVana PARIS kit (Ambion, 
Life Technologies, USA) under the same conditions. 
 
3.2.3  RNA quantification and quality assessment 
MiRNA-seq analysis requires a large amount of very good quality RNA.  In order to assure the 
suitability of the samples we had, two types of analysis were performed: spectrophotometric 
and integrity analysis. 
Isolated total RNA was thawed on ice and quantity and quality was assessed 
spectrophotometrically using the Implen Nanophotometer (Implen, Germany).  Samples with 
A260/A280 (for protein contamination) and A260/A230 (for solvent –phenol contamination) 
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ratios of 1.8 to 2.0 (respectively) were considered suitable for integrity analysis using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). 
The technology of the Agilent 2100 Bioanalyzer relies on a microfluidic system where each 
well on a chip (12-wells for the RNA Nano Lab chip) runs a capillary electrophoresis where a 
laser-induced fluorescence detects labelled RNA molecules in each sample.  As in gel 
electrophoresis,  RNA molecules have different migration rates depending on their size; which 
is calculated by interpolating it in a standard ladder.  Data collected by the laser can be 
translated into bands (gel-like images) and peaks (electropherograms)  (Figure 3.1, Panel A-B), 
allowing a rapid visual inspection of the general state of a RNA sample.  Well conserved 
samples should show two distinctive well-defined peaks for the ribosomal subunits  –18S and 
28S and a flat baseline with the absence of small peaks between both main peaks.  The Agilent 
2100 Expert Software (Agilent Technologies, Palo Alto, CA, USA) generates the RNA Integrity 
Number (RIN) (Schroeder et al. 2006), a numbering system from 1 to 10, that helps to classify 
samples according to their integrity. 
Samples with RIN values equal or above 7.0 (as suggested by Illumina and typically used for 
microarray analysis (Koufaris 2011; Ibberson et al. 2009)) were considered suitable for 
small-RNA library construction for miRNA-seq analysis.  RNA integrity analysis was performed 
at the Genomics Laboratory (Imperial College London, Hammersmith Campus). 
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Figure 3.1  Assessment of total RNA integrity and quality.  Example of (A) Bioanalyzer gel-like image 
obtained using the RNA Nano Lab chip,  (B) Electropherogram where both peaks represent ribosomal 
RNA, 18S and 28S respectively, and  (C) RIN number.  FU –Fluorescence Units. 
 
3.2.4  miRNA Sequencing Analysis.  Library Construction 
Small-RNA libraries for miRNA-seq analysis were prepared using Illumina TruSeq Small RNA 
Sample Preparation kit (Illumina, San Diego, CA, USA) following the sample preparation guide. 
MiRNA profiling was initiated by analysing the Day 28th sample set to determine changes in 
miRNA expression after long-term exposure to PB or SYN (n=5 per treatment).  For this, 
one µg of liver total RNA was used for library construction;  3´and 5´adaptors were attached 
to the ends of the small-RNAs.  Then, the construct was used as template for RT reaction 
followed by PCR amplification (Figure 3.2, Panel A), using a specific primer to tag each sample, 
30 in total.  Amplification conditions were: 30 seconds at 98°C,  11 cycles of  10 seconds at 
98°C, 30 seconds at 60°C 15 seconds at 72°C; 10 minutes at 72°C, and constructs were kept at 
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4°C.  After PCR amplification, samples were analysed with the Agilent 2100 Bioanalyzer to 
assess that both adaptors were attached to the small-RNA (Figure 3.2, Panel B).  If the 
Bioanalyzer electropherogram showed positive results (peaks around 50 sec or 150 bp) they 
were kept for lane pooling, if there was a negative result then the protocol was repeated. 
Twelve samples with different index tags were pooled into four lanes allowing each lane to 
contain 1-2 samples from each treatment (Control, PB 50 or 1000 ppm, and SYN 50, 500 or 
3000 ppm –Day 28th).  To enrich and purify the construct, pooled samples were fractionated 
by polyacrylamide gel electrophoresis, and bands between 145-160 pb (small-RNA + 3’-5’ 
adaptors) were cut for further purification by Ethanol precipitation.  Concentration and purity 
of cDNA construct were assessed (Figure 3.2, Panel B-C) and Ethanol precipitation using 
Agilent 2100 Bioanalyzer, with the Agilent High Sensitive DNA kit (Agilent Technologies, Palo 
Alto, CA, USA).  During Ethanol precipitation, glycogen was used as a carrier to maximize the 
DNA yield.  The final product was dissolved in Tris-HCl 10 mM, pH 8.5 and kept at -20°C. 
Pooled library construct were loaded to a sequencing flow cell, which was run on the Illumina 
Hi-Seq machine at the Genomics Laboratory (Imperial College London, Hammersmith 
Campus)  and raw data was demultiplexed using CASAVA 1.8.2  (Illumina, San Diego, CA, USA). 
 
For miRNA-seq analysis of days 1 and 3, four samples from each day/treatment were 
randomly selected for library construction, which was performed by LGC Genomics, Berlin, 
Germany, following the protocol used for Day 28.  Sample pooling and lane construction were 
done by us and the sequencing flow cell was run at the Genomic Laboratory, as for the rat 
liver Day 28 samples. 
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Figure 3.2  Small-RNA library construction scheme.  (A) 3’ and 5’ adaptors are ligated to the small-RNA. 
Construct was reverse transcribed by RT-PCR for cDNA amplification.  PCR product was purified by gel 
electrophoresis; Agilent 2100 Bioanalyzer traces  (B) before and  (C) after sample pooling and Ethanol 
precipitation purification.  FU –Fluorescence Units, s –seconds. 
 
 
3.2.5  miRNA Sequencing Analysis.  Data Analysis 
Once all data sets were demultiplexed (CASAVA 1.8.2, Illumina, San Diego, CA, USA) and 
separated into files by treatment and day of treatment (1st, 3rd, and 28th), the pipeline shown 
in Figure 3.3 was followed. 
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Figure 3.3  Bioinformatics analysis pipeline of the reads obtained from Illumina Hi-Seq machine after 
sequencing.  QC-Quality control. 
 
The Cutadapt 1.2.1 (Martin 2011) algorithm was designed to remove adapter sequences from 
high-throughput sequencing data, in this case 3’ adapter, it was installed and run in Ubuntu 
14.04.  Fastq (demultiplexed) files were analysed using the following command in the 
command-line: 
> $ cutadapt –discard-untrimmed –minimum-length=15 –maximum-length=35 
–a 3’ADAPTER SEQUENCE File-in.fastq > File-out.fastq 
 
In the command-line:  --discard untrimmed, removes/discards those reads that do not have 
the 3’ adapter attached to it;  --minimum/maximum-length, reads out of the range 
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established are discarded;  –a, trims 3’adapter sequence from each read.  [3’adapter 
sequence  TGGAATTCTCGGGTGCCAAGG] 
 
FastQC  (Andrews 2010)  is an open access algorithm for quality control analysis of sequencing 
data.  It was downloaded from the Babraham Bioinformatics website 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and installed/ran in Windows 
as a standalone application.  Fastq files originated from Cutadapt were open directly in FastQC 
and analysed.  We ensured that results for sequence quality analysis were located within the 
highest quality scores (green area) as shown in Figure 3.4, higher scores mean better 
sequence quality. 
 
 
Figure 3.4.  Example of FastQC Sequence Quality results.  Y-axis- quality scores in which the green area 
refers to very good quality reads, orange area to reasonable quality, and red area indicates poor 
quality. 
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Once quality control analysis was done, sequences were collapsed into a new file: text or 
Tab-delimited file, using the CLC Genomics Workbench v.6.5 (Qiangen, NL).  Fastq files from 
Cutadapt were uploaded to the CLC Genomics Workbench and the following path was used: 
 
Toolbox  Transcriptomics Analysis  Small-RNA Analysis  Extract 
and Count 
 
These files contained all sequences and the number of times they occurred in each file.  After 
exporting from the CLC Genomics Workbench, collapsed files were uploaded to the 
miRanalyzer web server (http://bioinfo5.ugr.es/miRanalyzer/miRanalyzer.php) for 
differential expression analysis. 
 
The miRanalyzer v.2.0  (Hackenberg, Rodríguez-Ezpeleta, and Aransay 2011; Hackenberg et 
al. 2009) algorithm is a web server tool for small-RNA NGS data mining, that allows 
detection/prediction of miRNAs.  miRanalyzer carries out the study in different steps, as 
explained in their 2011 paper (Hackenberg, Rodríguez-Ezpeleta, and Aransay 2011).  First, 
reads containing “N” (indicative of an inconclusive signal) or irregular bases were removed 
from the file, as well as reads shorter than 17 bases or longer than 26 bases;  the rest of the 
reads were aligned to the miRBase v.19.0 (Kozomara and Griffiths-Jones 2014; Kozomara and 
Griffiths-Jones 2011) database sequences to detect known miRNAs, then remaining reads 
were aligned to different transcriptome libraries –RefSeq (Pruitt et al. 2014), to detect mRNA 
contamination, and RFam (E. P. Nawrocki et al. 2015) for other non-coding RNAs.  All these 
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reads were removed to avoid false positive results when aligning to the genome (Rat -Rattus 
norvergicus Rn  4) to detect/predict putative miRNAs. 
Statistical analysis to determine miRNA differential expression was performed using the 
DESeq (Anders and Huber 2010) package.  Although this is an open access program through 
Bioconductor, it is also part of the miRanalyzer web server tool.  To run it, different ID job 
numbers were assigned by miRanalyzer to each analysed data set, this number can be input 
as a group to define each treatment.  A table with all known/putative miRNAs detected, fold 
change and P adjusted values is given.  For known miRNAs, miRNAs with P Adj<0.05 were 
considered significant and were considered for further analysis (Chapter 4 –Effects of PB and 
SYN treatment on the liver miRNAome).  The same criteria was used for putative miRNAs 
detected, in this case sequences of interest (mature sequences) were mapped to the miRBase 
repository (Kozomara and Griffiths-Jones 2014) (using blastn) for detection of putative rat 
homologous miRNAs; Clustal W v2.0 (Larkin et al. 2007; Thompson, Higgins, and Gibson 1994) 
was used for full-length alignments of mature miRNAs (http://www.clustal.org/clustal2/), and 
RNA secondary structure (precursor sequences) was constructed using the RNAfold (Gruber 
et al. 2008; Hofacker et al. 1994) web server (http://rna.tbi.univie.ac.at/). 
 
3.2.6  Principal Component Analysis of known miRNA 
Principal Component Analysis (PCA) is a statistical technique used to analyse large datasets 
by reducing the number of variables present in the data (Lindon, Holmes, and Nicholson 
2001).  For this an eigenvector/eigenvalue from each variable present in the dataset is 
calculated, the eigenvector(s) with the highest eigenvalue(s), which explains the variance of 
the data in a certain direction, is considered the principal component.  PCA uses an 
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unsupervised method to identify different patterns within the data; this method relies only 
on the information provided in the feature matrix, without considering the class membership 
of samples (Edmands 2011). 
PCA results can be visualised by scores plot of the principal components, these graphs allow 
an easier detection of clusters, trends, and outliers within the dataset.  In multivariate analysis 
like PCA, it is important to determine how well the R2 and Q2 statistical parameters 
performed.  These two parameters evaluate the amount of variation explained by the 
principal component (R2) and by the robustness of the model (Q2)  (Eriksson et al. 2001). 
For PCA, normalised read counts of all known miRNAs detected by sequencing analysis at each 
treatment (PB or SYN) and time of exposure (1, 3, and 28 days) were computed.  The analysis 
was conducted using SIMCA-P+ v.13.0 (Umetrics, Umea, Sweden) with unit variance-scaled 
data. 
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3.3  RESULTS 
3.3.1  miRNA-Seq.  Library Construction 
In order to start library construction for small-RNA (miRNA) with the Illumina TruSeq small 
RNA prep kit, the protocol sent by the manufacturer was optimized.  For this, total RNA (1 µg) 
from one sample was tested using two different T4 RNA ligases-2, Deletion mutant (Epicentre, 
WI, USA) and Truncated (New England Biolabs, MA, USA) at 200 U, both enzymes suggested 
by Illumina for the 3’ adapter ligation (Figure 3.5, Panel A).  These enzymes are used to ligate 
single-stranded adenylated oligonucleotides to the 3’ end, while the 5’ end ligation requires 
a T4 RNA ligase that uses non-adenylated nucleotides, but its activity is dependent on ATP, 
making the enzymes specific for both reactions. 
PCR was performed using 11 cycles and the product obtained from the 3’ and 5’ ligation was 
separated in an acrylamide gel.  Bands between 145-160 bp were expected if a successful 
3’-5’ ligation reaction had occurred.  A band was observed with the Deletion Mutant enzyme 
but not with the Truncated enzyme (Figure 3.5, Panel A).  PCR product was also analysed with 
Agilent 2100 Bioanalyzer (Figure 3.5, Panel B); low traces of the construct were detected for 
the Deletion Mutant enzyme (blue line) but not for the Truncated. 
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Figure 3.5  PCR product from 3’-5’ adaptor ligation to small-RNAs using two different T4 RNA ligase 2, 
Deletion Mutant and Truncated,  (A) was separated in an acrylamide gel and  (B) traces were analysed 
with the Agilent 2100 Bioanalyzer (black arrow).  The white frame marks the expected band containing 
the construct.  HRL –High Resolution Ladder, CL –Custom Ladder, FU –Fluorescent Units, s –seconds.  
PCR conditions: 1 µg of total RNA and 11 cycles.  
 
After deciding that the Deletion Mutant enzyme was most efficient for the 3’ ligation step, 
different amounts of total RNA (1, 2, and 4 µg) were tested and PCR cycles augmented from 
11 to 15 to increase the amount of final construct product. 
PCR product was analysed in the Bioanalyzer (Figure 3.6, panel B); traces of the construct 
were detected (black arrow) and peaks increases with the amount of total RNA used.  Again, 
construct was separated in an acrylamide gel and bands between 145-160 bp were detected 
(Figure 3.6, Panel A, white frames), intensity of the band also increased when increasing the 
quantity of RNA. 
Chapter 3 
[ 75 ] 
 
 
 
 
Figure 3.6  Separation of PCR product using 1, 2, and 4 µg of total RNA and 15 cycles of PCR 
amplification.  (A) Acrylamide gel electrophoresis of the PCR product, and  (B) Agilent 2100 Bioanalyzer 
analysis of PCR product traces (black arrows).  White frames enclose bands of interest.  HRL –High 
Resolution Ladder, CL –Custom Ladder, FU –Fluorescence Units, s –seconds. 
 
In order to purify and concentrate the small-RNA construct, bands of interest were cut from 
the gel and purified by Ethanol precipitation and analysed in the Agilent 2100 Bioanalyzer.  
Figure 3.7, panel A, shows the gel after bands of interest were cut, panel B shows the 
Bioanalyzer analysis of the construct after purification. 
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Figure 3.7  Separation of PCR product using 1, 2, and 4 µg of total RNA and 15 cycles of PCR 
amplification II.  (A) Acrylamide gel after bands were cut (white frame).  (B) Traces from Bioanalyzer 
of final library construct (black arrow) using 1, 2, and 4 µg of total RNA and 15 cycles of PCR 
amplification.  HRL –High Resolution Ladder, CL –Custom Ladder, FU –Fluorescence Units, s –seconds. 
 
It was concluded that the conditions for optimum library construction from total RNA of liver 
samples should use T4 RNA ligase 2, Deletion Mutant for the 3’ adaptor ligation, 2 µg of total 
RNA, and PCR amplification of 15 cycles. 
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3.3.2  miRNA-Seq.  Data Analysis 
3.3.2.1  Known miRNAs 
After miRanalyzer (Hackenberg et al. 2009; Hackenberg, Rodríguez-Ezpeleta, and Aransay 
2011) and DESeq (Anders and Huber 2010) analysis for known miRNAs, general results for 
each day of treatment showed that on Day 1 an average of 220 miRNAs were detected, 250 
for Day 3, and 230 miRNAs on Day 28th as seen in Figure 3.8-Panel A.  The same figure in Panel 
B shows that on days 3rd and 28th different treatments or doses did not have an impact on the 
general perturbation of the miRNAome, almost the same number of miRNAs were detected 
on each day.  However, for the first day of treatment there appears to be a dose/treatment 
trend for both compounds where PB had a slight increase between 50 and 1000 ppm and for 
the SYN compound doses 500 and 3000 ppm the number of miRNAs were higher than the 50 
ppm dose but a peak was seen with 500 ppm.  The number of miRNAs detected on days 3 and 
28 of treatment were more uniform between treatments. 
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Figure 3.8  Number of known miRNAs detected after bioinformatics analysis.  (A) Average of miRNAs 
by Day of Treatment ± S.D.  (B) Number of miRNAs detected by treatment on each Day of Treatment 
after DESeq Analysis.  n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 28. 
 
 
A list of all known miRNAs identified is in Appendix-2 for Day-1, Appendix-3 for Day-3 and 
Appendix-4 for Day-28.  The following chapters (Chapters 4 and 5) explore which miRNAs 
were significantly altered by PB/SYN treatment (Chapter 4 –Effects of PB and SYN treatment 
on the liver miRNAome) and the consequences of their altered expression (Chapter 5 –Effects 
of miRNA deregulation). 
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3.3.2.1.1  Principal component analysis of known miRNA expression 
As mentioned before PCA is a multivariate analysis that aids to study and visualization of large 
datasets and aids in the identification of data patterns (clusters, trends, and outliers), recently 
reviewed and summarised by (Jolliffe and Cadima 2016).  In this study, PCA was used to detect 
major time- or dose-dependent patterns in the expression of known miRNAs detected 
(regardless of the P Adj values) by sequencing analysis after continuous treatment with PB or 
SYN for up to 28 days (Figure 3.8).  For PB treatment, PCA results showed that the 50 ppm 
dose denoted a cluster separation only after chronic treatment –28 days, however with 
1000 ppm an earlier cluster separation between both groups (Control and treatment) was 
detected on the third and 28th day (Figure 3.9), showing a time and dose effect on miRNA 
expression after treatment with PB. 
Clusters of known miRNA were also identified with SYN treatment, in this case a distinct 
separation between Control and the SYN compound treatment was observed at all doses 
since the beginning of the treatment until the 28 day as shown in Figure 3.10,  where the 
score plots show that the SYN compound seems to have a more powerful effect on miRNA 
expression than PB. 
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Figure 3.9.  Principal Component Analysis (PCA) score plots of miRNAs expressed on Days 1, 3, and 28 (columns) after treatment with PB (rows).  Control 
(black) vs. PB 50 ppm (blue) and PB 1000ppm (red).  Circles denote clusters.  n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 
28.  R2Q2 plots for each PCA are shown on the top-right of each score plot and values in the table below the score plots.
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Figure 3.10.  Principal Component Analysis (PCA) score plots of miRNAs expressed on Days 1, 3, and 28 (columns) after treatment with different doses of SYN (rows).  
Control (black) vs. SYN 50 ppm (dark yellow), SYN 500 ppm (green), and SYN 3000 ppm (purple).  Circles denote clusters;  n=4 rats per treatment for days 1st and 3rd 
and n=5 rats per treatment for day 28.  R2Q2 plots for each PCA are shown on the top-right of each score plot and values in the table below the score plots.
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3.3.2.3  Putative novel miRNAs 
As described before (3.2.4 miRNA-seq Analysis.  Data analysis)  detection and prediction of 
putative novel miRNA are part of the data mining analysis performed with the miRanalyzer 
algorithm (Hackenberg et al. 2009; Hackenberg, Rodríguez-Ezpeleta, and Aransay 2011).  
Results from this analysis showed that on the first day of treatment 95 putative novel miRNA 
sequences were detected but only 5 were significant, for the 3rd day 377 sequences were 
identified from which 19 had a P Adj < 0.05, finally the 28th day had 209 novel sequences with 
6 being significant.  From the significant-selected sequences, three of them were detected as 
a possible rat homologous miRNA and one-sequence was detected as an isomiR and putative 
member of a rat miRNA family. 
 
3.3.2.3.1  Rat homologous novel miRNAs 
A putative miRNA sequence could be considered a homologous sequence if the novel 
sequence is present in different species but has not been identified in the species of study 
(Griffiths-Jones et al. 2006; Fanxue Meng et al. 2012) (rat, in this case) and if they have a very 
similar sequence.  In this study, three of the sequences detected as putative miRNAs –
Candidate –10, Candidate –40, and Candidate –64, were identified as possible putative novel 
rat homologous miRNAs of hsa-miR-4488 (human) (Jima et al. 2010) and ggo-miR-4488 
(gorilla) (Dannemann et al. 2012) both miRNAs were recently described from different 
sequencing data analysis.  Putative novel miRNAs –mature and precursor sequences, were 
detected after treatment with PB 1000 ppm on Day 1 for Candidate –10, PB 50 ppm on Day 3 
for Candidate –64, and finally Candidate –40 with PB 50 ppm on Day 28.  Similar sequences 
were detected for treatment with SYN, but they were not significant (Appendix 5). 
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Tables 3.1 and 3.2 show the genomic location of each candidate and precursor sequences 
predicted by the miRanalyzer analysis. 
 
Table 3.1  Mature sequences and genomic location of putative miRNAs homologous to miR-4488 
Treatment Name Mature Sequence Chr Start- End Strand P Adj 
PB1000-D1 Candidate –10 CGTGGGTCGGGCGCCGGCGGCT chrUn 
23403911-
23404017 
+ 0.047 
PB50-D3 Candidate –64 CGGGGGTCGGGCGCCGGCG chrUn 
438269-
438374 
+ 0.037 
PB50-28 Candidate –40 
GTCGGGGCGGGGTCCGCCGGCC
TCG 
chr5 
24497501-
24497595 
+ 0.001 
NOTE:  chrUn refers to those sequences that cannot be related to a specific chromosome. 
 
 
Table 3.2  Precursor sequence of putative miRNAs homologous to miR-4488. 
Treatment Name Precursor Sequence 
PB1000-D1 Candidate –10 
GGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGG 
CTCCGGCCGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGG 
PB50-D3 Candidate –64 
GGGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCC 
GGCTCCGGCCGGGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCG 
PB50-28 Candidate –40 
TGAGAGGTGTAGAATAAGTGGGAGGCCCCCAGCGCCCCCCCGTTCCCCGCGA 
GGGGTCGGGGCGGGGTCCGCCGGCCTCGCATATGAATATAACA 
NOTE:  Mature putative miRNA sequences are marked in bold and underlined font. 
 
MiRBase (blastn) alignment of both, hsa/ggo-miR-4488 and putative mature sequences 
showed that they have high similarity.  Figures 3.11-3.13 (Panel A and B) show the alignments 
between each candidate and the hsa/ggo-miR-4488 sequence.  According to (Ambros et al. 
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2003) miRNA annotation system, putative mature miRNA should have at least 16 base 
pairings to the opposite arm in the hairpin, the RNA secondary structure of each Candidate 
precursor was determined with RNAfold (Gruber et al. 2008; Hofacker et al. 1994), with 16-16 
bases (Figures 3.11-3.13, Panel C). 
 
MiRNA seed region is located at the 5’ end and comprises nucleotides 2-8 of the sequence.  
This region is important for target recognition by partial base complementarity (Moreno-
Moya, Vilella, and Simón 2014).  Although ideally seed region amongst homologous 
sequences should be the same (S. K. Singh et al. 2008), for some important families 
mismatches in this area have been detected, for example: the myomiR family (McCarthy 
2008) or the miR-200 family.  According to miRBase, hsa/ggo-miR-4488 seed region is 
GGGGGCG, Candidates putative seed sequence are as follows, Candidate 10 –UGGGUCG, 
Candidate 64 –GGGGUCG,  and Candidate 40 –CGGGGCG. 
Further experimental analysis regarding expression and biogenesis criteria, i.e. identification 
of mature miRNAs by northern blot, as explained by (Ambros et al. 2003), are needed in order  
to annotate any candidate sequence as a miRNA in the miRBase database. 
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Figure 3.11  Sequence and secondary structure of Candidate –10 as possible rat homologous miRNA.  
Alignment of Candidate –10 (mature sequence) to hsa-miR-4488 and ggo-miR-4488 with (A) miRBase 
and (B) Clustal W, and (C) RNA secondary structure of Candidate –10 (precursor sequence) determined 
by RNAfold, minimum free energy (MFE) was calculated.  Candidate –10 mature sequence within the 
precursor sequence is in grey.  Asterisk (*) indicates bases in common between sequences, black line 
indicates putative seed sequence. 
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Figure 3.12  Sequence and secondary structure of Candidate –64 as possible rat homologous miRNA.  
Alignment of Candidate –64 (mature sequence) to hsa-miR-4488 and ggo-miR-4488 with (A) miRBase 
and (B) Clustal W, and (C) RNA secondary structure of Candidate –64 (precursor sequence) determined 
by RNAfold, minimum free energy (MFE) was calculated.  Candidate –64 mature sequence within the 
precursor sequence is in grey.  Asterisk (*) indicates bases in common between sequences, black line 
indicates putative seed sequence. 
 
 
 
Figure 3.13  Sequence and secondary structure of Candidate –40 as possible rat homologous miRNA.  
Alignment of Candidate –40 (mature sequence) to hsa-miR-4488 and ggo-miR-4488 with (A) miRBase 
and (B) Clustal W, and (C) RNA secondary structure of Candidate –40 precursor determined by 
RNAfold, minimum free energy (MFE) was calculated.  Candidate –40 mature sequence within the 
precursor sequence is in grey.  Asterisk (*) indicates bases in common between sequences, black line 
indicates putative seed sequence. 
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3.3.2.3.2  Candidate –28 a polymorphic isomiR of miR-6215 
IsomiRNAs are length or sequence variants of a miRNA that can be detected by NGS analysis 
(Neilsen, Goodall, and Bracken 2012).  These miRNAs variants can be classified into three 
groups: those miRNAs with modification at either the 5’ end (5’ IsomiRs) or the 3’ end 
(3’ IsomiRs) and polymorphic IsomiR, which have internal nucleotide modifications (Neilsen, 
Goodall, and Bracken 2012; Mishra and Bertino 2009). 
MiR-6215 was described as a novel miRNA, in 2012, from rat kidney sequencing data 
analysis (Fanxue Meng et al. 2012) and has been mentioned to be present in obese rat liver 
tissue samples (Y. Lu et al. 2014) and rat astrocytes(Sun and Pei 2015), but no data related to 
its possible function has been found.  In our data set, this miRNA was detected throughout 
the experiment (Chapter 4 –Tables 4.1-4.3), although its expression was variable, with 
significant values on the 1st day of treatment –PB 1000 ppm (P Adj=5.6E-48) and SYN 3000 
ppm (P Adj=0.01) and on the 3rd day for PB 1000 ppm (P Adj=8.6E-07), in both days it was 
downregulated.  However, it was upregulated on Day 28th with PB 50 ppm (P Adj=3.05E-12), 
SYN 50 ppm (P Adj=0.001) and 3000 ppm (P Adj=3.7E-04). 
Candidate-28 was downregulated on Day 1 with PB 1000 ppm (P Adj=4.45E-31).  When 
comparing this putative rat miRNA to rno-miR-6215, it seems to be a polymorphic isomiRNA 
of miR-6215.  As shown in Figure 3.14 (Panel A and B), both mature sequences have the same 
length (20 nt) and are very similar.  Although Candidate –28 has 2 mismatches at the 5’ end, 
which are denoted by grey areas on Figure 3.14. 
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Figure 3.14  Sequence and secondary structure of Candidate –28 as possible member of miR-6215 
family.  Alignment of Candidate –28 (mature sequence) to rno-miR6215 with (A) miRBase and 
(B) Clustal W, and (C) RNA secondary structure of Candidate –28 (precursor sequence) determined by 
RNAfold, minimum free energy (MFE) was calculated.  Candidate –28 mature sequence within the 
precursor sequence is in grey.  Asterisk (*) indicates bases in common between sequences, black line 
indicates putative seed sequence. 
 
As for Candidates in section 3.3.2.3.1, genomic location (Table 3.3) and putative precursor 
sequence (Table 3.4) were also determined for Candidate –28 by the bioinformatics analysis 
with miRanalyzer. 
 
Table 3.3  Mature sequences and genomic location of putative isomiRNA –Candidate –28. 
Treatment Name Mature Sequence Chr Start- End Strand P Adj 
PB1000-D1 Candidate –28 AGTAGGGTGGCAGAGCCAGG chr1 
207336699-
207336833 
- 4.45E-31 
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Table 3.4  Precursor sequence of putative isomiRNA –Candidate –28. 
Treatment Name Precursor Sequence 
PB1000-D1 Candidate –28 
CTAAAGACGAACAAGCTCTACAAGTTCTCCACCTCACAACAGTAGGGTGGC 
AGAGCCAGGATTTGAACTCAGGGACTTTAAACTTGGATTCTTATAACTTTGC 
TGTGGCTTGTGAAGAGCTTGTAGCCTACTTCT 
NOTE:  Mature putative miRNA sequences are marked in bold and underlined font. 
 
As for putative homologous sequences to miR-4488, further experimental analysis (Ambros 
et al. 2003) need to be done to classify and annotate Candidate –28 as miRNAs in the miRBase 
repository (Kozomara and Griffiths-Jones 2014). 
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3.4  DISCUSSION 
Even though it is perceived as an expensive tool, NGS analysis is one of the most used 
platforms for miRNA profiling, one of its advantages is that it is able to not only detect low 
copy number of miRNAs (Hackenberg et al. 2009) present in a sample but it can also detect 
changes in a single nucleotide (Pritchard, Cheng, and Tewari 2012).  However it is necessary 
to have a large amount (one µg) of very good quality RNA (intact RNA), and in the case of  
tissue samples this requirement is relatively easy to fulfil, but for plasma samples it is a 
drawback due to the low amount of RNA present in this type of body fluid (Spornraft et al. 
2014).  Library preparation is a very important and limiting step for NGS analysis, it usually 
requires the same operator during the process to avoid bias and decrease error (Head et al. 
2014). 
Optimization of the methodology is also a critical step in library preparation. It helps to make 
better use of the reagents and samples available.  In this study, the library construction 
protocol was optimized for ligation of the 3’ end adapter and quantity of total RNA used.  For 
ligation of the 3’ end adapter to the small-RNA two T4 RNA ligase-2 enzymes –Truncated and 
Deletion Mutant enzymes, were tested.  These enzymes are mainly used to ligate 
single-stranded adenylated oligonucleotides to the 3’ end of the sequence of interest, this 
avoids the ligation of two fragments of total RNA and it also blocks the miRNA 3’end to 
prevent self-ligation (Head et al. 2014).  For the 5’ end ligation a T4 RNA ligase is used, this 
enzyme uses the miRNAs 5’ phosphate group as substrate for ligation (Head et al. 2014), this 
is the reason why non-adenylated nucleotides are needed and the reaction is ATP-dependant. 
Results showed that the Deletion mutant enzyme was most suitable for 3’ end ligation of the 
small-RNAs (Figure 3.5).  Different amounts of total RNA –1, 2, and 4 µg, were tested; the 
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number of PCR cycles increased from 11 to 15.  As the concentration of RNA increased the 
gel-band of the library construct was more concentrated and had a better definition 
(Figure 3.6).  Gel purification and size selection of the library construct is also a critical step in 
this process, side products such as primer dimers can be present (Head et al. 2014), Figure 3.7 
shows the results of ethanol purification after size selection of a band (150 bp) containing the 
miRNA library construct. 
There are different tools for bioinformatics analysis for miRNA-seq data  (Kang and 
Friedländer 2015), we used miRanalyzer (Hackenberg et al. 2009; Hackenberg, Rodríguez-
Ezpeleta, and Aransay 2011) because this algorithm can be used as a web-server tool, accepts 
text files, there are no limits on the file size it can take, and statistical analysis, for differential 
expression analysis, can be performed within the tool, making the analysis easier for users 
with little experience in bioinformatics.  Other programs only accept files with a specific 
size -miRNAkey (Ronen et al. 2010) and miRTools (Wu et al. 2013) or statistical analysis has to 
be done separately –miRDeep (Friedländer et al. 2008). 
In this chapter analysis of known miRNAs, refers to the number of these small-RNAs detected 
in each treatment (PB or SYN) and day of treatment (1, 3, and 28 days), results of the 
differential expression analysis are shown in following chapters.  Previous PB miRNA profiling 
studies have used the hybridisation system (Koufaris et al. 2012; Koufaris et al. 2013),  
however, they have not reported the number of miRNAs detected in these analyses and we 
cannot compare the results to those detected by NGS under similar conditions.  To our 
knowledge, this is the first work where PB miRNA profiling has been performed using NGS 
and where PB related putative miRNAs have been detected, Candidates –10, 64, 40 which 
were significantly expressed with doses of PB 1000 ppm Day 1 for Candidate –10, and 50 ppm 
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Day 3 for Candidate –24 and Candidate –40 at Day 28.  Further analysis to fulfil the biogenesis 
and expression criteria according to the guideline developed to uniform miRNA annotations 
(Ambros et al. 2003)  needs to be done in order to introduce these sequences into the 
miRBase repository (Kozomara and Griffiths-Jones 2014). 
In summary, NGS analysis has improved our knowledge of miRNA deregulation in response to 
treatment with chemical compounds such as PB in the rat and has also helped to identify 
potentially novel rat miRNAs.  The following chapters will explore the findings of the NGS 
analysis in more depth, looking at changes in the expression of known miRNAs (Chapter 4) 
and the consequences of the altered expression of specific key miRNAs (Chapter 5). 
  
 
Chapter 4 
Effect of PB and SYN treatment on the 
liver miRNAome 
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4.1  INTRODUCTION 
As mentioned before miRNA profiling is an important tool for detection and assessment of 
miRNAs expression under certain conditions to identify possible biomarkers (Pritchard, 
Cheng, and Tewari 2012).  This has also become an important area of research that has helped 
to understand different cellular process and malignancies.  In the liver, miRNA profiling 
studies have assessed the influence of miRNAs in liver development, from early/late 
embryonic to adult stages (Tzur et al. 2009).  Furthermore, miRNA profiling analysis has been 
also used to show that miRNA expression is higher in normal healthy tissues than in tumour 
tissue, and that this expression is highly related to cell differentiation (J. Lu et al. 2005).  
(Volinia et al. 2006) profiled cancer-related miRNAs by analysing more than 500 tumour 
samples from six different types of cancer (breast, prostate, lung, pancreas, thyroid, and 
stomach), they identified a cancer miRNAome that consisted of 36 upregulated and 21 
downregulated miRNAs including miR-17-5p, miR-20a, miR-21, miR-92, miR-106a, and 
miR-155.  They concluded that each tumour may have a different miRNA profile, which 
depends on the developmental history of the disease (Volinia et al. 2006; J. Lu et al. 2005).  
For example, profiles of tumour samples from epithelial origin (carcinomas) will cluster 
together and may have a different miRNA pattern when compared to haematopoietic 
malignancies (Di Leva and Croce 2013).  MiRNA profiling of tissue or cell culture samples and 
some body fluids such as plasma or serum, have also been used for this type of analysis.  A 
variety of miRNAs have been identified in healthy and cancer patient serum samples and in 
different animals; in all of them results were consistent in samples from the same species 
(Chen et al. 2008).  Other studies have demonstrated that miRNAs found in tissue (liver) 
correlate with those ones detected in plasma samples (G. Chen, Wang, and Cui 2013). 
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This chapter focuses on those known miRNAs detected with miRNA-seq analysis in Chapter 3 
and the miRanalyzer algorithm that identified several miRNAs that were significant after 
statistical analysis, P Adj < 0.05.  Different miRNAs that were significantly altered were 
identified in each treatment and time of exposure.  From this group of significantly different 
miRNAs, three were selected as key miRNAs in the liver after treatment with PB or SYN –the 
miR-200 family, miR-30b, and miR-21.  Levels of the miR-200 family in plasma samples after 
28 days of treatment, with PB 1000 ppm and SYN 3000 ppm, were evaluated to determine if 
their expression reflected the altered miRNA expression seen in liver tissue sequencing data. 
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4.2  MATERIAL AND METHODS 
4.2.1  miRNA-seq Analysis 
Library construction, sequencing, and bioinformatics analysis of RNA extracted from Liver 
tissue samples from rats treated with PB (50 ppm or 1000 ppm) or SYN (50, 500 and 
3000 ppm) after 1, 3 and 28 days of treatment was performed as described in Chapter 3 –
Sections 3.2.1 to 3.2.4.   
 
4.2.2  Plasma RNA extraction 
RNA extraction from plasma samples (Day 28th) was performed following the protocol 
described in Chapter 2 –2.2.2 RNA Extraction, using the mirVana PARIS kit (Ambion, Life 
Technologies, USA) with minor changes.  For each plasma sample, from animals treated with 
PB 1000 ppm or SYN 3000 ppm, 300 µL were used.  After addition and incubation with the 
Cell Disruption buffer, synthetic cel-miR-39 (Applied Biosystems, Foster City, CA, USA) was 
added (5 fmol/µL) to the plasma-buffer mix, the protocol was carried out as previously 
described (Chapter 2 –Section 2.2.2) and final RNA elution was completed with 50 µL of 
Nuclease-free water.  Cel-miR-39 (6 µL) was used as a spike-in control to assess RNA extraction 
and as a normalizing control for qPCR analysis. 
RNA extracted from plasma samples was used to assess the expression of circulating 
miR-200a, miR-200b, and miR-429.  Due to the low amount of RNA present in these samples, 
RNA spectrophotometric analysis was not possible, therefore it was not possible to assess 
RNA quality or quantity.  
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4.2.3  qPCR analysis for Circulating miRNAs 
For RT reaction, the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Foster 
City, CA, USA) was used.  RT master mix consisted of: 100 mM dNTPs, MultiScribe Reverse 
Transcriptase (50 U/L), 10x Reverse Transcription Buffer, RNase Inhibitor (20 U/µL), and 
Nuclease-free water for a final volume of 7 µL.  The amplification master mix was pipetted in 
a 0.2 mL PCR tube, then 5 µL of total RNA and 3 µL of 5x RT primer were added, for a final 
volume of 15 µL.  Amplification was performed using a MJ Research PTC-200 Thermocycler 
(GMI Inc. USA).  Amplification conditions were: 30 minutes at 16°C, 30 minutes at 42°C and 
5 minutes at 85°C.  cDNA was stored at -20°C until use for qPCR.  
For qPCR, RT product (cDNA) was mixed with TaqMan Universal Master Mix II (2x) –no UNG 
(Applied Biosystems, Foster City, CA, USA), TaqMan Small RNA Assay probes (20x) for, 
miR-200a, miR-200b, miR-429, and cel-miR-39 as normalizing control, and Nuclease-free 
water for a final volume of 20 µL, details of the primers used are mentioned in Appendix 1.  
qPCR reactions were run triplicate in  96-well plates (Thermo Scientific) on the StepOne 
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).  The following conditions 
were used:  10 minutes at 95°C; 40 cycles of 15 seconds at 95°C and 60 seconds at 60°C. 
MiRNA analysis expression was determined using StepOne Software v2.3 (Applied 
Biosystems, Foster City, CA, USA).  For quantification, the 2-ΔCt comparative method was used, 
normalizing to cel-mi-39 spike-in.  A miRNA was considered significant when the value 
calculated by 2-ΔCt method was higher than 1.5 SD or less expressed when the value was below 
0.5 SD.  Statistical analysis was performed using One-way ANOVA with Dunnett’s comparison 
to control samples. 
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4.3  RESULTS 
4.3.1  Differentially Expressed miRNAs 
As described in Chapter 3 –miRNA-seq Analysis, an average of 200 to 250 known miRNAs were 
detected on each day of treatment after the miRanalyzer analysis.  From these number of 
miRNAs, we selected those that had a cutoff P adjusted value of less than 0.05, after statistical 
analysis with DESeq, as differentially expressed.  DESeq analysis does not use standard 
deviation to determine statistical significance, but P Adj values.  Because of this, graphs of 
selected miRNAs (differentially expressed) show P Adj values on top of each bar. 
However, the number of significant or differentially expressed miRNAs is very different 
amongst treatment and day of treatment.  The PB 50 ppm dose, has been reported as a 
sub-toxic dose and it does not cause any changes in the liver weight (Waterman et al. 2010) 
(as shown in Chapter 2 –Figure 2.4).  Importantly, this treatment resulted in very few changes 
in the expression of hepatic miRNA and only 2 differentially expressed miRNAs by the end of 
the treatment (Day 28th).  For the hepatotoxic dose of PB (1000 ppm) (Waterman et al. 2010; 
Butler 1978), a peak in the number of differentially expressed miRNAs was seen by the third 
day, with 16 miRNAs; the first and 28th days had 2 and 4 miRNAs respectively differentially 
expressed. 
In general, the third day of treatment showed more changes in the perturbation of the 
miRNAome, especially with the lower dose of the SYN compound (50 ppm), where 33 
differentially expressed miRNAs were noted.  In contrast the 3000 ppm dose of SYN showed 
a negative trend (Figure 4.1) in which the first day of treatment had the highest number of 
significant miRNAs: 24 and the 28th day the lowest: 9. 
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Figure 4.1  Number of significant miRNAs Differentially Expressed with each treatment per Day of 
Treatment.  All data shown are significantly different from Control. (miRanalyzer results with DESeq 
statistical analysis, P Adj < 0.05).  n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment 
for day 28th. 
 
 
The tables below list which miRNAs were statistically different from Control (P Adj ≤ 0.05) by 
treatment (PB or SYN), as well as their fold change and P Adj values.  For Day 1 –Table 4.1; 
Day 3 –Table 4.2, and Day 28 –Table 4.3. 
 
 
 
 
 
Chapter 4 
[ 100 ] 
 
 
Table 4.1  miRNAs differentially expressed in the rat liver after Day 1. 
 PB 50 ppm PB 1000 ppm SYN 50 ppm SYN 500 ppm SYN 3000 ppm 
miRNA FC P Adj FC P Adj FC P Adj FC P Adj FC P Adj 
rno-miR-100-5p -  - - - -   - - - -2.86 4.39E-11 
rno-miR-10a-5p -  - - - -1.48 0.01 - - -2 7.06E-12 
rno-miR-125a-5p -  - - -  -  - - - -1.45 0.01 
rno-miR-125b-5p -  - - -  -  - - - -1.37 0.0032 
rno-miR-139-5p -  - - -  -  - - - 3.17 0.02 
rno-miR-146a-5p -  - - -  -  - - - -1.85 0.01 
rno-miR-150-5p -  - - -  -  - - - 2.75 0.0029 
rno-miR-183-5p -  - - - 3.45 0.02 - -  - -  
rno-miR-190a-5p -  - - -  -  - - - 13.28 0.01 
rno-miR-193-3p -  - - -  -  - - - 3.16 4.70E-09 
rno-miR-194-5p -  - - -  -  - - - 1.46 0.0044 
rno-miR-210-3p -  - - - 3.12 0.03 - - 3.64 0.0051 
rno-miR-26a-5p -  - - -  -  - - - -1.38 0.01 
rno-miR-30b-3p -  - - -  -  - - - 7.0 0.0051 
rno-miR-30e-5p -  - - -  -  - - - -1.46 0.01 
rno-miR-31a-3p -  - - -  -  - - - 26.53 0.0005 
rno-miR-328a-3p -  - - -  -  - - - 27.08 0.0012 
rno-miR-339-3p -  - - -  -  - - - 3.28 0.02 
rno-miR-378a-3p -  - 1.4 2.00E-04  -  - - -  -  - 
rno-miR-455-3p -  - - -  -  - - - 23.56 0.0044 
rno-miR-497-5p -  - - -  -  - - - 2.63 9.90E-05 
rno-miR-505-3p -  - - -  -  - - - 29.35 0.029 
rno-miR-6215 -  - -3.15 5.60E-48  -  - - - -1.45 0.01 
rno-miR-872-3p -  - - -  -  - - - 3.51 0.0044 
rno-miR-99a-5p -  - - -  -  - - - -1.51 0.0025 
rno-miR-99b-5p  - -   - -   - -   - -  -2.23 4.60E-11 
 
NOTE:  miRNA expression changes from miRNA-seq analysis after treatment with PB (50 or 1000 ppm) or SYN 
(50, 500, and 3000 ppm).  Fold change relative (FC) to Control, miRNAs with P Adj ≤ 0.05 (n=4 per treatment) 
after DESeq analysis were included. 
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Table 4.2  miRNAs differentially expressed in the rat liver after Day 3. 
 PB 50 ppm PB 1000 ppm SYN 50 ppm SYN 500 ppm SYN 3000 ppm 
miRNA FC P Adj FC P Adj FC P Adj FC P Adj FC P Adj 
rno-miR-100-5p - - - - - - - - -1.71 0.0117 
rno-miR-103-3p - - - - -1.55 0.0056 - - - - 
rno-miR-10a-5p - - -1.78 3.21E-11 1.43 0.0009 - - - - 
rno-miR-125a-5p - - -1.50 0.0383 - - - - - - 
rno-miR-126a-3p - - - - - - - - -1.47 0.0243 
rno-miR-126a-5p - - - - 2.11 1.66E-23 1.51 0.0142 - - 
rno-miR-127-3p - - - - 2.8 7.09E-07 - - 3.06 3.84E-07 
rno-miR-138-5p - - 3.2 0.0026 - - - - - - 
rno-miR-141-3p - - -2.32 2.24E-05 1.91 0.0015 - - - - 
rno-miR-142-5p - - - - 2.09 1.31E-09 - - - - 
rno-miR-145-3p - - -1.75 0.0255 1.91 0.0008 - - -2.03 0.0075 
rno-miR-145-5p - - - - -1.84 0.0004 - - - - 
rno-miR-146a-5p - - - - 3.73 1.09E-32 - - -1.41 0.026 
rno-miR-146b-5p - - - - 1.6 0.0063 - - - - 
rno-miR-148b-3p - - - - 1.59 0.0007 - - - - 
rno-miR-151-3p - - - - 1.77 5.32E-08 - - - - 
rno-miR-151-5p - - - - 1.82 5.46E-07 - - - - 
rno-miR-183-5p - - - - 2.81 1.64E-09 - - - - 
rno-miR-184 - - - - - - 3.18 0.0274 - - 
rno-miR-191a-5p - - - - 2.27 2.10E-26 1.58 0.0026 - - 
rno-miR-192-5p - - - - 1.36 0.0009 - - - - 
rno-miR-193-3p - - 1.71 0.0001 -2.23 4.05E-09 - - - - 
rno-miR-195-5p - - - - 1.42 0.0349 - - - - 
rno-miR-199a-5p - - - - 1.66 0.016 - - - - 
rno-miR-19b-3p - - - - -1.89 0.0002 - - - - 
rno-miR-200a-5p - - 5.25 5.82E-05 - - - - - - 
rno-miR-200b-3p - - 1.72 2.24E-05 - - - - - - 
rno-miR-204-5p - - - - 1.41 0.0349 - - - - 
rno-miR-21-3p - - 2.02 5.82E-05 2.7 1.25E-13 2.37 0.0003 2.11 6.38E-05 
rno-miR-26a-5p - - - - 1.26 0.0427 - - - - 
rno-miR-27a-3p - - - - 1.5 0.016 - - - - 
rno-miR-28-3p - - - - 1.35 0.021 - - 1.58 0.0058 
rno-miR-30b-3p - - 2.53 0.0003 2.0 0.0058 - - - - 
rno-miR-31a-5p - - - - -1.41 0.0197 - - - - 
rno-miR-326-3p - - - - -2.31 0.016 - - - - 
rno-miR-351-5p - - - - 1.43 0.0205 - - - - 
rno-miR-361-5p - - - - 2.02 0.0002 - - - - 
rno-miR-378a-3p - - - - - - - - 1.35 0.0046 
rno-miR-423-3p - - - - -1.78 0.0031 - - - - 
rno-miR-484 - - -3.19 5.82E-05 - - -3.55 2.78E-05 -3.07 0.0041 
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Table 4.2  miRNAs differentially expressed in the rat liver after Day 3.  Continue. 
 
 PB 50 ppm PB 1000 ppm SYN 50 ppm SYN 500 ppm SYN 3000 ppm 
miRNA FC P Adj FC P Adj FC P Adj FC P Adj FC P Adj 
rno-miR-497-5p - - 1.65 0.0041 - - - - - - 
rno-miR-6215 - - -2.19 8.59E-07 - - - - - - 
rno-miR-671 - - 1.98 0.0095 - - - - 2.04 0.0289 
rno-miR-802-5p - - 1.71 5.87E-05 - - - - 1.45 0.028 
rno-miR-872-3p - - 2.27 4.03E-06 - - - - - - 
rno-miR-92a-3p - - - - - - - - 1.39 0.0154 
rno-miR-99a-5p - - - - 2.3 2.28E-13 1.73 0.0066 - - 
rno-miR-99b-5p - - - - 2.02 1.62E-09 - - - - 
 
NOTE:  miRNA expression changes from high-throughput sequencing analysis after treatment with PB (50 or 
1000 ppm) or SYN (50, 500, and 3000 ppm).  Fold change (FC) relative to Control.  miRNAs with P Adj ≤ 0.05 (n=4 
per treatment) after DESeq analysis were included.  
 
 
Table 4.3  miRNAs differentially expressed in the rat liver after Day 28. 
 PB 50 ppm PB 1000 ppm SYN 50 ppm SYN 500 ppm SYN 3000 ppm 
miRNA FC P Adj FC P Adj FC P Adj FC P Adj FC P Adj 
rno-miR-182 - - 2.40 2.96E-13 - - - - 3.26 1.12E-21 
rno-miR-183-5p - - - - - - - - 5.02 0.0479 
rno-miR-192-5p - - - - - - - - -1.27 0.0130 
rno-miR-200a-3p - - 4.44 0.045 - - - - 4.18 5.88E-03 
rno-miR-200b-3p - - 4.00 1.00E-13 - - - - 3.53 3.95E-16 
rno-miR-3068-3p 3.19 1.92E-03 - - - - - - - - 
rno-miR-375-3p - - - - - - - - -2.94 4.83E-10 
rno-miR-429 - - 2.78 0.037 - - - - 2.42 0.0479 
rno-miR-6215 3.58 3.05E-12 - - 2.24 0.001 - - 3.31 3.69E-11 
rno-miR-92a-3p - - - - - - - - -1.51 1.59E-04 
 
NOTE:  miRNA expression changes from high-throughput sequencing analysis after treatment with PB (50 or 
1000 ppm) or SYN (50, 500, and 3000 ppm).  Fold change (FC) relative to Control.  miRNAs with P Adj ≤ 0.05 (n=5 
per treatment) after DESeq analysis were included. 
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As seen in tables 4.1 – 4.3, changes in the expression of these miRNAs at the different time 
points selected seem to be transient, only few miRNAs were consistently dysregulated across 
two days of treatment with the same chemical treatment.  Examples of these miRNAs are:  
miR-200a, miR-200b, miR-10a, miR-146, miR-183, and miR-6215. 
 
4.3.2  Effect of treatment on key miRNAs 
From the differentially expressed miRNAs detected, I decided to further study the miR-200 
family, miR-21-3p, and miR-30b.  Each of these miRNAs have been implicated as important in 
the epithelial-to-mesenchymal transition (EMT).  The EMT is important in the development of 
cancer and has recently been reported to be disturbed after PB treatment of rats (Koufaris et 
al. 2012). 
 
4.3.2.1  The miR-200 Family 
The miR-200 family comprises five members: miR-200a, miR-200b, miR-200c, miR-429, and 
miR-141.  These miRNAs are arranged into two clusters based on their chromosomal location, 
miR-200a, miR-200b, and miR-429 on chromosome 1p36 and miR-200c/miR-141 on 
chromosome 12p3 (Feng et al. 2014; Korpal et al. 2008).  For this family two types of seed 
sequence have been recognised: AAUACUG for miR-200b, miR-200c, and miR-429, and 
AACACUG for miR-200a and miR-141 (Feng et al. 2014). 
Consistent with previous data from our group using a microarray hybridisation platform for 
miRNA analysis (Koufaris et al. 2012), two members of the miR-200 family (miR-200a and 
miR-200b) were induced 5.5 and 1.7-fold by the 3rd day of treatment with high doses of PB 
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(1000 ppm).  By day 28 expression of both miR-200a, miR-200b, and miR-429 had increased 
4.4, 4.0, and 2.78-fold, respectively compared to Control, as shown in Figure 4.2. 
Interestingly, only the highest dose of the SYN compound (3000 ppm) produced an increase 
in the expression of these three miRNAs: miR-200a 4.2-fold, miR-200b 3.5-fold, and miR-429 
2.4-fold after 28 days of treatment (Figure 4.3). 
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Figure 4.2  miRNA-seq results for the expression of miR-200a/b and miR-429 after the 1st , 3rd or 28th 
day of treatment with PB (50 or 1000 ppm).  Fold Change relative to Control, P Adj ≤ 0.05 after DESeq 
analysis, n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 28. 
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Figure 4.3  miRNA-seq results for the expression of miR-200a/b and miR-429 after the 1st, 3rd or 28th 
day of treatment with SYN (50, 500, and 3000 ppm).  Fold Change relative to Control, P Adj ≤ 0.05 after 
DESeq analysis, n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 28. 
 
 
As previously mentioned, the miR-200 family has been strongly linked with 
Epithelial-to-Mesenchymal transition (EMT) (Bullock et al. 2012).  EMT is a process in which 
epithelial cells lose their differentiated characteristics to acquire mesenchymal features, such 
as increased motility and resistance to apoptosis, and develop an increased capability to 
invade surrounding tissues (Bullock et al. 2012; Thiery 2003).  Although this transition is very 
important for organogenesis and wound healing (Kalluri and Neilson 2003), it is also 
considered to be an initial event for cancer metastasis.  The role this group of miRNAs play in 
EMT is as suppressors, since they regulate ZEB1 and ZEB2 expression.  These transcription 
factors are members of the zinc-finger E-box binding homeobox family and important 
regulators of EMT (Feng et al. 2014; Bullock et al. 2012).  It has been shown that upregulation 
of miR-200 represses ZEB1/2 expression (Park et al. 2008).  However, the downregulation of 
miR-200 leads to an induction of ZEB1/2 causing an inhibition in the expression of E-cadherin, 
a cell adhesion molecule and important marker of epithelial cells phenotype (Feng et al. 2014; 
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Bullock et al. 2012).  The expression of E-cadherin is often downregulated in cancer (Pećina-
Slaus 2003). 
 
 
4.3.2.2  miR-30b 
Besides the miR-200 family, other miRNAs such as miR-30 have been reported to be involved 
in preventing EMT.  According to miRBase (Kozomara and Griffiths-Jones 2011; Kozomara and 
Griffiths-Jones 2014), the miR-30 family consists of five members: miR-30a, miR-30b, miR-30c, 
miR-30d, and miR-30e; they all share the same seed sequence UGUAAACA.  However, results 
of sequencing analysis showed that after PB (1000 ppm) and SYN (50 ppm) treatment, only 
one member of the family, miR-30b, was upregulated, primarily at early time points and 
particularly by high dose SYN (3000 ppm) (Figure 4.4).  Three days after treatment with 
PB 1000 ppm and SYN 50 ppm there was a 2.5 and 2.0-fold increase in miR-30b expression 
respectively.  At day 1, a 7.0-fold increase was observed with SYN 3000 ppm.  (J. Zhang et al. 
2012) showed that miR-30b could target Snail-1, another transcription factor that inhibits 
E-cadherin expression inducing and promoting EMT (Peinado, Olmeda, and Cano 2007). 
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Figure 4.4  miRNA-seq results for the expression of miR-30b after 1, 3 or 28 days of treatment with PB 
(50 or 1000 ppm) or SYN (50, 500, and 3000 ppm).  Fold Change relative to Control, P Adj ≤ 0.05 after 
DESeq analysis, n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 28th. 
 
 
4.3.2.3  miR-21 
There are some miRNAs that have the capability to behave as tumour promoters or better 
known as oncomiRs (B. Zhang et al. 2007), miR-21 is an example of this class of miRNA.  
MiR-21 has been reported to be expressed in different types of mammalian cells and 
overexpressed in different types of cancer (Krichevsky and Gabriely 2009), such as colon 
cancer.  MiR-21 targets include several tumour suppressors such as PTEN (Fanyin Meng et al. 
2007).  In our experiment, this miRNA was induced after 3 days of treatment with PB 
1000 ppm (2.0 –fold) and by SYN at all doses (50 ppm: 2.7 –fold, 500 ppm: 2.4 –fold, and 
3000 ppm: 2.1 –fold) as shown in Figure 4.5. 
In hepatocellular carcinoma cells, overexpression of miR-21 has been shown to regulate cell 
proliferation, invasion, and tumour growth by EMT due to the downregulation of hSulf-1 and 
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PTEN (Bao et al. 2013).  hSulf-1, the human sulfatase-1, is downregulated in some types of 
tumour including hepatocellular carcinoma (Ji et al. 2011); its upregulation causes a decrease 
in the ERK/AKT signalling pathway and reduces cell growth, migration, and invasion (H. Zhang, 
Newman, and Sannes 2012). 
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Figure 4.5  miRNA-seq results for the expression of miR-21-3p after 1, 3 or 28 days of treatment with 
PB (50 or 1000 ppm) or SYN (50, 500, and 3000 ppm).  Fold Change relative to Control, P Adj ≤ 0.05 
after DESeq analysis, n=4 rats per treatment for days 1st and 3rd and n=5 rats per treatment for day 
28th. 
 
 
Overall, from the miRNA-seq data it would appear that SYN has a PB-like behaviour, at doses 
that are lower than that required for PB to have an effect.  Upregulation of miR-21 (Figure 4.5) 
suggest that both PB and SYN encourage EMT, however co-expression and upregulation of 
miR-30b and miR-200a at the 3rd day (Figures 4.2, 4,3, and 4.4) and the miR-200 family after 
28 days (Figures 4.2 and 4.3) might be expected to counteract the EMT effect and therefore 
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could represent a homeostatic control response of the liver in order to preserve the epithelial 
nature of the hepatocytes and possibly to antagonise the remarkable increase in the 
expression of miR-21 at the 3rd day of treatment. 
 
4.3.3  miR-200 as a Circulating miRNA 
Due to the level of hepatic expression of the miR-200 family after 28th days of treatment with 
both compounds, it was aimed to determine if the blood (plasma) also reflected altered 
miRNA expression levels. 
 
4.3.3.1  miR-200 in plasma after PB-SYN treatment 
As described in Chapter 1 –1.2.4 Circulating miRNAs, miRNAs have been found in several body 
fluids such as blood, urine, and saliva (Weber et al. 2010).  In this study, it was possible to 
detect members of the miR-200 family (miR-200a/b and miR-429) in plasma samples 
(Figure 4.6) after PB or SYN treatment.  Unlike tissue samples, the SYN 3000 ppm treatment 
had higher fold change values for the miRNAs of interest, than PB 1000 ppm where miR-200b 
and miR-429 were identified but only the latter was significantly different compared to the 
Control (P<0.0001).  SYN 3000 ppm fold change values were more or less similar to the fold 
change values found in the tissue, SYN 50 ppm: 2.6 –fold, SYN 500 ppm: 3.7 –fold, and 
SYN 3000: 3.8-fold. 
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Figure 4.6  qPCR detection of the miR-200 family in plasma.  RNA was extracted from plasma from rats 
treated with PB 1000 ppm or SYN 3000 ppm after 28th days of treatment.  Fold Change relative to 
Control ± S.D.  One-way ANOVA  **** p < 0.0001,  n= 5 rats per treatment. 
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4.4  DISCUSSION 
Treatment with PB and SYN induced hepatic miRNA expression changes that were in some 
cases transient and in others persistent.  These changes were dose as well as time-dependent.  
Although the expression of many miRNAs were deregulated by treatment with PB and SYN, 
especially at the 3rd day of treatment (Tables 4.1-4.3), only a few miRNAs were consistently 
affected by a particular treatment and these included the miR-200 family, miR-21-3p, and 
miR-30b.  These responses for PB treatment are consistent with previous reports where PB 
treatment (1000 ppm), during 1, 3, 7, 14 (Koufaris et al. 2013) and 90 (Koufaris et al. 2012) 
days, showed a progressive increase in the induction of the miR-200 family, especially 
miR-200a and miR-200b, from the 7th day of treatment onwards.  MiR-429, another member 
of the miR-200 family, was not detected in these previous experiments (Koufaris et al. 2013) 
where a microarray platform was used for miRNA profiling, however, the results in this 
chapter showed that miRNA-seq analysis was able to detect expression of miR-429 in liver 
tissue samples at the 28th day of treatment (Figures 4.2 and 4.3), possible due to the excellent 
sensitivity of this technique.  It has been reported that PB treatment can cause changes in the 
expression of EMT related genes (Phillips, Burgoon, and Goodman 2009).  EMT is an important 
process in organogenesis and wound healing (Kalluri and Neilson 2003), in which epithelial 
cells acquire mesenchymal characteristics, such as increased motility and resistance to 
apoptosis, to develop the capability to invade surrounding tissues (Bullock et al. 2012; Thiery 
2003), as in the metastatic event.  Induction of the miR-200s has been related to EMT 
prevention, because these miRNAs repress the expression of two transcription factors 
important in the regulation of this process –ZEB1 and ZEB2 (Burk et al. 2008).  MIR-30b 
expression was also induced by PB/SYN treatment, although this miRNA has not yet been 
Chapter 4 
[ 112 ] 
 
associated to PB treatment, it has been reported to be an important regulator of EMT in 
human pancreatic epithelial cells (Joglekar et al. 2009).  Sequencing miRNA profiling results 
showed that this miRNA had a positive response to both PB/SYN treatment (Figure 4.4) at the 
3rd day of treatment.  MiR-30b is related to EMT by targeting Snail-1 (J. Zhang et al. 2012), an 
E-cadherin repressor (Peinado, Olmeda, and Cano 2007).  By inhibiting E-cadherin expression 
Snail-1 induces and promotes EMT, furthermore ZEB1/2 have also been reported to target 
this adhesion molecule (Korpal et al. 2008; Park et al. 2008).  In addition to miRNAs that could 
possible prevent the EMT process deregulated by PB/SYN treatment, miR-21 is a well-known 
oncomiR (B. Zhang et al. 2007; Krichevsky and Gabriely 2009) that is upregulated in many 
different types of cancer, such as colon (Yamamichi et al. 2009), brain (Chan, Krichevsky, and 
Kosik 2005), pancreas (Eun et al. 2007), and hepatocellular carcinoma (Fanyin Meng et al. 
2007) was also affected.  This miRNA targets directly PTEN (Han et al. 2012), a tumour 
suppressor, leading to changes in cell proliferation, migration, and invasion (Fanyin Meng et 
al. 2007).  A significant increase in the expression of miR-21 after treatments with PB and SYN, 
at the 3rd day of treatment was detected (Figure 4.5). 
Coordinate expression of these three miRNAs suggests that important changes that preserve 
the epithelial nature and phenotype of the hepatocyte might have been taking place at the 
3rd day of treatment.  A sustained induction of the miR-200 family, as detected at the 28th day 
of treatment, might indicate the importance of this family for the longer-term conservation 
of the epithelial status of the cell.  (Braun et al. 2010) previously reported changes in the 
expression of the miR-200 family, miR-30, and miR-21 in anaplastic thyroid carcinoma (ATC).  
In ATC, which derives from the mesenchymal dedifferentiation of the epithelial thyroid cells, 
miR-21 is induced and the miR-200s/miR-30 were downregulated due to the mesenchymal 
phenotype of the cells.  However, when the levels of both miRNAs were restored, changes to 
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the epithelial phenotype were noticed as well as induction of E-cadherin for the miR-200 
family and reduced vimentin expression for miR-30.  Thus this indicated how co-ordinated 
miRNA expression has an important role in preserving cell homeostasis. 
 
It is thought that circulating miRNAs can play important hormone-like roles, especially in 
cell-to-cell communication (Creemers, Tijsen, and Pinto 2012).  Examination of the circulating 
expression of the miR-200 family indicated that both treatments influenced the expression of 
these key miRNAs in the circulation, mainly the miR-200 family.  From these results it appears 
that the changes in the expression of circulating miRNAs broadly reflected changes seen in 
the liver; this poses the question of whether circulating miRNAs could protect other tissues 
from damage related to non-genotoxic carcinogenesis by preventing EMT?  (G. Chen, Wang, 
and Cui 2013) showed that in blood samples from cancer patients, the number of 
tumour-suppressor miRNAs detected was higher than the number of oncogenic miRNAs; the 
abundance of the number of tumour-suppressor miRNAs could prevent metastasis and help 
to the healing process.  Whether these changes in circulating miRNAs as a result of PB 
treatment may have any of these effects on extrahepatic tissues is an intriguing question. 
  
 
Chapter 5 
Effect of miRNA deregulation 
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5.1  INTRODUCTION 
MiRNA deregulation refers to the alterations in miRNA expression, as a consequence of 
changes in the cell due to different events, for example cell/tissue development (Tzur et al. 
2009), diseases such as cancer (Croce 2009), or after exposure to different chemical 
compounds (Koufaris et al. 2012), amongst others.  These changes in miRNA expression can 
affect important molecular events in the cell by targeting a wide variety of mRNAs.  In cancer, 
miRNA can modulate the expression of oncogenes, tumour suppressor genes, and 
transcription factors causing alterations in cell proliferation, apoptosis or tumorigenesis 
(Croce 2009; Garzon, Calin, and Croce 2009); toxicological implications of miRNA deregulation 
(Yokoi and Nakajima 2011) include alteration in the expression of different nuclear receptors 
such as ERα (miR-206, miR-221), PXR (miR-148a), PPARα (miR-21, miR-27b) or PPARγ 
(miR-27a) and drug metabolizing enzymes, like different members of the CYP family such as 
CYP1B1 (miR-27b), CYP3A4 (miR-27b) or CYP2E1 (miR-378) (Yokoi and Nakajima 2011). 
MiRNA can recognize target mRNA by complementarity of the miRNA’s seed region (2nd -8th 
nucleotide, 5’ end) (Moreno-Moya, Vilella, and Simón 2014)  to the 3’ UTR region in the mRNA 
(Lewis, Burge, and Bartel 2005; J. Liu 2008; S. K. Singh et al. 2008),  the miRNA-mRNA duplex.  
These small-RNAs can regulate mRNA expression by two mechanisms (Cloonan 2015; Wahid 
et al. 2010) translational repression and mRNA cleavage.  During protein synthesis, miRNAs 
can interfere with the initiation (Humphreys et al. 2005) or elongation (Nottrott, Simard, and 
Richter 2006) steps of this process;  these small-molecules can also affect mRNA stability by 
shortening the 3’ poly-A tail, which increases the rate of mRNA degradation (Eulalio et al. 
2009).  mRNA cleavage and degradation might take place when the complementarity 
between the miRNA-mRNA duplex is high, allowing the Argonaut proteins to have slicer 
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activity (Meister et al. 2004) , similarly to siRNA, and cleave the target mRNA.  As mentioned 
a high level of homology and complementarity between the miRNA-mRNAs promotes mRNA 
degradation.  In contrast, the presence of mismatches leads to inhibition of mRNA translation 
(R. W. Carthew and Sontheimer 2009).  Because of the reduced size of the recognition 
elements (3’UTR/seed region),  one miRNA can target a wide variety of mRNA and a single 
mRNA target can also be susceptible to a large number of miRNAs (Moreno-Moya, Vilella, and 
Simón 2014).  Compared with other mechanisms of gene expression, miRNAs act before the 
process of protein synthesis and therefore they are involved in fine-tuning gene expression 
or quantitative regulation (Bartel and Chen 2004; Ying et al. 2006). 
This chapter evaluates the effect of miRNA deregulation.  Therefore, changes in gene 
expression of different targets that are related to the key miRNAs identified in Chapter 4 –the 
miR-200 family, miR-30b, and miR-21, are determined.  Continuing with the idea that these 
miRNAs were possibly counteracting EMT (Figure 5.1) and participating as a homeostatic 
control to preserve the epithelial nature of the liver, targeted qPCR was performed to assess 
gene expression of miRNA targets related to EMT:  ZEB1, ZEB2, E-cadherin (miR-200 family), 
Snail-1 (miR-30b), PTEN, MMP-2, and MMP-9 (miR-21) at different days of treatment (1st, 3rd, 
and 28th).   Changes in protein expression of ZEB1, ZEB2, and E-cadherin were also determined 
by immunoblotting. 
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Figure 5.1  Representation of the EMT progression.  During EMT, epithelial cells suffer morphological 
and biochemical changes such as loss of adhesion molecules, resistance to apoptosis, and enhanced 
cell migration.  These changes, enable cells to present a mesenchymal phenotype and possibly invade 
other tissues. 
 
 
5.2  MATERIALS AND METHODS 
5.2.1  Rat liver samples 
Ten-week old male Han Wistar rats were treated with PB (50 and 1000 ppm) or SYN (50, 500, 
and 3000 ppm) for up to 28 days as described in Chapter 2 –2.2.1  Experimental design, animal 
treatment, and sample collection.  Liver tissue samples were harvested at different time 
points and kept at -80°C until used.  Treated liver samples from Days 1st, 3rd, and 28th were 
processed for RNA extraction, as described below. 
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5.2.2  RNA Extraction 
RNA extraction from liver tissue samples (Days 1st, 3rd, and 28th) was performed following the 
protocol described in Chapter 2 –2.2.2 RNA Extraction, using the mirVana PARIS kit (Ambion, 
Life Technologies, USA) under the same conditions. 
 
5.2.3  Reverse Transcription and Quantitative PCR (qPCR) 
Messenger RNA (mRNA) expression analysis was done by qPCR.  It was performed as 
previously described in Chapter 2 –2.2.3  Reverse Transcription and Quantitative Polymerase 
Chain Reaction (qPCR).  The TaqMan Gene Expression Assay probes (20x) used were Zeb-1, 
Zeb-2, Snail-1, E-cadherin, PTEN, MMP-2, MMP-9, and GAPDH as housekeeping control;  
details of these primers are mentioned in Appendix 1. 
 
5.2.4  Protein Extraction 
After tissue harvest (Chapter 2 –Animal Study), liver samples were store at -80°C until used.  
Protein was extracted from small pieces of frozen tissue (  ̴100 mg) that were homogenised 
on ice, without allowing any excessive thaw, using the polytron homogenizer with ice cold 
Lysis Buffer (50 mM Tris-HCl, pH 7.4, 1% v/v Igepal, 0.25% w/v sodium deoxycholate, 150 mM 
NaCl, 1mM EDTA) with 100X Halt Protease Inhibitor Cocktail (Thermo Scientific, Surrey UK).  
After homogenisation, the mixture was centrifuged at 12,000 r.p.m. for 20 minutes at 4°C.  
Supernatant was separated from cellular debris pellet and collected into fresh eppendorf 
tubes.  Protein samples were kept at -80°C for quantification and immunoblotting. 
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5.2.5  Protein Quantification 
Protein quantification was done using the BCA Protein Assay Kit (Thermo Scientific, Surrey 
UK).  The Bicinchoninic Acid (BCA) (Smith et al. 1985) assay is a colorimetric assay based on 
the reduction of Cu2+ to Cu1+, cuprous cation.  This cation, formed as a by-product of the 
reduction of Cu2+ by protein peptide bonds, is detected by the BCA reagent.  The reaction 
between BCA and Cu1+ produces a purple coloured complex that absorbs light at 562 nm;  the 
intensity of the colour developed is proportional to the amount of protein present in each 
sample. 
Samples tested for BCA protein quantification analysis were thawed on ice and diluted (1:40) 
with deionized water;  Bovine Serum Albumin (BSA) standard was diluted for standard curve 
construction (125, 250, 500, 750, 1000, 1500, and 2000 µg/mL).  Ten-µL of each sample or 
BSA standard dilution were pipetted, by triplicate, in 96-well plate; then 200 µL of BCA 
working reagent (prepared according to the manufacturer’s protocol) were added to each 
well.  The plate was incubated at 37°C for 30 minutes and cooled at room temperature.  
Absorbance was measured at 562 nm on the Synergy H1 Plate Reader (Biotek, Potton, UK).  
Protein concentration was calculated by interpolation to the BSA standard curve, dilution 
factors were taken into account for the calculation of the final concentration. 
 
5.2.6  Immunoblotting 
Sample preparation for immunoblotting consisted of mixing 2 µg/µL of protein (as 
determined by BCA assay) with Loading Sample Buffer Laemmeli 2x (Sigma-Aldrich, Germany) 
[4% SDS, 20% v/v glycerol, 10% v/v 2-mercaptoethanol, 0.0004% w/v bromophenol blue, and 
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0.125 M Tris-HCl pH 6.8], for a final volume of 20 µL.  Samples were then mixed thoroughly 
and boiled at 95°C for 5 minutes for protein denaturation, after this samples were centrifuged 
for 5 minutes at 10,000 r.p.m. 
A Sodium-Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used to 
separate denatured protein samples by size.  These were loaded, one per well, into a 8-20 % 
polyacrylamide gel, two more wells were loaded with the Novex Sharp Pre-stained Protein 
Standard (Invitrogen) and a Biotinylated Protein Ladder (Cell Signalling, NEB) to track and 
estimate protein size.  The gel was ran at 60 V, the voltage was increased to 100 V once the 
samples/ladder have passed the stacking gel (20%) and until the end of the resolving gel (8%).  
Once the run was finished, separated proteins were transferred (Towbin, Staehelin, and 
Gordon 1979) from the gel onto a Nitrocellulose membrane (Sigma-Aldrich, Dorset, UK) at 
100 V for 1 hour on ice;  complete transfer of protein samples was confirmed by staining the 
membrane with Ponceau S Red Solution (Sigma-Aldrich, Dorset, UK).  After transfer 
confirmation, the nitrocellulose membrane was washed with PBS-T buffer (PBS-Tween 20 
0.1% v/v) until the staining was removed, then it was blocked for 1 hour at room temperature 
with PBS-T 5% w/v  fat-free milk (blocking buffer) and washed again with PBS-T (10 mL, 3 times, 
10 minutes each).  Primary antibody was added to 5 mL of blocking buffer at the concentration 
suggested by the provider (Table 5.1); secondary antibody (conjugated with Horse Radish 
Peroxidase –HRP) was prepared as the primary antibody but an anti-biotin antibody was 
added to detect the Biotinylated Protein Ladder (Cell Signalling, NEB), both antibodies were 
incubated for 1 hour at room temperature or overnight at 4°C. 
Finally, after incubation with the HRP-secondary antibody and washing with PBS-T buffer 
(10 mL, 3 times, 10 minutes each), the signal was developed using the Luminata Forte HRP 
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substrate (Merck Millipore).  Nitrocellulose membranes were covered with 1 mL of Luminata 
Forte HRP substrate, protein bands were detected and quantified using KODAK Image Station 
4000 MM and normalised to GAPDH.  All samples used for immunoblotting (4 for PB 
treatment and 3 for SYN treatment) were randomly selected.  
 
Table 5.1  Primary and Secondary antibodies used for Immunoblotting. 
Antibody Dilution used 
Provider 
(Product code) 
Zeb-1 1:500 Abcam (ab81972) 
Zeb-2 1:1000 Abcam (ab138222) 
E-cadherin 1:1000 Abcam (ab133597) 
GAPDH 1:1000 Abcam (ab8245) 
Anti-Goat 1:10,000 Abcam (ab97100) 
Anti-Rabbit 1:10,000 Abcam (ab97051) 
Anti-biotin for Biotinylated 
Protein Ladder 
1:1,000 
Cell Signalling, NEB 
(7727) 
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5.3  RESULTS 
5.3.1  ZEB1 and ZEB2, targets of the miR-200 Family 
As mentioned before the miR-200 family comprises five members –miR-200a, miR-200b, 
miR-200c, miR-429, and miR-141 (Feng et al. 2014).  Validated targets of this family are 
transcription factors ZEB1 and ZEB2 (Burk et al. 2008; Bracken et al. 2008), which are 
members of the zinc-finger E-box binding homeobox family and are important regulators of 
EMT (Feng et al. 2014; Bullock et al. 2012).  These transcription factors are not only targets 
but also regulators of the expression of the miR-200 family.  Both ZEB1 and ZEB2 can repress 
the polycistronic transcription of these miRNAs, by binding to specific motifs with different 
locations (Figure 5.2).  For regulation of miR-200c and miR-141, ZEB1 binds to the putative 
promoter region of both miRNAs and in the spaces between each miRNA stem-loop where 
there are two Z-box motifs and four E-box binding motifs (Burk et al. 2008; Feng et al. 2014).  
However, to regulate miR-200a, miR-200b, and miR-429 both transcription factors bind to the 
regulatory E-boxes (Bracken et al. 2008; Feng et al. 2014) (Figure 5.2). 
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Figure 5.2  Regulation of the miR-200 family gene expression by transcription factors –ZEB1/2. 
 
 
Sequencing results showed that this miRNA family was upregulated by PB treatment after 3 
and 28 days of treatment, and by SYN at the 28th day (Chapter 4). 
ZEB1 gene expression, after one-day of treatment with PB, was primarily affected by the 
1000 ppm dose and it was downregulated (Figure 5.3); a pronounced decreased expression 
effect was seen at the third day of treatment with both doses (50 and 1000 ppm), as shown 
in Figure 5.4.  By the 28th day of treatment ZEB1 expression levels were restored to those seen 
for Control samples (Figure 5.5).  SYN treatment only had a significant effect on ZEB1 
expression at the third day of treatment, where this transcriptional factor was downregulated 
at all doses, especially 500, and 3000 ppm (Figure 5.4). 
ZEB2 mRNA expression by PB treatment was also downregulated throughout the treatment, 
from the first day to the 28th in dose-dependent manner (Figures 5.6 –5.8).  On day 28th, a 
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significant downregulation trend was observed (Figure 5.8, P val=0.034).  As seen for ZEB1, 
treatment with the SYN compound mainly had an effect on ZEB2 mRNA expression at the 
third day of treatment (Figure 5.7).  Although the first day of treatment also shows a decrease, 
this was not significant (Figure 5.6) and on the 28th day a downregulation trend was 
determined (Figure 5.6, P val=0.0033). 
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Figure 5.3  Zeb-1 gene expression by qPCR after one-day of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  **p<0.001.  n=5 rats per treatment. 
 
Chapter 5 
[ 125 ] 
 
Z e b -1  D a y -3
F
o
ld
 c
h
a
n
g
e
C
o
n
tr
o
l
P
B
 5
0
 p
p
m
P
B
 1
0
0
0
 p
p
m
C
o
n
tr
o
l
S
Y
N
 5
0
 p
p
m
S
Y
N
 5
0
0
 p
p
m
S
Y
N
 3
0
0
0
 p
p
m
0 .0
0 .5
1 .0
1 .5
*
***
***
*
 
Figure 5.4  Zeb-1 gene expression by qPCR after three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.5  Zeb-1 gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.6  Zeb-2 gene expression by qPCR  after one-day of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way  ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.7  Zeb-2 gene expression by qPCR after three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s  post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.8  Zeb-2 gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
 
 
5.3.2  Snail-1 as target of miR-30b 
The miR-30 family comprises five members –miR-30a, miR-30b, miR-30c, miR-30d, and 
miR-30e, however as shown in Chapter 4, only miR-30b was differentially expressed in miRNA 
sequencing analysis after PB/SYN treatment.  NGS results showed that this miRNA was 
upregulated at the first day of treatment with SYN 3000 ppm and at the third day with PB 
1000 ppm and SYN 50 ppm.  Recently, Snail-1 was showed to be a target of this miRNA (J. 
Zhang et al. 2012).  Snail-1, like ZEB1/2, is  an EMT-related transcription factor that has 
important effects in cell invasive and motility capacities (A Cano et al. 2000).  Gene expression 
results after PB treatment showed lack of changes at the first and 28th days of treatment 
(Figures 5.9 and 5.11), the third day seems to have dose-dependent decrease effect although 
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it was not significant (Figure 5.10).  Snail-1 mRNA response to SYN treatment was similar to 
PB treatment and again on Day 3 dose-dependent decrease trend was seen (Figure 5.10, 
P val=0.0016); Day 28th also showed Snail-1 downregulation with SYN 50 and 3000 ppm 
(Figure 5.11). 
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Figure 5.9  Snail-1 gene expression by qPCR after one-day of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.10  Snail-1 gene expression after by qPCR three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D; line indicates a significant 
linear trend.  One-way ANOVA and Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 
rats per treatment. 
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Figure 5.11  Snail-1 gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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5.3.2.1  Effect of ZEB1/2 and Snail-1 on E-cadherin expression 
E-Cadherin is an adhesion molecule and a very important marker of epithelial cell 
phenotype (Feng et al. 2014; Korpal et al. 2008; Bullock et al. 2012) whose expression in the 
cell is controlled by both ZEB1/2 (Comijn et al. 2001; Spaderna et al. 2008; Burk et al. 2008) 
and Snail-1 (A Cano et al. 2000).  Changes in gene expression of these transcription factors 
may also have an effect in the abundance of E-cadherin.  mRNA expression of this molecule 
was also determined by qPCR, however few statistically significant changes were detected 
(Figures 5.12 –5.14).  PB treatment showed significant upregulation, at the first day with the 
50 ppm dose.  Similar results were seen with SYN treatment where E-cadherin was increased 
at Day 1 and downregulated at Day 28 with SYN 3000 ppm. 
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Figure 5.12  E-cadherin gene expression by qPCR after one-day of treatment with PB (50 and 1000 
ppm) or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA 
and Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.13  E-cadherin gene expression by qPCR after three days of treatment with PB (50 and 1000 
ppm) or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA 
and Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.14  E-cadherin gene expression by qPCR after 28 days of treatment with PB (50 and 1000 
ppm) or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA 
and Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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5.3.3  miR-21 –PTEN and MMPs,  opposite effects? 
MiR-21 is a well-known oncomiR that has been detected in different types of cancer 
(Krichevsky and Gabriely 2009), in EMT overexpression of this miRNA leads to changes in cell 
migration, proliferation, and invasion (Krichevsky and Gabriely 2009).  PTEN is a well-known 
tumour suppressor (Goberdhan and Wilson 2003) with phosphatase activity that inhibits 
cancer-promoting proteins.  Mutated PTEN not only has lost its normal function allowing 
cancer-promoting proteins to act but also interferes with the activity of normal PTEN (Papa 
et al. 2014).  In hepatocellular carcinoma (HCC),  PTEN has been identified as a direct target 
of miR-21; modulation in the expression of this miRNA affected PTEN expression and 
contributed to the presence of EMT-related characteristics in the cell (Fanyin Meng et al. 
2007). 
NGS analysis of miR-21 after PB/SYN treatment (Chapter 4) showed that this miRNA was 
upregulated at the third day of treatment with PB 1000 ppm and all doses of SYN. 
Different doses of PB showed little effect on PTEN mRNA expression, the third day of 
treatment seemed to have dose-dependent decrease, although this effect was not significant 
(Figure 5.16).  The SYN compound had similar results on PTEN as PB, Day-3 also showed a 
decreasing effect especially with the 3000 ppm dose (Figure 5.16). 
 
Chapter 5 
[ 133 ] 
 
P T E N   D a y -1
F
o
ld
 c
h
a
n
g
e
C
o
n
tr
o
l
P
B
 5
0
 p
p
m
P
B
 1
0
0
0
 p
p
m
C
o
n
tr
o
l
S
Y
N
 5
0
 p
p
m
S
Y
N
 5
0
0
 p
p
m
S
Y
N
 3
0
0
0
 p
p
m
0 .0
0 .5
1 .0
1 .5
 
Figure 5.15  PTEN gene expression by qPCR after one-day of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.16  PTEN gene expression by qPCR after three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.17  PTEN gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
 
The matrix metalloproteases (MMPs) is a family of zinc-dependent endopeptidases that can 
degrade different components of the extracellular matrix (Visse and Nagase 2003), this 
degradation can in consequence promote endothelial cell mobility.  MMPs are involved in 
tumour growth, invasiveness, and metastasis (Egeblad and Werb 2002).  MMP-2 and MMP-9 
are not direct targets of miR-21, yet the expression of these MMPs is positive modulated by 
miR-21, as reported in HCC and HepG2 cells, where  inhibition of miR-21 reflected in inhibition 
of both MMP-2/9 and upregulation of PTEN (Zhu et al. 2012).  MMPs mRNA expression was 
assessed to determine if upregulation of miR-21 had an effect on this molecules. 
Expression of MMP-2 mRNA with PB treatment was downregulated across the experiment 
compared to control, on the first day of treatment both doses (50 and 1000 ppm) showed this 
effect (Figure 5.18); on the third day a MMP-2 downregulation trend was observed 
(Figure 5.19, P val=0.03), and finally at the 28 day PB 50 ppm was significantly decreased.  
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Exposure to the SYN compound also reduced the expression of MMP-2 to the same level on 
days 1 and 28 (Figures 5.18 and 5.20, respectively) and dose-dependent downregulation trend 
was observed at the third day of treatment (Figure 5.19, P val=0.009). 
MMP-9 gene expression was similar to MMP-2; PB treatment downregulated this 
metalloprotease to a similar magnitude on days 3rd and 28th (Figures 5.21 and 5.22, 
respectively).  MMP-9 after treatment with SYN also showed decreased expression on day 3 
(Figure 5.21) and a dose-dependent decrease on the 28th day of treatment (Figure 5.22). 
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Figure 5.18  MMP-2 gene expression by qPCR after one-day of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.19  MMP-2 gene expression by qPCR after three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D, line indicates a significant 
linear trend.  One-way ANOVA and Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 
rats per treatment. 
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Figure 5.20  MMP-2 gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.21  MMP-9 gene expression by qPCR after three days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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Figure 5.22  MMP-9 gene expression by qPCR after 28 days of treatment with PB (50 and 1000 ppm) 
or SYN (50, 500, and 3000 ppm).  Mean fold change relative to Control ± S.D.  One-way ANOVA and 
Dunnett’s post hoc test,  *p<0.05, **p<0.001, ***p<0.0001.  n=5 rats per treatment. 
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5.3.4  Immunoblotting of miR-200 targets 
Due to the striking effects seen in ZEB1/2 mRNA expression analysis, protein expression of 
these transcription factors was also assessed by immunoblotting. 
After one-day of treatment with PB (50 and 1000 ppm) no effects were detected on ZEB1 
protein expression (Figure 5.23), at the 3rd day of treatment this compound showed 
dose-dependent protein decrease of ZEB1 (Figure 5.24) consistent with the mRNA expression 
analysis (Figure 5.4).  Finally, dose-dependent decrease trend on the last day of treatment 
(Figure 5.25, P val=0.035) was also observed.  SYN treatment also had no effects on ZEB1 at 
Day 1 (Figure 5.23) and like the PB treatment, the 28th day showed a dose-dependent trend 
(Figure 5.25, P val < 0.0001) as well. 
ZEB2 protein was also unaffected by PB at the beginning of the treatment (Figure 5.26);  PB 
1000 ppm significantly increased this transcription factor on the third day of treatment 
(Figure 5.27) and on Day 28th a dose-dependent decrease trend was observed (Figure 5.28, 
P val=0.0004).  Very similar results were seen with SYN treatment, where the first and third 
day of treatment had no significant changes (Figures 5.26 and 5.27, respectively), the 28th day 
showed dose-dependent downregulation trend (Figure 5.28, P val=0.0005) with the main 
effect seen with SYN 3000 ppm. 
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Figure 5.23  Immunoblotting of Zeb-1 after one-day of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control.  One-way ANOVA 
and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001.  n= 3-4 rats (1 lane per rat) 
 
 
Figure 5.24  Immunoblotting of Zeb-1 after three days of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm)  [A].  (B) Graphs show the mean fold change from Control.  One-way ANOVA 
and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. n= 3-4 rats (1 lane per rat) 
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Figure 5.25  Immunoblotting of Zeb-1 after 28 days of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control, line indicates a 
significant linear trend.  One-way ANOVA and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. 
n= 3-4 rats (1 lane per rat) 
 
Figure 5.26  Immunoblotting of Zeb-2 after one-day of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control.  One-way ANOVA 
and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. n= 3-4 rats (1 lane per rat). 
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Figure 5.27  Immunoblotting of Zeb-2 after three days of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control.  One-way ANOVA 
and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. n= 3-4 rats (1 lane per rat). 
 
Figure 5.28  Immunoblotting of Zeb-2 after 28 days of treatment with PB (50 and 1000 ppm) or SYN 
(50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control, line indicates a 
significant linear trend.  One-way ANOVA and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. 
n= 3-4 rats (1 lane per rat). 
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As mentioned before, altered expression of ZEB1/2 (Wong, Gao, and Chan 2014) has been 
related to repression of E-cadherin and EMT promotion in breast cell lines (Eger et al. 2005), 
and in the early development of zebrafish (Vannier et al. 2013).  Protein expression of 
E-cadherin was also analysed (Figures 5.29 and 5.30), PB treatment did not significantly affect 
this adhesion molecule.  SYN 3000 ppm significantly increased E-cadherin protein expression 
at the third day of treatment (Figure 5.29), however it appears that the same dose at the 28th 
day of treatment had the opposite effect, although this was not significant (Figure 5.30). 
 
 
Figure 5.29  Immunoblotting of E-cadherin after 3 days of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control.  One-way 
ANOVA and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. n= 3-4 rats (1 lane per rat) 
 
Chapter 5 
[ 143 ] 
 
 
Figure 5.30  Immunoblotting of E-cadherin after 28 days of treatment with PB (50 and 1000 ppm) or 
SYN (50, 500, and 3000 ppm) [A].  (B) Graphs show the mean fold change from Control.  One-way 
ANOVA and Dunnett’s post hoc test; *p<0.05, **p<0.01, ***p<0.001. n= 3-4 rats (1 lane per rat) 
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5.4  DISCUSSION 
Chapter 4 shows which miRNAs were identified by miRNA-seq analysis, in the rat liver, as 
differentially expressed after treatment with PB (50 and 1000 ppm) or SYN (50, 500 and 
3000 ppm) for up to 28 days.  From this set, we selected a group of key miRNAs (miR-200 
family, miR-30b, and miR-21), that are related to EMT by either preventing this process 
(miR-200s and miR-30b) or promoting it (miR-21).  It seems that co-expression of these 
miRNAs at the third day of treatment, could be an early homeostatic response of the cell to 
preserve an epithelial phenotype.  Because of this we decided to evaluate gene expression of 
targets related to the key miRNAs, ZEB1/2, E-cadherin for the miR-200 family, Snail-1 for 
miR-30b, and for miR-21 PTEN, MMP-2/9. 
Treatment with PB and SYN induced mRNA expression changes in the liver of proteins related 
to EMT.  ZEB1/2 are transcription factors whose expression is regulated by the miR-200 
family (Burk et al. 2008; Feng et al. 2014).  Acute exposure to PB (50 and 1000 ppm) caused a 
dose-dependent decrease in ZEB1 gene expression (Figures 5.3 and 5.4), however on the 28th 
day ZEB1 mRNA levels recover to control values (Figure 5.5).  SYN treatment only 
downregulated ZEB1 gene expression on the 3rd day of treatment, for the other two days (1st 
and 28th) mRNA level of this transcription factor were similar to control (Figures 5.3-5.5).  Both 
compounds decreased ZEB2 expression in dose-dependent fashion across the treatment 
(Figures 5.6-5.8), primarily at the third day of treatment.  (Koufaris et al. 2013) previously 
explored the effect of PB (1000 ppm) on ZEB1/2 expression, however this was only done for 
protein expression.  In their study, these molecules were decreased after 14 days of 
treatment.  Our results show that downregulation of ZEB1 proteins expression with PB 
treatment was detected at the 3rd and 28th days (Figures 5.25-5.26).  SYN treatment also 
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altered this molecule; it was downregulated at the 28th day in a dose-dependent manner, with 
the highest dose (SYN 3000 ppm) [Figure 5.25].  ZEB2 protein was also downregulated with 
both PB and SYN after 28 days of treatment (Figure 5.28);  but the third day of treatment 
showed an upregulation of this protein with both compounds (PB 1000 ppm and SYN 3000 
ppm). According to (Burk et al. 2008),  ZEB1 is a predominant target of the miR-200 family and 
this could be the reason for decreased  ZEB1 protein and an increase in ZEB2 protein 
expression at the 3rd day of treatment.  Like ZEB1/2,  Snail-1 is also an important transcription 
factor related to EMT (Bullock et al. 2012).  Transient hepatic changes in Snail-1 mRNA 
expression were mainly detected at the third day of treatment, where it was downregulated 
in a dose-dependent manner.  Although Snail-1 has not been related to PB treatment 
previously, it has been demonstrated to be negatively regulated by miR-30 (J. Zhang et al. 
2012). 
E-Cadherin is a cell-to-cell adhesion molecule and an important marker of epithelial cells, 
downregulation of this molecule is related to the establishment of EMT (Kalluri and Weinberg 
2009).  It has been reported that  ZEB1/2  (Galván et al. 2015; Eger et al. 2005)  and  Snail-1  
(A Cano et al. 2000; Galván et al. 2015) can repress E-cadherin expression.  Although previous 
studies have not found changes in protein expression of this adhesion molecule after a 14-day 
treatment with PB 1000 ppm  (Koufaris et al. 2013), our results showed a few changes in gene 
expression.  However protein expression was induced after 3 days of treatment with SYN 
3000 ppm;  with PB 1000 ppm, the protein expression was slightly induced but not significant, 
in agreement with ZEB1/2 and Snail-1 downregulation at this time point.  Lack of changes in 
E-cadherin might be due to redistribution of this molecule from the cytoplasm to the 
nucleus (B. Nawrocki et al. 1998; Calvisi 2004).  In bronchopulmonary carcinomas, changes in 
E-cadherin have not been seen early in the invasion process  (B. Nawrocki et al. 1998). 
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Beside transcription factors, oncogenes and tumour suppressor genes are also susceptible to 
miRNA modulation.  PTEN is a well-known tumour suppressor that has been identified as a 
direct target of miR-21 in HCC  (Fanyin Meng et al. 2007; Zhu et al. 2012);  due to the transient 
expression of this miRNA at the 3rd day of treatment with both PB and SYN, changes in PTEN 
gene expression were assessed by qPCR.  PTEN mRNA expression was downregulated at the 
3rd day of treatment with both compounds, although significant results were only detected 
with SYN treatment (Figure 5.16).  In colorectal cancer, PTEN downregulation favoured 
EMT-related changes such as cell invasion and migration (Bowen et al. 2009).  (Fanyin Meng 
et al. 2007) showed that, in HCC, PTEN repression by miR-21 enhances EMT by upregulation 
of MMP-2/9;  which are part of the metalloproteases family with the ability to hydrolyze and 
degradate different components of the extracellular matrix (Visse and Nagase 2003) 
contributing to cancer development and metastasis (Egeblad and Werb 2002).  Contrary to 
what we expected MMP-2/9 gene expression was downregulated by treatment with PB/SYN 
throughout the experiment (Figures 5.18-5.22). 
Overall these result show that PB and SYN treatment exert similar effects on the molecules 
studied in this chapter.  Most of the changes in these targets were detected at the third day 
of treatment and occurred in a dose-dependent manner.  These gene expression results are 
consistent with an inverse association at this time point with expression of the key miRNAs 
identified in Chapter 4. 
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6.1  RNA-seq for miRNA analysis. 
One of the aims of this project is to determine how miRNA expression could change after 
exposure to NGTX carcinogens like PB and possibly the SYN 546 compound.  Following this 
and as mentioned in Chapter 1 –Introduction, despite its cost or technical specificities 
(Chapter 3)  RNA-seq analysis is considered a valuable approach for miRNA expression 
analysis and profiling  (Pritchard, Cheng, and Tewari 2012).  This tool has enabled us to 
perform a richer and deeper analysis to get a better understanding of how miRNAs behave 
under different conditions.  Merits of this technique include not only miRNA expression 
profiling but also, due to its high levels of sensitivity, identification of isomiRNAs (length or 
sequence variants of a miRNA (Neilsen, Goodall, and Bracken 2012)), prediction of putative 
novel miRNAs, and can also help to predict potential miRNA target molecules (Motameny et 
al. 2010).  As shown in Chapter 3 –miRNA-seq analysis, after a time/dose-dependent 
treatment with PB (50 and 1000 ppm) or SYN (50, 500, and 3000 ppm) around 200 known 
miRNAs were detected on each treatment and time of treatment.  Other miRNA profiling 
studies have been performed using the miRNA microarray platform (Koufaris et al. 2013), 
under similar conditions (PB treatment);  when comparing to those miRNAs significantly 
expressed, NGS data was able to detect new PB-related miRNAs –miR-429, miR-21 and 
miR-30b.  Because of this different target mRNAs can be related to PB treatment in the liver 
–Snail-1 and PTEN  (Chapters 3 and 4). 
As mentioned in Chapter 3, sequencing bioinformatics analysis was divided into two 
segments: known and novel miRNAs.  Regarding the latter, we were able to detect three 
putative novel miRNAs (Candidates –10, 64, and 40) that are homologous to miR-4488, a 
miRNA previously described in human (Jima et al. 2010) and gorilla (Dannemann et al. 2012); 
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acute high doses of PB (1000 ppm, Day 1) induced Candidate-10 and chronic exposure to 
lower PB doses (50 ppm) induced Candidates –64 and 40 after 3 and 28 days of treatment, 
respectively.  A putative polymorphic isomiRNA of miR-6215 (Fanxue Meng et al. 2012) 
(Candidate –28) in the liver was also identified;  miR-6215 was first described in kidney tissue.  
Identification and further study of these sequences may bring new information about the 
effects of PB (and PB-like compounds) exposure in the rat liver tissue.  To our knowledge this 
is the first work where PB miRNA profiling analysis has been performed using NGS and where 
PB related putative novel miRNAs have been detected.  In this study, the miRNA-seq approach 
enabled a more detailed exploration of miRNAome and their response to hepatotoxicants. 
 
 
6.2  Is the SYN 546 compound a PB-like compound? 
To determine if the SYN 546 compound could be acting as a PB-like carcinogen, we first looked 
at the expression of the Cyp2b subfamily and also assessed the effect of the treatment on the 
liver weight.  First, mRNA expression of both Cyp2b1 and Cyp2b2, which are known to be 
inducible by PB treatment (Czekaj 2000; Z.-Y. Chen and Eaton 1993) was determined.  These 
drug metabolizing enzymes were upregulated by PB and SYN in a time and dose-dependent 
manner.  Cyp induction associated to PB treatment has been reported to be mediated by 
indirect activation of the nuclear receptor CAR (Omiecinski et al. 2011; Elcombe et al. 2014); 
previous reports (Pustylnyak, Gulyaeva, and Lyakhovich 2005) have shown that PB-like 
compounds, i.e. triphenyldioxane, can also upregulate Cyp2b1/2 expression via CAR 
activation.  Even though we did not assess changes in the expression of this receptor, this 
could be the mechanism by which SYN is promoting Cyp2b induction.  Phenotypic changes in 
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the liver, such as weight increase are also characteristic of PB treatment in the rat;  liver 
enlargement includes hepatocyte hyperplasia and hypertrophy (P. Carthew, Edwards, and 
Nolan 1998; Elcombe et al. 2014).  Results in Chapter 2 showed that for rats treated with PB, 
liver weight was significantly increased, dose-dependently, after 3 and 28 days of treatment;  
SYN treatments showed similar results at the same time points, although only the 3rd day was 
significant.  Together, these results are consistent with the known mode of action and toxicity 
of PB (Elcombe et al. 2014) in the liver. 
Deregulated hepatic miRNAs were also examined after treatment with PB or SYN (Chapter 4) 
to determine any similarities between them.  In this case, treatment with these compounds 
produced changes in the expression of different miRNAs, although some of these changes 
were sometimes transient and in others persistent, most variations in miRNA expression were 
detected at the 3rd day of treatment (especially by SYN), moreover major similarities in miRNA 
expression were seen by the 28th day.  When comparing which of these small-RNAs were 
consistent between treatments and time of exposure, we found that the miR-200 family, 
miR-21, and miR-30b were mainly affected under experimental conditions.  As mentioned 
before, Day 3 seems to be important, since these key miRNAs were detected at this time 
point, and a continuous presence of the miR-200 family was also seen on Day 28. 
These miRNA expression results in conjunction with the Cyp and liver weight data gives us 
more evidence that SYN is behaving similar to a PB-like compound. 
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6.3  Is the liver trying to keep things under control? 
As mentioned before, at the 3rd day of treatment three key miRNAs were detected with both 
compounds, the miR-200 family (miR-200a/b, PB 1000 ppm), miR-21 (PB 1000 ppm and SYN 
50, 500, and 3000 ppm), and miR-30b (PB 1000 ppm and SYN 50 ppm).  This group of 
small-RNA are related to EMT in two ways, by either preventing it (miR-200 and miR-30b) or 
promoting its development (miR-21).  As commented in Chapter 4, EMT refers to a process 
where epithelial cells lose their differentiated characteristics such as cell adhesion molecules, 
to acquire mesenchymal components –motility, invasiveness, and apoptosis resistance.  
Although this is an important event during embryonic development, it is also relevant in the 
metastatic process (A. Singh and Settleman 2010).  Following the idea that by Day 3 the liver 
might be trying to keep control of the homeostasis of the tissue, to then preserve the 
epithelial nature of the hepatocyte, we evaluated the expression of those mRNAs targeted by 
the group of key miRNAs.  Upregulation in the expression of the miR-200 family, was 
associated with downregulation of targets ZEB1 and ZEB2 –both mRNA and protein 
(Chapter 5);  similar results were shown for miR-30b.  Here an increase in the expression of 
this miRNA saw a decrease in mRNA expression of its target Snail-1.  Both ZEB1/2 and Snail-1, 
are transcription factors that when upregulated target the adhesion molecule E-cadherin, an 
important epithelial marker (Kalluri and Weinberg 2009).  Due to the upregulation of the 
miR-200 family and miR-30b, E-cadherin was protected as very little changes were detected 
(mRNA and protein, Chapter 5) after treatment with PB/SYN.  Similar results were seen in 
non-small lung cancer cell lines (Kumarswamy et al. 2012), where increase expression of 
miR-30a led to decreased in the expression of Snail-1 and a positive expression of E-cadherin; 
this also altered cell morphology and reduced invasiveness of this cell line.  On the other hand, 
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upregulation of miR-21, a well-known oncomiR (Krichevsky and Gabriely 2009), was also 
associated with downregulation of PTEN mRNA, a target of this miRNA (Fanyin Meng et al. 
2007) and tumour suppressor (Goberdhan and Wilson 2003); opposite to the miR-200 family 
and miR-30b, this event contributes to the establishment of the EMT process . 
As shown in Figure 6.1, co-expression of these key miRNAs is evidence of how the liver is 
possibly trying to preserve homeostatic control and the characteristic phenotype of the 
hepatocytes by balancing the effect of miR-21 overexpression with the induction of miR-30b 
and the miR-200 family by the 3rd day of exposure, and the miR-200 family at the 28th day of 
treatment, for longer treatments. 
 
 
Figure 6.1  Scheme of miRNA counteraction of EMT after three days of treatment with PB or SYN. 
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6.4  CONCLUSIONS 
In this project, NGS analysis of miRNA expression proved to be a valuable tool not only for 
miRNA profiling but also to detect putative novel miRNAs after a time/dose-dependent 
treatment with NGTX carcinogens. 
The SYN 546 compound caused changes in miRNA expression and in drug metabolizing 
enzymes similarly to the prototype NGTX carcinogen –PB.  These similarities were also 
reflected in the expression of the mRNA miRNA-targets like ZEB1/2, Snail-1, E-cadherin, and 
PTEN in the rat liver tissue.  However, circulating miRNA expression was higher for SYN than 
PB. 
MiR-30b and miR-21 (3rd day of treatment), and the miR-200 family (3rd and 28th days of 
treatment) are affected by treatment with NGTX carcinogens and are effectors of the 
epithelial-to-mesenchymal transition in the rat liver. 
 
6.5  FUTURE WORK 
Further analyses (bioinformatics and experimental) on the putative miRNAs detected 
(Chapter 4) should be performed to 1) confirm the existence of these sequences as novel 
homologous miRNAs (Candidates –10, 64, and 40) and putative isomiRNAs (Candidate –28), 
and 2) to annotate them into the miRBase repository, following the criteria for miRNA 
expression and biogenesis established by(Ambros et al. 2003). 
It is also of great interest to determine putative targets of these miRNAs and establish any 
possible relationship to treatment with NGTX carcinogens such as PB or SYN in the liver. 
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Very little is known about the function and targets of both miR-6215 and miR-4488, which 
were recently described from sequencing data (Dannemann et al. 2012; Fanxue Meng et al. 
2012).  As mentioned before, these miRNAs (miR-6215 and putative homologous sequences 
for miR-4488) were detected in the rat liver after PB/SYN treatment, it would be of interest 
to determine their relationship with the liver (tissue or cells), NGTX carcinogens, EMT, and 
putative targets. 
 
After evaluating the expression of circulating miRNAs, miR-200 family, in plasma samples.  It 
would be interesting to determine if these miRNAs have any effect in distant tissues.  Could 
these circulating miRNAs protect different tissues/organs from damages related to NGTX 
carcinogens by preventing EMT? 
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Appendices 
 
 
 
  
Appendix-1.  qPCR Taqman primers 
 
Primers used for qPCR analysis were purchased from the TaqMan Gene Expression Assay for 
mRNA and TaqMan Small RNA Assay for miRNAs  (Applied Biosystems, Foster City, CA, USA). 
 
Table A1.1  Taqman qPCR probes used for mRNA and miRNA studies. 
 
mRNA  miRNA 
Gene Taqman assay ID  miRNA Taqman assay ID 
CYP2B1 Rn01457875_m1  miR-200a 000502 
CYP2B1 Rn02786833_m1  miR-200b 001800 
E-cadherin Rn00580109_m1  miR-429 001077 
GAPDH Rn01775763_g1  cel-miR-39 000200 
Snail-1 Rn 00441533_g1    
Zeb-1 Rn01538408_m1    
Zeb-2 Rn00497196_m1    
MMP-2 Rn01538170_m1    
MMP-9 Rn00579162_m1    
PTEN Rn00477208_m1    
 
  
Appendix-2.  Day-1 known miRNAs 
 
List of all known miRNAs detected at the 1st day of treatment by miRanalyzer.  miRNAs listed 
are ordered by treatment and ranked by P Adj values. 
 
PB 50 ppm_______________________________________________________ 
miRNA ID FC P Adj 
rno-miR-127-3p Inf 0.1074 
rno-miR-31a-5p 1.09 1 
rno-miR-34a-5p 0.00 1 
rno-miR-190a-5p 0.00 1 
rno-miR-103-3p 1.17 1 
rno-miR-199a-5p 1.07 1 
rno-miR-3068-3p 1.16 1 
rno-miR-872-3p 1.34 1 
rno-miR-21* 0.91 1 
rno-miR-664-3p 0.00 1 
rno-miR-101b-3p 0.99 1 
rno-miR-191a-5p 1.07 1 
rno-miR-7a-5p 1.28 1 
rno-miR-203a-3p 1.14 1 
rno-miR-28-3p 1.01 1 
rno-miR-203b-3p 0.84 1 
rno-miR-192-3p 1.14 1 
rno-miR-27a-3p 0.98 1 
rno-miR-27b-3p 1.09 1 
rno-miR-30d-5p 1.14 1 
rno-miR-152-3p 1.19 1 
rno-miR-142-5p 0.91 1 
rno-miR-181d-5p 0.00 1 
rno-let-7c-5p 1.03 1 
rno-miR-146a-5p 1.25 1 
rno-miR-31a-3p 0.00 1 
rno-miR-194-5p 0.98 1 
rno-miR-22-5p 1.19 1 
miRNA ID FC P Adj 
rno-miR-497-5p 1.08 1 
rno-miR-542-3p 0.49 1 
rno-miR-335 0.83 1 
rno-miR-223-3p 0.45 1 
rno-miR-28-5p 1.41 1 
rno-miR-6329 0.69 1 
rno-miR-139-5p 1.62 1 
rno-let-7f-1-3p 0.47 1 
rno-miR-29a-3p 0.99 1 
rno-miR-322-3p 0.82 1 
rno-miR-152-5p 0.00 1 
rno-miR-142-3p 0.90 1 
rno-miR-192-5p 1.14 1 
rno-miR-320-3p 0.99 1 
rno-miR-126a-5p 1.03 1 
rno-miR-219-5p 0.00 1 
rno-miR-20a-5p 0.97 1 
rno-let-7a-1-3p... 0.85 1 
rno-miR-423-5p 1.03 1 
rno-mir-21* 0.91 1 
rno-miR-425-5p 1.62 1 
rno-miR-301a-3p 0.89 1 
rno-miR-30e-5p 0.90 1 
rno-miR-10a-5p 0.97 1 
rno-miR-22-3p 0.92 1 
rno-miR-98-5p 0.94 1 
rno-miR-143-3p 1.16 1 
rno-miR-195-3p 0.00 1 
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miRNA ID FC P Adj 
rno-miR-122-3p 1.05 1 
rno-miR-30b-5p 0.99 1 
rno-miR-145-3p 0.79 1 
rno-miR-450a-5p 0.92 1 
rno-miR-339-3p 1.15 1 
rno-miR-1843-5p 1.66 1 
rno-miR-126a-3p 0.99 1 
rno-miR-3577 Inf 1 
rno-miR-17-5p 1.14 1 
rno-miR-128-3p 3.16 1 
rno-miR-802-5p 1.07 1 
rno-miR-181a-2-... 0.00 1 
rno-miR-505-3p 0.00 1 
rno-miR-181a-5p 1.11 1 
rno-miR-185-5p 0.00 1 
rno-miR-199a-3p 0.98 1 
rno-miR-30e-3p 1.10 1 
rno-let-7b-5p 0.95 1 
rno-miR-872-5p 0.92 1 
rno-miR-130a-3p 0.98 1 
rno-miR-150-5p 1.36 1 
rno-miR-195-5p 1.20 1 
rno-miR-101a-3p 0.95 1 
rno-miR-145-5p 0.92 1 
rno-miR-122-5p 1.08 1 
rno-miR-466c-5p 0.00 1 
rno-miR-21-5p 1.00 1 
rno-miR-191a-3p 0.00 1 
rno-miR-140-3p 1.15 1 
rno-miR-30b-3p 0.00 1 
rno-miR-340-5p 1.08 1 
rno-miR-141-3p 1.03 1 
rno-miR-338-3p 0.00 1 
rno-miR-27b-5p 0.00 1 
rno-miR-330-5p 0.00 1 
rno-miR-24-3p 1.01 1 
rno-miR-30d-3p 0.81 1 
rno-miR-30c-5p 0.92 1 
rno-miR-182 1.29 1 
rno-let-7d-3p 1.02 1 
rno-miR-451-5p 0.63 1 
rno-miR-1839-5p 1.34 1 
rno-miR-92a-3p 1.09 1 
rno-miR-184 0.00 1 
rno-miR-16-5p 1.12 1 
miRNA ID FC P Adj 
rno-let-7b-3p 1.07 1 
rno-miR-188-5p 0.00 1 
rno-miR-326-3p 0.00 1 
rno-miR-140-5p 0.00 1 
rno-miR-455-3p 0.00 1 
rno-miR-582-3p 0.00 1 
rno-miR-378a-3p 1.19 1 
rno-miR-186-5p 0.90 1 
rno-miR-200b-3p 0.92 1 
rno-miR-200a-5p 0.00 1 
rno-miR-221-3p 0.48 1 
rno-miR-466b-2-... 0.00 1 
rno-miR-23a-3p 1.04 1 
rno-miR-3559-5p 1.97 1 
rno-miR-802-3p 1.18 1 
rno-miR-181b-5p 1.44 1 
rno-miR-21-3p 1.27 1 
rno-miR-674-3p 0.00 1 
rno-miR-374-5p 0.52 1 
rno-miR-30a-5p 0.96 1 
rno-miR-328a-3p 0.00 1 
rno-let-7i-5p 0.96 1 
rno-miR-23b-3p 0.95 1 
rno-miR-361-5p 0.93 1 
rno-miR-19a-3p 0.72 1 
rno-miR-204-5p 1.56 1 
rno-miR-144-5p 1.50 1 
rno-miR-455-5p 1.42 1 
rno-miR-200a-3p 0.99 1 
rno-miR-99a-3p 0.81 1 
rno-let-7a-5p 1.02 1 
rno-miR-25-3p 1.18 1 
rno-miR-378a-5p 1.28 1 
rno-let-7d-5p 0.96 1 
rno-miR-3585-5p Inf 1 
rno-miR-339-5p 1.66 1 
rno-miR-181c-5p 1.11 1 
rno-miR-125b-2-... 0.90 1 
rno-miR-29b-3p 1.38 1 
rno-miR-652-3p 0.00 1 
rno-miR-106b-5p 0.87 1 
rno-miR-107-3p 1.00 1 
rno-miR-30a-3p 1.05 1 
rno-miR-429 1.53 1 
rno-miR-6215 0.80 1 
Appendix –2 
[ 184 ] 
miRNA ID FC P Adj 
rno-miR-374-3p 0.00 1 
rno-miR-423-3p 1.18 1 
rno-miR-93-5p 0.90 1 
rno-miR-144-3p 0.62 1 
rno-miR-33-5p 0.00 1 
rno-miR-361-3p 0.00 1 
rno-miR-210-3p 1.71 1 
rno-miR-151-5p 0.95 1 
rno-miR-193-3p 0.85 1 
rno-miR-194-3p 0.75 1 
rno-miR-365-3p 1.06 1 
rno-miR-214-3p 0.00 1 
rno-miR-99a-5p 0.99 1 
rno-miR-181a-1-... 1.12 1 
rno-miR-322-5p 0.80 1 
rno-miR-24-2-5p 1.41 1 
rno-miR-30c-2-3... 1.04 1 
rno-let-7f-2-3p 1.54 1 
rno-miR-148b-5p 0.00 1 
rno-miR-26b-5p 1.05 1 
rno-miR-26a-3p 0.33 1 
rno-let-7f-5p 1.00 1 
rno-miR-351-5p 1.17 1 
rno-miR-34c-5p 0.66 1 
miRNA ID FC P Adj 
rno-miR-484 Inf 1 
rno-miR-151-3p 1.29 1 
rno-miR-15b-5p 0.93 1 
rno-miR-32-5p 0.74 1 
rno-miR-29c-3p 1.19 1 
rno-miR-342-3p 0.00 1 
rno-miR-100-5p 1.12 1 
rno-let-7e-5p 0.82 1 
rno-miR-125b-5p 0.99 1 
rno-miR-92a-1-5... 0.57 1 
rno-miR-345-5p 0.00 1 
rno-miR-146b-5p 1.53 1 
rno-miR-19b-3p 0.80 1 
rno-miR-30c-1-3... 0.77 1 
rno-miR-26a-5p 0.95 1 
rno-miR-99b-5p 1.04 1 
rno-miR-148b-3p 1.02 1 
rno-miR-183-5p 2.26 1 
rno-miR-375-3p 1.09 1 
rno-miR-532-5p 1.39 1 
rno-miR-125a-5p 0.93 1 
rno-miR-671 0.00 1 
rno-miR-511-3p 0.00 1 
PB 1000 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-6215 0.32 9.78E-48 
rno-miR-378a-3p 1.40 0.0002 
rno-miR-127-3p Inf 0.002 
rno-miR-183-5p 3.57 0.063 
rno-miR-192-5p 1.30 0.134 
rno-miR-140-3p 1.48 0.134 
rno-miR-203a-3p 1.59 0.143 
rno-miR-182 1.30 0.143 
rno-miR-3559-5p 2.02 0.143 
rno-miR-802-3p 1.54 0.143 
rno-miR-200c-3p Inf 0.143 
rno-miR-25-3p 1.41 0.143 
rno-miR-210-3p 2.66 0.143 
rno-miR-484 Inf 0.143 
miRNA ID FC P Adj 
rno-miR-151-3p 1.35 0.143 
rno-miR-125a-5p 0.79 0.143 
rno-miR-152-3p 1.71 0.179 
rno-miR-184 2.23 0.182 
rno-miR-335 0.52 0.185 
rno-miR-30e-5p 0.80 0.192 
rno-miR-375-3p 1.46 0.199 
rno-miR-203b-3p 2.44 0.271 
rno-miR-30b-3p 4.97 0.271 
rno-miR-30e-3p 1.43 0.281 
rno-miR-3068-3p 0.57 0.325 
rno-miR-505-3p 3.22 0.325 
rno-miR-92a-3p 1.15 0.325 
rno-miR-181a-1-... 2.47 0.325 
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miRNA ID FC P Adj 
rno-miR-31a-3p 13.13 0.358 
rno-miR-150-5p 1.44 0.377 
rno-miR-186-5p 0.80 0.377 
rno-miR-214-3p 1.46 0.377 
rno-miR-322-5p 0.75 0.377 
rno-miR-19b-3p 0.73 0.377 
rno-miR-30b-5p 0.84 0.390 
rno-mir-425* Inf 0.390 
rno-miR-23a-3p 0.78 0.390 
rno-miR-374-3p 1.48 0.390 
rno-miR-26a-5p 0.84 0.390 
rno-miR-27b-3p 1.18 0.399 
rno-miR-15b-5p 0.78 0.399 
rno-miR-3559-3p Inf 0.429 
rno-miR-339-3p 2.15 0.438 
rno-miR-181b-5p 1.71 0.438 
rno-miR-340-5p 1.41 0.443 
rno-miR-331-3p Inf 0.443 
rno-miR-142-5p 0.83 0.454 
rno-miR-143-3p 1.13 0.454 
rno-miR-802-5p 1.22 0.454 
rno-let-7d-5p 0.80 0.454 
rno-miR-125b-2-... 1.37 0.454 
rno-miR-497-5p 1.22 0.469 
rno-miR-1249 Inf 0.469 
rno-miR-499-5p Inf 0.469 
rno-miR-195-5p 1.16 0.524 
rno-miR-425-5p 1.51 0.544 
rno-miR-6329 2.65 0.557 
rno-miR-22-3p 0.88 0.557 
rno-miR-145-5p 0.84 0.557 
rno-miR-30a-3p 1.29 0.557 
rno-miR-144-3p 0.74 0.557 
rno-miR-193-3p 1.32 0.557 
rno-miR-125b-5p 0.95 0.557 
rno-miR-146b-5p 1.27 0.557 
rno-miR-126a-5p 1.11 0.557 
rno-let-7i-5p 0.88 0.557 
rno-let-7f-5p 0.92 0.560 
rno-let-7b-5p 0.85 0.561 
rno-miR-671 1.96 0.561 
rno-miR-188-5p 3.45 0.569 
miRNA ID FC P Adj 
rno-miR-138-5p Inf 0.573 
rno-miR-450a-5p 0.87 0.573 
rno-miR-361-3p 5.80 0.573 
rno-miR-455-3p 13.46 0.576 
rno-miR-190a-5p 6.52 0.585 
rno-miR-28-3p 1.04 0.585 
rno-miR-22-5p 1.53 0.585 
rno-miR-139-5p 1.69 0.585 
rno-miR-152-5p 7.71 0.585 
rno-miR-219-5p 0.00 0.585 
rno-miR-301a-3p 0.81 0.585 
rno-miR-10a-5p 0.87 0.585 
rno-miR-195-3p 4.49 0.585 
rno-miR-1843-5p 1.59 0.585 
rno-miR-17-5p 1.49 0.585 
rno-miR-181a-5p 1.09 0.585 
rno-miR-185-5p 0.00 0.585 
rno-miR-130a-3p 0.88 0.585 
rno-miR-191a-3p 0.00 0.585 
rno-miR-330-5p 0.00 0.585 
rno-miR-451-5p 0.81 0.585 
rno-miR-1839-5p 2.37 0.585 
rno-miR-326-3p 0.00 0.585 
rno-miR-140-5p 2.05 0.585 
rno-miR-582-3p 0.00 0.585 
rno-miR-23b-3p 0.84 0.585 
rno-miR-361-5p 0.77 0.585 
rno-miR-378a-5p 1.54 0.585 
rno-miR-339-5p 1.50 0.585 
rno-miR-222-3p Inf 0.585 
rno-miR-106b-5p 1.76 0.585 
rno-miR-107-3p 1.23 0.585 
rno-miR-532-5p 1.49 0.585 
rno-miR-511-3p 9.31 0.585 
rno-miR-199a-5p 1.40 0.597 
rno-miR-99b-5p 1.15 0.597 
rno-miR-32-5p 2.16 0.601 
rno-miR-28-5p 1.22 0.609 
rno-miR-204-5p 1.53 0.610 
rno-miR-151-5p 0.86 0.615 
rno-let-7c-5p 0.91 0.624 
rno-miR-144-5p 1.50 0.624 
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miRNA ID FC P Adj 
rno-miR-16-5p 1.05 0.627 
rno-miR-674-3p 2.01 0.627 
rno-miR-33-5p 2.14 0.627 
rno-miR-103-3p 1.16 0.630 
rno-miR-31a-5p 1.06 0.644 
rno-miR-30d-5p 0.92 0.644 
rno-miR-26a-3p 0.66 0.658 
rno-miR-34a-5p 6.34 0.676 
rno-miR-146a-5p 0.86 0.676 
rno-miR-466c-5p 5.04 0.676 
rno-miR-27b-5p 2.69 0.676 
rno-let-7a-5p 0.91 0.676 
rno-miR-328a-3p 6.33 0.684 
rno-miR-200a-3p 1.22 0.684 
rno-miR-29c-3p 1.16 0.684 
rno-miR-128-3p 4.78 0.684 
rno-miR-21-5p 0.92 0.696 
rno-miR-26b-5p 1.05 0.696 
rno-let-7e-5p 0.86 0.696 
rno-miR-29a-3p 0.91 0.736 
rno-miR-101b-3p 1.09 0.746 
rno-miR-30c-5p 0.90 0.746 
rno-miR-652-3p 1.62 0.746 
rno-miR-30c-1-3... 1.49 0.746 
rno-miR-322-3p 1.43 0.780 
rno-miR-101a-3p 1.08 0.780 
rno-miR-30c-2-3... 1.37 0.780 
rno-miR-122-3p 0.97 0.783 
rno-miR-423-5p 0.85 0.813 
rno-miR-24-3p 0.94 0.813 
rno-miR-21-3p 1.14 0.813 
rno-miR-10a-3p Inf 0.813 
rno-miR-664-3p 1.90 0.818 
rno-miR-126a-3p 0.95 0.818 
rno-miR-455-5p 1.42 0.818 
rno-miR-148b-3p 1.06 0.818 
rno-miR-21* 0.64 0.843 
rno-miR-181d-5p 1.54 0.843 
rno-mir-21* 0.64 0.843 
rno-miR-338-3p 0.98 0.843 
rno-miR-351-5p 1.01 0.843 
rno-miR-34c-5p 0.73 0.843 
miRNA ID FC P Adj 
rno-miR-872-3p 1.19 0.849 
rno-miR-194-5p 1.01 0.849 
rno-let-7d-3p 1.07 0.864 
rno-miR-100-5p 1.24 0.864 
rno-miR-7a-5p 1.11 0.866 
rno-miR-411-5p Inf 0.878 
rno-miR-20a-5p 0.93 0.903 
rno-miR-93-5p 1.12 0.903 
rno-miR-27a-3p 0.95 0.913 
rno-miR-542-3p 0.97 0.913 
rno-miR-30d-3p 0.96 0.913 
rno-let-7b-3p 1.38 0.913 
rno-miR-29b-3p 1.12 0.913 
rno-miR-26b-3p Inf 0.913 
rno-miR-342-3p 1.41 0.913 
rno-miR-99a-3p 1.36 0.923 
rno-miR-423-3p 0.86 0.923 
rno-miR-24-2-5p 0.99 0.923 
rno-miR-345-5p 1.75 0.923 
rno-miR-191a-5p 1.00 0.924 
rno-miR-96-5p Inf 0.924 
rno-miR-200b-3p 1.00 0.924 
rno-miR-374-5p 1.25 0.924 
rno-miR-145-3p 0.86 0.938 
rno-miR-98-5p 1.02 0.939 
rno-miR-141-3p 0.86 0.939 
rno-miR-3585-5p Inf 0.939 
rno-miR-92a-1-5... 0.93 0.939 
rno-miR-99a-5p 1.10 0.939 
rno-let-7f-1-3p 0.67 0.941 
rno-miR-142-3p 1.03 0.943 
rno-miR-181c-5p 1.13 0.943 
rno-miR-223-3p 0.93 0.956 
rno-miR-19a-3p 0.94 0.956 
rno-miR-872-5p 0.96 0.957 
rno-miR-122-5p 0.95 0.959 
rno-miR-221-3p 1.12 0.959 
rno-let-7a-1-3p... 0.96 0.960 
rno-miR-199a-3p 1.07 0.960 
rno-miR-429 1.01 0.960 
rno-miR-365-3p 0.98 0.960 
rno-miR-30a-5p 0.98 0.962 
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miRNA ID FC P Adj 
rno-miR-194-3p 1.27 0.962 
rno-let-7f-2-3p 1.11 0.962 
rno-miR-320-3p 0.97 0.977 
   
   
miRNA ID FC P Adj 
rno-miR-466b-2-... 1.26 0.997 
rno-miR-148b-5p 0.85 0.997 
rno-miR-192-3p 0.87 1.000 
rno-miR-181a-2-... 0.00 1.000 
rno-miR-200a-5p 0.00 1.000 
SYN 50 ppm______________________________________________________ 
miRNA ID FC P Adj 
rno-miR-10a-5p 0.6747 0.009 
rno-miR-127-3p Inf 0.01 
rno-miR-183-5p 3.45 0.02 
rno-miR-484 Inf 0.03 
rno-miR-210-3p 3.12 0.04 
rno-miR-21-3p 2.11 0.07 
rno-miR-31a-3p 14.6 0.07 
rno-miR-203b-3p 2.64 0.09 
rno-miR-30b-3p 5.88 0.09 
rno-miR-21* 0.00E+00 0.13 
rno-mir-21* 0.00E+00 0.13 
rno-miR-190a-5p 10.66 0.16 
rno-miR-122-5p 1.14 0.16 
rno-miR-33-5p 5.78 0.16 
rno-miR-664-3p 3.62 0.19 
rno-miR-146a-5p 1.33 0.19 
rno-miR-1843-5p 2.05 0.19 
rno-miR-455-3p 16.85 0.19 
rno-miR-3559-5p 2.17 0.19 
rno-miR-125b-5p 0.8796 0.19 
rno-miR-331-3p Inf 0.19 
rno-miR-125a-5p 0.785 0.19 
rno-miR-194-5p 1.25 0.24 
rno-miR-425-5p 2.19 0.24 
rno-miR-140-3p 1.45 0.24 
rno-miR-200c-3p Inf 0.24 
rno-miR-6329 3.22 0.26 
rno-miR-802-3p 1.53 0.26 
rno-miR-328a-3p 12.09 0.26 
rno-miR-106b-5p 2.66 0.26 
rno-miR-34a-5p 10.11 0.27 
miRNA ID FC P Adj 
rno-miR-192-3p 2.4 0.27 
rno-miR-142-5p 0.8413 0.27 
rno-miR-378a-3p 1.07 0.27 
rno-miR-186-5p 0.777 0.27 
rno-miR-200a-3p 1.53 0.27 
rno-miR-222-3p Inf 0.27 
rno-miR-223-3p 2.42 0.27 
rno-miR-100-5p 0.9538 0.27 
rno-miR-26a-5p 0.8506 0.27 
rno-miR-139-5p 1.87 0.29 
rno-miR-181a-1-... 1.86 0.29 
rno-miR-455-5p 2.07 0.29 
rno-miR-339-3p 2.43 0.30 
rno-miR-152-3p 1.93 0.31 
rno-miR-99a-5p 0.9189 0.31 
rno-miR-30e-5p 0.8374 0.31 
rno-miR-140-5p 2.5 0.31 
rno-miR-6215 0.9112 0.38 
rno-miR-339-5p 1.68 0.39 
rno-miR-542-3p 2.12 0.43 
rno-miR-335 0.6709 0.43 
rno-miR-195-3p 5.93 0.43 
rno-miR-1839-5p 2.78 0.43 
rno-miR-184 0.5219 0.43 
rno-miR-16-5p 1.14 0.43 
rno-miR-511-3p 9.94 0.43 
rno-miR-322-5p 0.7585 0.43 
rno-miR-30a-3p 1.36 0.45 
rno-miR-199a-5p 1.44 0.46 
rno-miR-191a-5p 0.864 0.46 
rno-miR-203a-3p 1.48 0.46 
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miRNA ID FC P Adj 
rno-miR-22-5p 1.66 0.46 
rno-miR-301a-3p 0.7609 0.46 
rno-miR-128-3p 7.69 0.46 
rno-miR-30c-5p 0.8194 0.46 
rno-miR-10a-3p Inf 0.46 
rno-miR-652-3p 2.13 0.46 
rno-miR-194-3p 1.75 0.46 
rno-miR-146b-5p 1.37 0.46 
rno-miR-19b-3p 0.7309 0.46 
rno-miR-466c-5p 5.91 0.46 
rno-miR-32-5p 2.95 0.46 
rno-miR-181b-5p 1.57 0.52 
rno-miR-185-5p 0.9568 0.54 
rno-miR-7a-5p 3.11 0.54 
rno-miR-505-3p 12.28 0.57 
rno-miR-195-5p 1.16 0.57 
rno-miR-330-5p 1.22 0.57 
rno-miR-24-3p 1.18 0.57 
rno-miR-451-5p 0.7228 0.57 
rno-miR-23a-3p 0.8009 0.57 
rno-miR-361-3p 10.37 0.57 
rno-miR-181d-5p 1.79 0.58 
rno-miR-17-5p 1.39 0.62 
rno-miR-30c-2-3... 1.51 0.62 
rno-miR-671 2.19 0.62 
rno-miR-450a-5p 0.9126 0.63 
rno-miR-363-3p Inf 0.63 
rno-miR-125b-1-... Inf 0.63 
rno-miR-200a-5p 1.2 0.63 
rno-miR-214-3p 7.23 0.63 
rno-miR-99b-5p 0.9255 0.63 
rno-miR-18a-5p Inf 0.63 
rno-miR-25-3p 1.21 0.63 
rno-miR-30b-5p 0.8996 0.64 
rno-miR-30e-3p 1.31 0.64 
rno-let-7f-5p 0.9481 0.64 
rno-miR-351-5p 0.8722 0.64 
rno-miR-92b-3p Inf 0.65 
rno-miR-1839-3p Inf 0.65 
rno-miR-145-5p 0.7367 0.65 
rno-mir-350* Inf 0.65 
rno-miR-17-1-3p Inf 0.65 
rno-miR-324-5p Inf 0.66 
miRNA ID FC P Adj 
rno-miR-181c-3p Inf 0.66 
rno-miR-33-3p Inf 0.66 
rno-miR-497-5p 1.27 0.68 
rno-miR-26b-5p 1.07 0.68 
rno-miR-26a-3p 0.8029 0.68 
rno-miR-421-3p Inf 0.68 
rno-miR-434-3p Inf 0.68 
rno-miR-143-3p 1.05 0.69 
rno-miR-28-3p 0.8586 0.69 
rno-miR-674-3p 2.14 0.70 
rno-miR-342-3p 1.93 0.70 
rno-miR-148b-3p 0.8219 0.70 
rno-miR-101b-3p 1.09 0.70 
rno-miR-30d-5p 0.8924 0.70 
rno-miR-126a-3p 1.14 0.70 
rno-miR-28-5p 1.38 0.71 
rno-miR-219-5p 2.45 0.71 
rno-miR-141-3p 0.8632 0.71 
rno-miR-92a-3p 0.8686 0.71 
rno-miR-293-5p Inf 0.71 
rno-miR-30a-5p 0.9112 0.71 
rno-let-7i-5p 0.9235 0.71 
rno-miR-378a-5p 1.13 0.71 
rno-miR-29b-3p 1.41 0.71 
rno-miR-429 1.35 0.71 
rno-miR-3557-3p Inf 0.71 
rno-miR-92a-1-5... 0.8541 0.71 
rno-miR-345-5p 1.57 0.71 
rno-miR-375-3p 1.28 0.71 
rno-miR-320-3p 1.22 0.73 
rno-miR-98-5p 0.9098 0.73 
rno-miR-150-5p 1.33 0.73 
rno-miR-340-5p 1.17 0.73 
rno-miR-151-5p 0.8995 0.73 
rno-miR-193-3p 1.13 0.73 
rno-miR-34c-5p 0.8994 0.73 
rno-miR-193-5p Inf 0.74 
rno-miR-3068-3p 1.57 0.74 
rno-miR-148b-5p 0.962 0.75 
rno-miR-31a-5p 1.08 0.76 
rno-miR-423-5p 0.9174 0.76 
rno-miR-145-3p 1.28 0.76 
rno-miR-181a-5p 0.8745 0.76 
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miRNA ID FC P Adj 
rno-miR-3473 Inf 0.76 
rno-miR-152-5p 5.87 0.77 
rno-miR-322-3p 1.28 0.77 
rno-miR-192-5p 1.06 0.77 
rno-miR-181a-2-... 2.66 0.77 
rno-miR-182 0.861 0.77 
rno-miR-582-3p 3.29 0.77 
rno-miR-21-5p 0.9239 0.77 
rno-miR-490-3p Inf 0.77 
rno-miR-374-3p 5.66 0.77 
rno-miR-125b-2-... 1.17 0.77 
rno-miR-151-3p 1.07 0.77 
rno-miR-188-5p 2.96 0.78 
rno-miR-423-3p 1.15 0.79 
rno-let-7d-3p 1.01 0.79 
rno-miR-29c-3p 1.29 0.79 
rno-miR-204-5p 1.35 0.79 
rno-miR-142-3p 1.03 0.81 
rno-miR-22-3p 0.9848 0.81 
rno-miR-542-5p Inf 0.81 
rno-miR-374-5p 1.25 0.81 
rno-miR-99a-3p 1.33 0.81 
rno-miR-30c-1-3... 2.03 0.81 
rno-miR-103-3p 1.09 0.82 
rno-let-7a-1-3p... 0.9991 0.83 
rno-miR-29a-3p 0.9425 0.87 
rno-let-7f-1-3p 0.8479 0.88 
rno-miR-326-3p 4.26 0.88 
rno-let-7d-5p 0.9014 0.88 
rno-miR-15b-5p 0.9836 0.88 
rno-miR-27b-5p 1.95 0.91 
rno-miR-532-5p 1.34 0.92 
rno-miR-340-3p Inf 0.95 
rno-miR-191a-3p 6.99 0.95 
rno-miR-23b-3p 0.8718 0.95 
rno-miR-126a-5p 1.05 0.96 
rno-miR-30d-3p 1.03 0.96 
rno-miR-199a-3p 1.18 0.97 
rno-let-7c-5p 0.9555 0.98 
rno-miR-122-3p 1.15 0.98 
rno-miR-802-5p 1.1 0.98 
rno-miR-144-5p 1.29 0.98 
rno-miR-3577 Inf 0.98 
miRNA ID FC P Adj 
rno-miR-130a-3p 1.15 0.98 
rno-miR-338-3p 1.27 0.98 
rno-miR-466b-2-... 1.29 0.98 
rno-miR-143-5p Inf 0.98 
rno-miR-361-5p 1.09 0.98 
rno-miR-7a-1-3p Inf 0.98 
rno-miR-872-5p 1.12 0.99 
rno-miR-664-2-5... Inf 0.99 
rno-let-7a-5p 0.9178 0.99 
rno-miR-872-3p 1.11 0.99 
rno-miR-350 Inf 0.99 
rno-miR-96-5p Inf 0.99 
rno-miR-93-5p 1.08 0.99 
rno-miR-411-5p Inf 1 
rno-miR-27a-3p 0.9932 1 
rno-miR-27b-3p 0.9803 1 
rno-miR-218a-5p Inf 1 
rno-miR-20a-5p 0.9888 1 
rno-mir-126* Inf 1 
rno-miR-132-3p Inf 1 
rno-let-7b-5p 0.9427 1 
rno-miR-101a-3p 0.9747 1 
rno-mir-425* Inf 1 
rno-let-7b-3p 0.9836 1 
rno-miR-1249 Inf 1 
rno-miR-200b-3p 0.9471 1 
rno-miR-221-3p 1.11 1 
rno-miR-106b-3p Inf 1 
rno-miR-19a-3p 1.25 1 
rno-miR-499-5p Inf 1 
rno-miR-3585-5p Inf 1 
rno-miR-181c-5p 1.08 1 
rno-miR-3559-3p Inf 1 
rno-miR-107-3p 1.07 1 
rno-miR-362-3p Inf 1 
rno-miR-144-3p 0.9884 1 
rno-miR-365-3p 0.8797 1 
rno-miR-24-2-5p 1.06 1 
rno-miR-190b-5p Inf 1 
rno-miR-26b-3p Inf 1 
rno-let-7f-2-3p 1.12 1 
rno-miR-532-3p Inf 1 
rno-let-7e-5p 0.9308 1 
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SYN 500 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-215 Inf 7.70E-11 
rno-miR-127-3p Inf 1.17E-05 
rno-miR-21* 0.00E+00 0.021 
rno-mir-21* 0.00E+00 0.021 
rno-miR-6215 0.6069 0.021 
rno-miR-100-5p 0.5882 0.021 
rno-miR-99b-5p 0.6459 0.021 
rno-miR-378a-3p 1.24 0.029 
rno-miR-328a-3p 27 0.029 
rno-miR-331-3p Inf 0.029 
rno-miR-99a-5p 0.6796 0.030 
rno-miR-31a-3p 14.14 0.040 
rno-miR-190a-5p 13.33 0.055 
rno-miR-3559-3p Inf 0.056 
rno-miR-200c-3p Inf 0.057 
rno-miR-466c-5p 8.45 0.068 
rno-miR-195-3p 10.77 0.071 
rno-miR-125b-5p 0.8314 0.077 
rno-miR-126a-5p 0.7316 0.115 
rno-miR-183-5p 3.2 0.144 
rno-miR-455-3p 15.99 0.154 
rno-miR-222-3p Inf 0.154 
rno-miR-664-3p 4.04 0.181 
rno-miR-33-5p 5.49 0.193 
rno-miR-1839-5p 4.56 0.246 
rno-miR-26b-3p Inf 0.246 
rno-miR-142-5p 0.7465 0.253 
rno-miR-484 Inf 0.260 
rno-miR-125a-5p 0.7951 0.262 
rno-miR-34a-5p 10.58 0.269 
rno-miR-10a-5p 0.7489 0.269 
rno-miR-30b-3p 4.43 0.269 
rno-miR-223-3p 3.25 0.511 
rno-miR-6329 3.94 0.511 
rno-miR-671 3.01 0.511 
rno-miR-182 1.18 0.580 
rno-miR-128-3p 7.17 0.584 
rno-miR-191a-5p 0.8107 0.622 
rno-miR-181d-5p 2.36 0.699 
rno-miR-25-3p 1.39 0.699 
miRNA ID FC P Adj 
rno-miR-146b-5p 1.55 0.699 
rno-miR-1843-5p 2.86 0.769 
rno-miR-151-3p 1.29 0.769 
rno-miR-30e-5p 0.812 0.776 
rno-miR-7a-5p 2.99 0.795 
rno-miR-200a-3p 1.56 0.812 
rno-miR-511-3p 8.83 0.812 
rno-miR-339-3p 2.86 0.851 
rno-miR-505-3p 12.95 0.851 
rno-miR-181a-5p 1.11 0.851 
rno-miR-140-5p 2.01 0.851 
rno-miR-802-3p 1.53 0.851 
rno-miR-361-3p 9.32 0.851 
rno-miR-322-5p 0.6865 0.881 
rno-miR-26a-5p 0.8647 0.881 
rno-miR-192-3p 1.77 0.961 
rno-miR-146a-5p 1.15 0.961 
rno-miR-335 0.6597 0.961 
rno-miR-139-5p 2.25 0.961 
rno-miR-122-5p 1.03 0.961 
rno-miR-451-5p 0.7066 0.961 
rno-miR-19a-3p 1.72 0.961 
rno-miR-210-3p 2.62 0.961 
rno-miR-181a-1-... 2.61 0.961 
rno-miR-31a-5p 1.18 1 
rno-miR-29c-5p Inf 1 
rno-miR-103-3p 1.17 1 
rno-miR-199a-5p 1.37 1 
rno-miR-3068-3p 0.9648 1 
rno-miR-411-5p Inf 1 
rno-miR-29a-5p Inf 1 
rno-miR-872-3p 1.47 1 
rno-miR-101b-3p 1.03 1 
rno-miR-350 Inf 1 
rno-miR-130b-3p Inf 1 
rno-miR-203a-3p 1.41 1 
rno-miR-381-3p Inf 1 
rno-miR-28-3p 0.9466 1 
rno-miR-203b-3p 2.39 1 
rno-miR-542-5p Inf 1 
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miRNA ID FC P Adj 
rno-miR-27a-3p 1.03 1 
rno-miR-9a-5p Inf 1 
rno-miR-345-3p Inf 1 
rno-miR-27b-3p 1.02 1 
rno-miR-30d-5p 0.9991 1 
rno-miR-152-3p 1.76 1 
rno-miR-421-3p Inf 1 
rno-miR-490-3p Inf 1 
rno-miR-210-5p Inf 1 
rno-let-7c-5p 0.9805 1 
rno-miR-92b-3p Inf 1 
rno-let-7e-3p Inf 1 
rno-miR-218a-5p Inf 1 
rno-miR-194-5p 1.03 1 
rno-miR-22-5p 1.58 1 
rno-miR-497-5p 1.32 1 
rno-miR-434-3p Inf 1 
rno-miR-542-3p 2.04 1 
rno-miR-28-5p 1.42 1 
rno-miR-138-5p Inf 1 
rno-let-7f-1-3p 1.24 1 
rno-miR-29a-3p 1.01 1 
rno-miR-322-3p 1.86 1 
rno-miR-27a-5p Inf 1 
rno-miR-152-5p 6.89 1 
rno-miR-142-3p 1.25 1 
rno-miR-192-5p 1.02 1 
rno-miR-320-3p 1.63 1 
rno-miR-466b-1-... Inf 1 
rno-miR-219-5p 5.49 1 
rno-miR-20a-5p 0.9979 1 
rno-let-7a-1-3p... 1.05 1 
rno-mir-126* Inf 1 
rno-miR-423-5p 1.2 1 
rno-miR-425-5p 2.15 1 
rno-miR-301a-3p 0.852 1 
rno-miR-221-5p Inf 1 
rno-miR-22-3p 0.9142 1 
rno-miR-98-5p 0.9908 1 
rno-miR-143-3p 1.08 1 
rno-miR-122-3p 1.31 1 
rno-miR-324-3p Inf 1 
rno-miR-132-3p Inf 1 
miRNA ID FC P Adj 
rno-miR-30b-5p 0.9601 1 
rno-miR-145-3p 1.04 1 
rno-miR-340-3p Inf 1 
rno-miR-450a-5p 0.9215 1 
rno-miR-363-3p Inf 1 
rno-miR-126a-3p 0.9723 1 
rno-miR-3577 Inf 1 
rno-miR-466b-5p Inf 1 
rno-miR-17-5p 1.45 1 
rno-miR-200b-5p Inf 1 
rno-miR-802-5p 1.01 1 
rno-miR-181a-2-... 6.82 1 
rno-miR-185-5p 2.83 1 
rno-miR-199a-3p 1.23 1 
rno-miR-30e-3p 1.33 1 
rno-let-7b-5p 0.9855 1 
rno-miR-872-5p 1.2 1 
rno-miR-130a-3p 0.9984 1 
rno-miR-150-5p 1.59 1 
rno-miR-195-5p 1.06 1 
rno-miR-101a-3p 1.03 1 
rno-miR-98-3p Inf 1 
rno-miR-10b-5p Inf 1 
rno-miR-18a-5p Inf 1 
rno-miR-664-2-5... Inf 1 
rno-miR-145-5p 0.8912 1 
rno-miR-674-5p Inf 1 
rno-miR-21-5p 0.9049 1 
rno-miR-191a-3p 6.32 1 
rno-miR-324-5p Inf 1 
rno-miR-503-3p Inf 1 
rno-miR-140-3p 1.29 1 
rno-miR-340-5p 1.21 1 
rno-miR-141-3p 0.7846 1 
rno-miR-338-3p 1.36 1 
rno-miR-1843-3p Inf 1 
rno-miR-27b-5p 2.2 1 
rno-miR-330-5p 4.76 1 
rno-miR-24-3p 1.01 1 
rno-miR-30d-3p 1.04 1 
rno-miR-30c-5p 0.8773 1 
rno-let-7d-3p 1.15 1 
rno-miR-92a-3p 1.06 1 
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miRNA ID FC P Adj 
rno-miR-184 4.85 1 
rno-miR-16-5p 0.9648 1 
rno-miR-101a-5p Inf 1 
rno-mir-425* Inf 1 
rno-miR-15b-3p Inf 1 
rno-let-7b-3p 1.55 1 
rno-miR-96-5p Inf 1 
rno-mir-350* Inf 1 
rno-miR-188-5p 7.32 1 
rno-miR-1249 Inf 1 
rno-miR-326-3p 9.84 1 
rno-miR-582-3p 2.99 1 
rno-miR-186-5p 0.8579 1 
rno-miR-200b-3p 1.16 1 
rno-miR-200a-5p 1.55 1 
rno-miR-449a-5p Inf 1 
rno-miR-221-3p 1.35 1 
rno-miR-466b-2-... 1.42 1 
rno-miR-293-5p Inf 1 
rno-miR-23a-3p 0.7919 1 
rno-miR-3559-5p 2.2 1 
rno-miR-181b-5p 1.94 1 
rno-miR-201-5p Inf 1 
rno-miR-106b-3p Inf 1 
rno-miR-21-3p 1.11 1 
rno-miR-674-3p 2.46 1 
rno-miR-374-5p 1.31 1 
rno-miR-30a-5p 0.928 1 
rno-let-7i-5p 0.8858 1 
rno-miR-193-5p Inf 1 
rno-miR-23b-3p 0.8695 1 
rno-miR-143-5p Inf 1 
rno-miR-361-5p 0.896 1 
rno-miR-204-5p 1.86 1 
rno-miR-3473 Inf 1 
rno-miR-500-3p Inf 1 
rno-miR-144-5p 1.67 1 
rno-miR-455-5p 1.53 1 
rno-miR-181c-3p Inf 1 
rno-miR-99a-3p 1.65 1 
rno-let-7a-5p 0.9579 1 
rno-miR-378a-5p 1.35 1 
rno-miR-499-5p Inf 1 
miRNA ID FC P Adj 
rno-miR-3585-5p Inf 1 
rno-let-7d-5p 0.9602 1 
rno-miR-10a-3p Inf 1 
rno-miR-339-5p 2.13 1 
rno-miR-181c-5p 1.12 1 
rno-miR-125b-2-... 1.39 1 
rno-miR-29b-3p 1.2 1 
rno-miR-652-3p 2.37 1 
rno-miR-106b-5p 2.39 1 
rno-miR-107-3p 1.17 1 
rno-miR-30a-3p 1.29 1 
rno-miR-429 1.36 1 
rno-miR-17-1-3p Inf 1 
rno-miR-374-3p 4.04 1 
rno-miR-423-3p 1.34 1 
rno-miR-93-5p 1.14 1 
rno-miR-362-3p Inf 1 
rno-miR-144-3p 0.9171 1 
rno-miR-151-5p 0.9789 1 
rno-miR-193-3p 1.41 1 
rno-miR-194-3p 1.86 1 
rno-miR-365-3p 0.9359 1 
rno-miR-214-3p 7.58 1 
rno-miR-3557-3p Inf 1 
rno-miR-136-3p Inf 1 
rno-miR-219-1-3... Inf 1 
rno-miR-24-2-5p 1.01 1 
rno-mir-455* Inf 1 
rno-miR-190b-5p Inf 1 
rno-miR-153-3p Inf 1 
rno-miR-30c-2-3... 1.68 1 
rno-let-7f-2-3p 1.21 1 
rno-miR-148b-5p 1.01 1 
rno-miR-26b-5p 0.9044 1 
rno-miR-26a-3p 0.8377 1 
rno-miR-532-3p Inf 1 
rno-let-7f-5p 0.9576 1 
rno-miR-351-5p 1.11 1 
rno-miR-34c-5p 1.23 1 
rno-miR-15b-5p 0.8924 1 
rno-miR-33-3p Inf 1 
rno-miR-32-5p 2.2 1 
rno-miR-29c-3p 1.39 1 
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miRNA ID FC P Adj 
rno-miR-342-3p 1.76 1 
rno-mir-28* Inf 1 
rno-let-7e-5p 1.02 1 
rno-miR-92a-1-5... 1.09 1 
rno-miR-345-5p 1.74 1 
rno-miR-19b-3p 0.8942 1 
   
miRNA ID FC P Adj 
rno-miR-30c-1-3... 2.16 1 
rno-miR-147 Inf 1 
rno-miR-148b-3p 0.8259 1 
rno-miR-133a-3p Inf 1 
rno-miR-7a-1-3p Inf 1 
rno-miR-375-3p 1.5 1 
rno-miR-532-5p 1.64 1 
SYN 3000 ppm____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-10a-5p 0.4997 7.77E-12 
rno-miR-100-5p 0.3491 4.71E-11 
rno-miR-99b-5p 0.4478 4.71E-11 
rno-miR-193-3p 3.16 7.74E-09 
rno-miR-331-3p Inf 4.79E-08 
rno-miR-127-3p Inf 7.06E-08 
rno-miR-497-5p 2.63 0.0001 
rno-miR-31a-3p 26.53 0.0006 
rno-miR-328a-3p 27.08 0.0014 
rno-miR-26b-3p Inf 0.0018 
rno-miR-99a-5p 0.6605 0.0029 
rno-miR-505-3p 29.35 0.0032 
rno-miR-150-5p 2.75 0.0032 
rno-miR-21* 0.00E+00 0.0033 
rno-mir-21* 0.00E+00 0.0033 
rno-miR-125b-5p 0.7289 0.0033 
rno-miR-194-5p 1.46 0.0039 
rno-miR-455-3p 23.56 0.0039 
rno-miR-872-3p 3.51 0.004 
rno-miR-210-3p 3.64 0.0049 
rno-miR-30b-3p 6.97 0.0049 
rno-miR-146a-5p 0.5403 0.0079 
rno-miR-6215 0.6875 0.0079 
rno-miR-30e-5p 0.6862 0.0082 
rno-miR-200c-3p Inf 0.0082 
rno-miR-26a-5p 0.7271 0.0088 
rno-miR-125a-5p 0.6918 0.0089 
rno-miR-190a-5p 13.28 0.012 
rno-miR-3577 Inf 0.0133 
rno-miR-339-3p 3.28 0.0185 
miRNA ID FC P Adj 
rno-miR-139-5p 3.17 0.0231 
rno-miR-222-3p Inf 0.0253 
rno-miR-3559-3p Inf 0.0253 
rno-miR-138-5p Inf 0.0362 
rno-miR-664-3p 4.16 0.0511 
rno-miR-326-3p 20.19 0.0511 
rno-miR-33-5p 4.81 0.0511 
rno-miR-1843-5p 2.68 0.0526 
rno-miR-339-5p 2.52 0.0526 
rno-miR-30b-5p 1.41 0.0615 
rno-miR-1839-5p 3.42 0.0615 
rno-miR-191a-5p 0.7591 0.063 
rno-miR-378a-3p 1.13 0.0632 
rno-miR-6329 3.55 0.064 
rno-miR-511-3p 12.78 0.068 
rno-miR-652-3p 3.55 0.0751 
rno-miR-532-3p Inf 0.0774 
rno-miR-22-5p 2.41 0.0785 
rno-miR-466c-5p 6.09 0.0832 
rno-miR-142-5p 0.7506 0.0843 
rno-miR-21-3p 2 0.0843 
rno-miR-128-3p 7.24 0.0844 
rno-miR-33-3p Inf 0.0879 
rno-miR-192-3p 2.39 0.088 
rno-miR-140-5p 2.76 0.088 
rno-miR-322-5p 0.6336 0.088 
rno-let-7f-5p 0.8211 0.0906 
rno-miR-203b-3p 2.76 0.0932 
rno-let-7d-3p 1.58 0.0932 
rno-miR-151-5p 0.7147 0.0951 
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miRNA ID FC P Adj 
rno-miR-1249 Inf 0.101 
rno-miR-425-5p 2.18 0.1017 
rno-miR-181b-5p 2.04 0.1017 
rno-miR-3585-5p Inf 0.1017 
rno-miR-10a-3p Inf 0.1017 
rno-let-7c-5p 1.21 0.1036 
rno-miR-378a-5p 1.96 0.1136 
rno-miR-181d-5p 2.9 0.1167 
rno-miR-335 0.6322 0.1167 
rno-miR-140-3p 1.52 0.1167 
rno-miR-674-3p 2.63 0.1295 
rno-let-7b-5p 1.28 0.1311 
rno-miR-455-5p 2.44 0.1436 
rno-miR-671 2.45 0.1478 
rno-miR-145-5p 1.51 0.1575 
rno-miR-188-5p 11.49 0.1575 
rno-miR-106b-5p 2.62 0.1575 
rno-miR-214-3p 9.73 0.1578 
rno-miR-126a-5p 0.8442 0.1661 
rno-miR-145-3p 0.7256 0.1661 
rno-miR-361-3p 9.96 0.1661 
rno-miR-182 0.6904 0.1773 
rno-miR-103-3p 1.37 0.1942 
rno-miR-342-3p 2.84 0.1942 
rno-miR-146b-5p 0.6922 0.2131 
rno-miR-3559-5p 2.1 0.2269 
rno-miR-152-5p 8.43 0.2465 
rno-miR-25-3p 1.38 0.2502 
rno-miR-181a-5p 1.13 0.2637 
rno-miR-141-3p 0.6044 0.2741 
rno-miR-99a-3p 1.96 0.2741 
rno-miR-194-3p 2.17 0.2741 
rno-miR-181a-1-... 2.23 0.2741 
rno-miR-195-3p 5.2 0.2752 
rno-miR-223-3p 2.07 0.2784 
rno-miR-192-5p 0.8832 0.2811 
rno-miR-183-5p 1.81 0.2832 
rno-miR-542-3p 2.36 0.3087 
rno-miR-200b-3p 0.7866 0.3212 
rno-miR-28-3p 0.798 0.323 
rno-miR-191a-3p 9.68 0.3277 
rno-let-7i-5p 0.8388 0.3277 
rno-miR-200a-3p 1.6 0.3277 
miRNA ID FC P Adj 
rno-miR-32-5p 2.82 0.3277 
rno-miR-29c-3p 1.55 0.3277 
rno-miR-122-3p 1.39 0.3347 
rno-miR-186-5p 0.8131 0.3347 
rno-miR-204-5p 1.91 0.3347 
rno-miR-345-5p 2.14 0.3347 
rno-miR-221-3p 1.83 0.3585 
rno-miR-152-3p 1.83 0.3653 
rno-miR-17-5p 1.63 0.3696 
rno-miR-320-3p 1.73 0.387 
rno-miR-34a-5p 7.89 0.4144 
rno-miR-30a-5p 0.8621 0.4312 
rno-miR-144-5p 1.79 0.4312 
rno-let-7b-3p 1.71 0.4382 
rno-miR-30c-2-3... 1.72 0.4382 
rno-miR-532-5p 1.72 0.4382 
rno-miR-92a-1-5... 0.7383 0.4435 
rno-miR-107-3p 1.39 0.4681 
rno-miR-144-3p 0.831 0.4886 
rno-miR-142-3p 1.67 0.4912 
rno-miR-143-3p 0.8884 0.4912 
rno-miR-450a-5p 0.9689 0.4912 
rno-miR-29b-3p 1.7 0.4912 
rno-miR-148b-3p 0.8064 0.4912 
rno-miR-28-5p 1.42 0.5316 
rno-miR-151-3p 1.2 0.5316 
rno-miR-96-5p Inf 0.5365 
rno-miR-381-3p Inf 0.5401 
rno-miR-30a-3p 1.3 0.5401 
rno-miR-30c-1-3... 1.82 0.5489 
rno-miR-205 Inf 0.585 
rno-miR-365-3p 0.7825 0.5963 
rno-miR-125b-2-... 1.27 0.606 
rno-miR-98-5p 0.8348 0.6101 
rno-miR-19a-3p 1.43 0.6203 
rno-miR-500-3p Inf 0.6581 
rno-miR-3557-3p Inf 0.6581 
rno-miR-26a-3p 0.9464 0.6581 
rno-miR-203a-3p 1.36 0.6831 
rno-miR-322-3p 1.66 0.6831 
rno-miR-22-3p 0.9362 0.6831 
rno-miR-451-5p 1.15 0.6831 
rno-miR-582-3p 2.29 0.6831 
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miRNA ID FC P Adj 
rno-miR-3585-3p Inf 0.6831 
rno-miR-193-5p Inf 0.6831 
rno-miR-374-3p 5.5 0.6831 
rno-miR-136-3p Inf 0.6831 
rno-miR-484 Inf 0.6831 
rno-miR-19b-3p 0.8175 0.6831 
rno-let-7i-3p Inf 0.6831 
rno-miR-1839-3p Inf 0.684 
rno-miR-143-5p Inf 0.6913 
rno-miR-30c-5p 1.05 0.692 
rno-miR-130a-3p 0.98 0.698 
rno-let-7e-5p 1.18 0.698 
rno-miR-219-5p 2.64 0.6994 
rno-miR-181a-2-... 5.7 0.6994 
rno-miR-16-5p 1.04 0.7008 
rno-miR-802-3p 1.22 0.7217 
rno-miR-361-5p 0.9549 0.7252 
rno-let-7a-5p 0.9996 0.7279 
rno-miR-466b-2-... 1.48 0.7311 
rno-miR-301a-3p 0.877 0.7631 
rno-let-7d-5p 1.06 0.7645 
rno-miR-29a-3p 1.08 0.7812 
rno-miR-93-5p 1.23 0.7927 
rno-miR-23a-3p 0.8977 0.7949 
rno-miR-27a-3p 1.12 0.8007 
rno-miR-122-5p 0.8638 0.8208 
rno-miR-340-5p 1.22 0.8208 
rno-miR-23b-3p 0.9734 0.8557 
rno-miR-24-3p 0.9261 0.8577 
rno-miR-351-5p 1.02 0.8761 
rno-miR-31a-5p 1.06 0.8769 
rno-miR-101b-3p 1.07 0.8769 
rno-miR-9a-5p Inf 0.8769 
rno-miR-210-5p Inf 0.8769 
rno-miR-185-5p 4.95 0.8769 
rno-miR-98-3p Inf 0.8769 
rno-miR-21-5p 0.9904 0.8769 
rno-miR-1843-3p Inf 0.8769 
rno-miR-293-5p Inf 0.8769 
rno-miR-133a-3p Inf 0.8769 
rno-miR-7a-5p 1.85 0.9047 
rno-miR-27b-3p 0.9866 0.9047 
rno-miR-199a-3p 1.26 0.9047 
miRNA ID FC P Adj 
rno-miR-330-5p 5.25 0.9047 
rno-miR-200a-5p 5.27 0.9047 
rno-miR-181c-5p 1.2 0.9047 
rno-miR-190b-5p Inf 0.9047 
rno-let-7f-2-3p 1.32 0.9047 
rno-miR-375-3p 1.23 0.9047 
rno-miR-30d-5p 0.9364 0.9462 
rno-miR-184 3.39 0.9462 
rno-miR-429 1.33 0.9462 
rno-miR-29c-5p Inf 1 
rno-miR-199a-5p 1.25 1 
rno-miR-3068-3p 1.14 1 
rno-miR-411-5p Inf 1 
rno-miR-29a-5p Inf 1 
rno-miR-350 Inf 1 
rno-miR-542-5p Inf 1 
rno-miR-215 Inf 1 
rno-miR-345-3p Inf 1 
rno-miR-421-3p Inf 1 
rno-miR-490-3p Inf 1 
rno-miR-92b-3p Inf 1 
rno-miR-218a-5p Inf 1 
rno-miR-434-3p Inf 1 
rno-let-7f-1-3p 1.2 1 
rno-miR-20a-5p 1.06 1 
rno-let-7a-1-3p... 1.15 1 
rno-mir-126* Inf 1 
rno-miR-423-5p 1 1 
rno-miR-132-3p Inf 1 
rno-miR-340-3p Inf 1 
rno-miR-363-3p Inf 1 
rno-miR-126a-3p 1.06 1 
rno-miR-802-5p 1.11 1 
rno-miR-30e-3p 1.12 1 
rno-miR-872-5p 1.08 1 
rno-miR-195-5p 1.07 1 
rno-miR-101a-3p 1.01 1 
rno-miR-18a-5p Inf 1 
rno-miR-664-2-5... Inf 1 
rno-miR-674-5p Inf 1 
rno-miR-324-5p Inf 1 
rno-miR-338-3p 1.12 1 
rno-miR-27b-5p 1.46 1 
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miRNA ID FC P Adj 
rno-miR-30d-3p 1.2 1 
rno-miR-92a-3p 0.9394 1 
rno-miR-101a-5p Inf 1 
rno-mir-425* Inf 1 
rno-mir-350* Inf 1 
rno-miR-106b-3p Inf 1 
rno-miR-374-5p 1.28 1 
rno-miR-3473 Inf 1 
rno-miR-181c-3p Inf 1 
rno-miR-499-5p Inf 1 
rno-miR-423-3p 0.8914 1 
rno-miR-362-3p Inf 1 
rno-miR-24-2-5p 1.17 1 
rno-miR-148b-5p 1.18 1 
rno-miR-26b-5p 1 1 
rno-miR-34c-5p 1.21 1 
rno-miR-15b-5p 1.06 1 
rno-miR-7a-1-3p Inf 1 
  
Appendix-3.  Day-3 known miRNAs 
 
List of all known miRNAs detected at the 3rd day of treatment by miRanalyzer.  miRNAs listed 
are ordered by treatment and ranked by P Adj values. 
 
PB 50 ppm________________________________________________________ 
miRNA ID FC P Adj 
rno-miR-378a-3p 1.3 0.1657 
rno-miR-100-5p 0.5644 0.329 
rno-miR-145-5p 0.6514 0.4586 
rno-miR-21-3p 1.72 0.4586 
rno-miR-10a-5p 0.8301 0.6826 
rno-let-7i-3p 1.46 0.7441 
rno-miR-125a-5p 0.7231 0.8755 
rno-miR-3068-3p 1.32 0.9186 
rno-miR-350 0.1385 0.9186 
rno-miR-150-5p 0.6654 0.9186 
rno-miR-340-5p 1.3 0.9186 
rno-miR-92a-3p 0.8096 0.9186 
rno-miR-184 2.2 0.9186 
rno-miR-802-3p 1.28 0.9186 
rno-miR-19a-3p 0.5695 0.9186 
rno-miR-6215 1.31 0.9186 
rno-miR-136-3p 1.91 0.9186 
rno-miR-342-3p 0.5705 0.9186 
rno-miR-19b-3p 0.7089 0.9186 
rno-miR-99b-5p 0.7687 0.9186 
rno-miR-138-5p 1.98 0.9594 
rno-miR-142-5p 1.26 0.9787 
rno-miR-22-5p 1.38 0.9787 
rno-miR-542-3p 1.42 0.9787 
rno-miR-223-3p 1.48 0.9787 
rno-miR-145-3p 0.732 0.9787 
rno-miR-674-5p 0.2509 0.9787 
rno-miR-26b-3p 0.548 0.9787 
miRNA ID FC P Adj 
rno-miR-26a-5p 0.8685 0.9787 
rno-miR-31a-5p 0.8526 1 
rno-miR-34a-5p 0.7507 1 
rno-miR-879-5p 0.00E+00 1 
rno-miR-29c-5p 0.3732 1 
rno-miR-190a-5p 0.8849 1 
rno-miR-103-3p 1.03 1 
rno-miR-199a-5p 0.8969 1 
rno-miR-411-5p 0.8919 1 
rno-miR-29a-5p 0.6788 1 
rno-miR-872-3p 1.07 1 
rno-miR-664-3p 0.7705 1 
rno-miR-101b-3p 1.19 1 
rno-miR-191a-5p 0.9154 1 
rno-miR-130b-3p Inf 1 
rno-miR-7a-5p 1.01 1 
rno-miR-203a-3p 1.07 1 
rno-miR-381-3p 1.16 1 
rno-miR-28-3p 0.8584 1 
rno-miR-203b-3p 1.21 1 
rno-miR-192-3p 1.01 1 
rno-miR-542-5p 0.7743 1 
rno-miR-215 0.5508 1 
rno-miR-27a-3p 1.09 1 
rno-miR-9a-5p Inf 1 
rno-miR-345-3p 0.00E+00 1 
rno-miR-27b-3p 1.03 1 
rno-miR-30d-5p 0.9056 1 
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miRNA ID FC P Adj 
rno-miR-152-3p 1.07 1 
rno-miR-181d-5p 0.6621 1 
rno-miR-421-3p 0.3055 1 
rno-miR-490-3p 1.14 1 
rno-let-7c-5p 1.03 1 
rno-miR-146a-5p 1.19 1 
rno-miR-31a-3p 0.866 1 
rno-miR-92b-3p 0.2121 1 
rno-miR-218a-5p 0.6439 1 
rno-miR-194-5p 1.03 1 
rno-miR-497-5p 0.9328 1 
rno-miR-434-3p 0.7937 1 
rno-miR-335 0.8737 1 
rno-miR-28-5p 1.01 1 
rno-miR-6329 0.9582 1 
rno-miR-139-5p 0.8889 1 
rno-let-7f-1-3p 0.8217 1 
rno-miR-29a-3p 1.02 1 
rno-miR-322-3p 0.9458 1 
rno-miR-27a-5p 0.00E+00 1 
rno-miR-152-5p 1.1 1 
rno-miR-192-5p 1.09 1 
rno-miR-142-3p 0.9637 1 
rno-miR-320-3p 0.9167 1 
rno-miR-466b-1-... 0.4059 1 
rno-miR-126a-5p 1.09 1 
rno-miR-219-5p 4.97 1 
rno-miR-20a-5p 0.8206 1 
rno-let-7a-1-3p... 0.9286 1 
rno-mir-126* 1.18 1 
rno-miR-423-5p 0.7522 1 
rno-miR-425-5p 1.12 1 
rno-miR-301a-3p 0.8758 1 
rno-miR-30e-5p 0.9846 1 
rno-miR-221-5p 0.00E+00 1 
rno-miR-410-3p Inf 1 
rno-miR-22-3p 1.09 1 
rno-miR-98-5p 1.16 1 
rno-miR-143-3p 1.09 1 
rno-miR-195-3p 0.7914 1 
rno-miR-122-3p 1.16 1 
rno-miR-132-3p 2.49 1 
rno-miR-30b-5p 0.9549 1 
rno-miR-1839-3p 0.00E+00 1 
rno-mir-322* 0.00E+00 1 
miRNA ID FC P Adj 
rno-miR-340-3p 0.8793 1 
rno-miR-450a-5p 1.09 1 
rno-miR-363-3p 1.31 1 
rno-miR-339-3p 1.18 1 
rno-miR-338-5p 0.00E+00 1 
rno-miR-1843-5p 1.12 1 
rno-miR-126a-3p 0.9744 1 
rno-miR-3577 0.7035 1 
rno-miR-17-5p 0.796 1 
rno-miR-128-3p 0.8089 1 
rno-miR-802-5p 1.07 1 
rno-miR-505-3p 1.2 1 
rno-miR-181a-2-... 0.6388 1 
rno-miR-185-5p 0.8429 1 
rno-miR-181a-5p 0.9875 1 
rno-miR-199a-3p 1.1 1 
rno-miR-30e-3p 0.9548 1 
rno-let-7b-5p 0.852 1 
rno-miR-872-5p 1.03 1 
rno-miR-130a-3p 1.08 1 
rno-miR-195-5p 0.9396 1 
rno-miR-101a-3p 1.2 1 
rno-miR-18a-5p 0.8558 1 
rno-miR-664-2-5... 0.622 1 
rno-miR-122-5p 0.9963 1 
rno-miR-466c-5p 0.9059 1 
rno-miR-21-5p 1.05 1 
rno-miR-191a-3p 1.02 1 
rno-miR-324-5p 1.43 1 
rno-miR-140-3p 1.02 1 
rno-miR-30b-3p 1.39 1 
rno-miR-141-3p 0.9713 1 
rno-miR-338-3p 1.04 1 
rno-miR-1843-3p 0.00E+00 1 
rno-miR-330-5p 0.6347 1 
rno-miR-27b-5p 1.23 1 
rno-miR-24-3p 1.06 1 
rno-miR-30c-5p 0.8338 1 
rno-miR-30d-3p 1.09 1 
rno-miR-182 0.866 1 
rno-let-7d-3p 1.02 1 
rno-miR-451-5p 1.16 1 
rno-miR-1839-5p 1.11 1 
rno-miR-16-5p 0.8766 1 
rno-miR-101a-5p 0.7322 1 
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miRNA ID FC P Adj 
rno-mir-425* 0.3968 1 
rno-miR-15b-3p 3.4 1 
rno-let-7b-3p 0.9524 1 
rno-miR-96-5p 0.3658 1 
rno-mir-350* 0.5272 1 
rno-miR-188-5p 1.15 1 
rno-miR-326-3p 1.05 1 
rno-miR-1249 0.7226 1 
rno-miR-140-5p 0.6446 1 
rno-miR-455-3p 0.8635 1 
rno-miR-582-3p 0.8123 1 
rno-miR-598-3p Inf 1 
rno-miR-186-5p 0.8647 1 
rno-miR-200a-5p 1.25 1 
rno-miR-200b-3p 0.9115 1 
rno-miR-221-3p 0.8522 1 
rno-miR-466b-2-... 0.8298 1 
rno-miR-293-5p 1.34 1 
rno-miR-23a-3p 1.12 1 
rno-miR-3559-5p 1.18 1 
rno-miR-181b-5p 0.9206 1 
rno-miR-201-5p Inf 1 
rno-miR-106b-3p 0.5525 1 
rno-miR-674-3p 0.8338 1 
rno-miR-374-5p 1.03 1 
rno-miR-30a-5p 1.02 1 
rno-miR-328a-3p 0.7671 1 
rno-let-7i-5p 1.08 1 
rno-miR-193-5p Inf 1 
rno-miR-23b-3p 1.06 1 
rno-miR-200c-3p 1.07 1 
rno-miR-143-5p 1.05 1 
rno-miR-361-5p 0.9902 1 
rno-miR-204-5p 0.7416 1 
rno-miR-500-3p 1.54 1 
rno-miR-3473 1.47 1 
rno-miR-144-5p 0.9136 1 
rno-miR-455-5p 1.14 1 
rno-miR-200a-3p 1.02 1 
rno-miR-181c-3p 1.06 1 
rno-miR-99a-3p 1.11 1 
rno-let-7a-5p 1.02 1 
rno-miR-25-3p 0.9813 1 
rno-miR-378a-5p 1.26 1 
rno-miR-499-5p 1.09 1 
miRNA ID FC P Adj 
rno-let-7d-5p 1.02 1 
rno-miR-3585-5p 0.8061 1 
rno-miR-339-5p 1.12 1 
rno-miR-10a-3p 0.7181 1 
rno-miR-181c-5p 1.12 1 
rno-miR-222-3p 0.6342 1 
rno-miR-125b-2-... 1.06 1 
rno-miR-29b-3p 1.07 1 
rno-miR-3559-3p 0.7875 1 
rno-miR-652-3p 1.17 1 
rno-miR-106b-5p 1.2 1 
rno-miR-107-3p 1.14 1 
rno-miR-30a-3p 1 1 
rno-miR-429 1.01 1 
rno-miR-374-3p 1.69 1 
rno-miR-423-3p 0.7356 1 
rno-miR-93-5p 0.9438 1 
rno-miR-362-3p 0.8867 1 
rno-miR-144-3p 1.16 1 
rno-miR-33-5p 1.32 1 
rno-miR-361-3p 0.8891 1 
rno-mir-421* Inf 1 
rno-miR-127-3p 0.9092 1 
rno-miR-210-3p 1.02 1 
rno-miR-151-5p 0.9982 1 
rno-miR-193-3p 0.8824 1 
rno-miR-194-3p 1.04 1 
rno-miR-365-3p 0.843 1 
rno-miR-214-3p 0.651 1 
rno-miR-99a-5p 1.05 1 
rno-miR-181a-1-... 1.02 1 
rno-miR-3557-3p 0.00E+00 1 
rno-miR-322-5p 0.8509 1 
rno-miR-24-2-5p 1.09 1 
rno-miR-190b-5p 0.9541 1 
rno-miR-30c-2-3... 1.02 1 
rno-let-7f-2-3p 1.13 1 
rno-miR-148b-5p 1.32 1 
rno-miR-26b-5p 0.9918 1 
rno-miR-26a-3p 1.16 1 
rno-let-7f-5p 1.08 1 
rno-miR-532-3p 0.6393 1 
rno-miR-351-5p 0.7913 1 
rno-miR-34c-5p 1.39 1 
rno-miR-484 0.9014 1 
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miRNA ID FC P Adj 
rno-miR-151-3p 0.9385 1 
rno-miR-15b-5p 0.9664 1 
rno-miR-32-5p 1.19 1 
rno-miR-33-3p 1.02 1 
rno-miR-29c-3p 1.09 1 
rno-let-7e-5p 0.9871 1 
rno-miR-125b-5p 0.8858 1 
rno-miR-136-5p Inf 1 
rno-miR-331-3p 1.29 1 
rno-miR-92a-1-5... 0.9219 1 
rno-miR-345-5p 1.03 1 
miRNA ID FC P Adj 
rno-miR-146b-5p 1.04 1 
rno-miR-30c-1-3... 0.5549 1 
rno-miR-147 Inf 1 
rno-miR-148b-3p 1.04 1 
rno-miR-133a-3p 0.00E+00 1 
rno-miR-7a-1-3p 0.8902 1 
rno-miR-183-5p 0.7915 1 
rno-miR-375-3p 0.9139 1 
rno-miR-532-5p 1.13 1 
rno-miR-511-3p 1.14 1 
rno-miR-671 0.9061 1 
PB 1000 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-10a-5p 0.56 3.36E-11 
rno-miR-6215 0.46 8.66E-07 
rno-miR-872-3p 2.27 4.18E-06 
rno-miR-141-3p 0.43 2.24E-05 
rno-miR-200b-3p 1.72 2.36E-05 
rno-miR-200a-5p 5.25 5.62E-05 
rno-miR-484 0.31 5.62E-05 
rno-miR-21-3p 2.02 5.99E-05 
rno-miR-802-5p 1.71 5.99E-05 
rno-miR-193-3p 1.71 0.0001 
rno-miR-30b-3p 2.53 0.0003 
rno-miR-138-5p 3.20 0.002 
rno-miR-497-5p 1.65 0.004 
rno-miR-671 1.98 0.009 
rno-miR-145-3p 0.57 0.026 
rno-miR-125a-5p 0.67 0.039 
rno-miR-378a-3p 1.22 0.063 
rno-miR-183-5p 1.60 0.063 
rno-miR-194-5p 1.31 0.067 
rno-miR-200a-3p 1.53 0.067 
rno-miR-125b-5p 0.71 0.069 
rno-miR-143-3p 0.83 0.086 
rno-miR-221-3p 0.64 0.086 
rno-miR-190b-5p 0.31 0.086 
rno-miR-802-3p 1.37 0.112 
rno-miR-100-5p 0.69 0.113 
rno-let-7i-3p 1.44 0.113 
rno-miR-33-3p 2.00 0.115 
rno-miR-26a-5p 0.81 0.115 
miRNA ID FC P Adj 
rno-miR-466b-1-... 0.00 0.117 
rno-miR-1839-3p 0.84 0.148 
rno-miR-126a-5p 1.22 0.160 
rno-miR-19a-3p 0.57 0.177 
rno-miR-22-5p 1.40 0.234 
rno-miR-136-3p 2.40 0.234 
rno-miR-195-5p 0.77 0.258 
rno-miR-338-3p 0.68 0.258 
rno-miR-19b-3p 0.73 0.262 
rno-miR-92a-3p 1.17 0.272 
rno-miR-150-5p 1.25 0.275 
rno-miR-200c-3p 0.57 0.277 
rno-miR-542-5p 4.32 0.308 
rno-miR-146a-5p 0.78 0.316 
rno-miR-301a-3p 0.71 0.316 
rno-miR-145-5p 0.76 0.410 
rno-miR-151-5p 0.82 0.410 
rno-miR-1839-5p 1.41 0.412 
rno-miR-25-3p 1.21 0.455 
rno-miR-146b-5p 0.78 0.506 
rno-miR-132-3p 2.39 0.506 
rno-miR-140-3p 1.20 0.506 
rno-miR-429 1.31 0.506 
rno-miR-188-5p 1.59 0.527 
rno-miR-218a-5p 0.61 0.567 
rno-miR-434-3p 2.13 0.567 
rno-let-7f-1-3p 1.51 0.567 
rno-miR-27a-5p 0.50 0.567 
rno-miR-30e-5p 0.86 0.567 
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miRNA ID FC P Adj 
rno-miR-30b-5p 1.16 0.567 
rno-miR-339-3p 1.28 0.567 
rno-miR-126a-3p 0.86 0.567 
rno-miR-340-5p 1.21 0.567 
rno-miR-27b-5p 1.44 0.567 
rno-miR-30d-3p 1.28 0.567 
rno-miR-182 0.77 0.567 
rno-miR-140-5p 1.32 0.567 
rno-miR-374-5p 0.73 0.567 
rno-miR-423-3p 0.77 0.567 
rno-miR-362-3p 0.48 0.567 
rno-miR-16-5p 0.88 0.571 
rno-miR-181a-2-... 0.59 0.571 
rno-miR-106b-3p 1.74 0.580 
rno-miR-24-3p 0.83 0.589 
rno-miR-378a-5p 1.22 0.603 
rno-miR-664-3p 0.73 0.616 
rno-miR-425-5p 1.23 0.670 
rno-miR-500-3p 2.82 0.670 
rno-miR-29b-3p 0.81 0.670 
rno-miR-26b-3p 1.31 0.670 
rno-miR-351-5p 0.79 0.670 
rno-miR-1843-5p 1.21 0.672 
rno-miR-345-5p 0.73 0.672 
rno-miR-29a-3p 0.90 0.698 
rno-miR-505-3p 1.33 0.698 
rno-miR-30c-5p 1.10 0.698 
rno-miR-466b-2-... 0.76 0.698 
rno-miR-451-5p 1.20 0.706 
rno-miR-214-3p 0.74 0.706 
rno-miR-107-3p 1.20 0.712 
rno-miR-350 0.59 0.723 
rno-miR-144-3p 0.90 0.729 
rno-miR-29c-5p 1.23 0.737 
rno-miR-3068-3p 0.80 0.737 
rno-miR-29a-5p 1.98 0.737 
rno-miR-22-3p 1.08 0.737 
rno-miR-674-5p 0.55 0.737 
rno-miR-674-3p 0.81 0.737 
rno-miR-193-5p Inf 0.737 
rno-miR-30c-2-3... 1.25 0.737 
rno-miR-103-3p 1.13 0.749 
rno-miR-322-5p 0.83 0.749 
rno-miR-142-3p 0.82 0.752 
rno-miR-421-3p 0.62 0.770 
miRNA ID FC P Adj 
rno-miR-184 0.47 0.770 
rno-miR-99a-3p 1.27 0.772 
rno-miR-365-3p 0.88 0.775 
rno-miR-17-1-3p Inf 0.776 
rno-miR-199a-5p 0.86 0.791 
rno-miR-3559-3p 0.79 0.791 
rno-miR-345-3p 0.46 0.810 
rno-miR-30d-5p 0.91 0.810 
rno-let-7b-3p 1.18 0.810 
rno-miR-27a-3p 0.89 0.816 
rno-miR-23a-3p 0.89 0.816 
rno-miR-3559-5p 1.18 0.816 
rno-miR-181c-5p 0.89 0.816 
rno-let-7f-5p 0.91 0.816 
rno-miR-511-3p 0.80 0.816 
rno-miR-33-5p 1.19 0.817 
rno-miR-532-3p 0.75 0.817 
rno-miR-96-5p 0.23 0.822 
rno-miR-342-3p 0.82 0.822 
rno-let-7e-5p 0.87 0.822 
rno-miR-30c-1-3... 1.16 0.841 
rno-miR-335 0.86 0.856 
rno-miR-28-5p 1.10 0.856 
rno-miR-191a-3p 1.49 0.856 
rno-miR-326-3p 0.84 0.856 
rno-miR-30a-5p 0.94 0.856 
rno-miR-361-5p 0.89 0.856 
rno-miR-125b-2-... 0.88 0.856 
rno-miR-99a-5p 1.12 0.873 
rno-miR-30e-3p 1.07 0.879 
rno-miR-181d-5p 0.84 0.889 
rno-miR-34a-5p 0.89 0.902 
rno-let-7d-3p 1.09 0.902 
rno-miR-186-5p 0.92 0.902 
rno-miR-293-5p 0.59 0.902 
rno-miR-181b-5p 1.10 0.902 
rno-miR-328a-3p 0.84 0.902 
rno-miR-26a-3p 1.15 0.902 
rno-miR-15b-5p 0.94 0.902 
rno-miR-148b-3p 1.07 0.902 
rno-mir-126* 0.67 0.902 
rno-miR-200b-5p Inf 0.902 
rno-miR-101a-5p 1.32 0.902 
rno-miR-106b-5p 1.12 0.902 
rno-miR-93-5p 1.07 0.902 
 Appendix –3 
  [ 202 ] 
miRNA ID FC P Adj 
rno-miR-29c-3p 1.12 0.902 
rno-miR-139-5p 0.92 0.903 
rno-miR-3473 0.64 0.903 
rno-miR-339-5p 1.13 0.903 
rno-miR-374-3p 1.36 0.903 
rno-miR-320-3p 0.93 0.924 
rno-miR-423-5p 1.07 0.943 
rno-miR-26b-5p 1.04 0.943 
rno-miR-23b-3p 0.94 0.943 
rno-miR-411-5p 1.44 0.954 
rno-miR-191a-5p 0.94 0.954 
rno-miR-381-3p 2.22 0.954 
rno-miR-27b-3p 1.03 0.954 
rno-miR-490-3p 1.23 0.954 
rno-miR-542-3p 1.14 0.954 
rno-miR-322-3p 0.86 0.954 
rno-let-7a-1-3p... 0.88 0.954 
rno-miR-195-3p 1.24 0.954 
rno-miR-340-3p 0.75 0.954 
rno-miR-181a-5p 0.94 0.954 
rno-miR-122-5p 0.96 0.954 
rno-miR-21-5p 0.98 0.954 
rno-miR-330-5p 0.80 0.954 
rno-miR-1249 1.06 0.954 
rno-miR-143-5p 0.71 0.954 
rno-let-7d-5p 0.93 0.954 
rno-miR-10a-3p 0.94 0.954 
rno-miR-222-3p 1.21 0.954 
rno-miR-361-3p 1.12 0.954 
rno-miR-24-2-5p 0.93 0.954 
rno-let-7f-2-3p 1.06 0.954 
rno-miR-148b-5p 1.15 0.954 
rno-miR-32-5p 0.92 0.954 
rno-miR-99b-5p 0.97 0.954 
rno-miR-532-5p 1.04 0.954 
rno-miR-3577 1.09 0.959 
rno-miR-92a-1-5... 1.06 0.959 
rno-miR-199a-3p 0.98 0.969 
rno-miR-31a-5p 0.97 1 
rno-miR-879-5p 0.00 1 
rno-miR-190a-5p 1.04 1 
rno-miR-101b-3p 0.99 1 
rno-miR-7a-5p 1.01 1 
rno-miR-203a-3p 0.99 1 
rno-miR-28-3p 1.01 1 
miRNA ID FC P Adj 
rno-miR-203b-3p 1.08 1 
rno-miR-192-3p 0.95 1 
rno-miR-215 1.44 1 
rno-miR-152-3p 1.05 1 
rno-miR-142-5p 1.01 1 
rno-let-7c-5p 0.99 1 
rno-miR-31a-3p 0.99 1 
rno-miR-92b-3p 1.12 1 
rno-miR-223-3p 1.05 1 
rno-miR-6329 1.00 1 
rno-miR-152-5p 1.02 1 
rno-miR-192-5p 1.00 1 
rno-miR-219-5p 0.00 1 
rno-miR-20a-5p 1.01 1 
rno-miR-221-5p 0.00 1 
rno-miR-98-5p 1.00 1 
rno-miR-122-3p 1.02 1 
rno-mir-322* 0.00 1 
rno-miR-450a-5p 1.01 1 
rno-miR-363-3p 0.00 1 
rno-miR-338-5p 0.00 1 
rno-miR-17-5p 1.03 1 
rno-miR-128-3p 1.07 1 
rno-miR-185-5p 0.86 1 
rno-let-7b-5p 0.95 1 
rno-miR-872-5p 1.02 1 
rno-miR-130a-3p 0.99 1 
rno-miR-101a-3p 1.01 1 
rno-miR-18a-5p 1.22 1 
rno-miR-664-2-5... 1.46 1 
rno-miR-466c-5p 1.12 1 
rno-miR-324-5p 0.00 1 
rno-miR-1843-3p 0.00 1 
rno-mir-425* 1.46 1 
rno-miR-15b-3p 0.00 1 
rno-mir-350* 0.79 1 
rno-miR-455-3p 1.02 1 
rno-miR-582-3p 0.88 1 
rno-let-7i-5p 0.99 1 
rno-miR-204-5p 0.87 1 
rno-miR-144-5p 1.03 1 
rno-miR-455-5p 1.14 1 
rno-miR-181c-3p 1.02 1 
rno-let-7a-5p 1.00 1 
rno-miR-499-5p 0.89 1 
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miRNA ID FC P Adj 
rno-miR-3585-5p 1.11 1 
rno-miR-652-3p 1.06 1 
rno-miR-30a-3p 0.97 1 
rno-miR-127-3p 1.16 1 
rno-miR-210-3p 0.99 1 
rno-miR-194-3p 1.05 1 
rno-miR-181a-1-... 1.02 1 
miRNA ID FC P Adj 
rno-miR-3557-3p 0.00 1 
rno-miR-34c-5p 0.99 1 
rno-miR-151-3p 0.98 1 
rno-miR-331-3p 1.02 1 
rno-miR-133a-3p 0.00 1 
rno-miR-7a-1-3p 1.20 1 
rno-miR-375-3p 0.93 1 
SYN 50 ppm______________________________________________________ 
miRNA ID FC P Adj 
rno-miR-146a-5p 3.73 6.99E-33 
rno-miR-191a-5p 2.27 1.56E-26 
rno-miR-126a-5p 2.1 9.75E-24 
rno-miR-21-3p 2.7 1.34E-13 
rno-miR-99a-5p 2.3 1.94E-13 
rno-miR-99b-5p 2.02 1.36E-09 
rno-miR-142-5p 2.09 2.02E-09 
rno-miR-183-5p 2.8 2.02E-09 
rno-miR-193-3p 0.4486 3.90E-09 
rno-miR-151-3p 1.77 4.65E-08 
rno-miR-151-5p 1.82 5.36E-07 
rno-miR-127-3p 2.8 9.53E-07 
rno-miR-19b-3p 0.53 0.0002 
rno-miR-361-5p 2.02 0.0002 
rno-miR-466b-1-... 0.00E+00 0.0003 
rno-miR-145-5p 0.542 0.0004 
rno-miR-148b-3p 1.59 0.0007 
rno-miR-10a-5p 1.43 0.0009 
rno-miR-145-3p 1.9 0.0009 
rno-miR-192-5p 1.36 0.0009 
rno-miR-141-3p 1.91 0.0016 
rno-miR-450a-5p 1.68 0.0029 
rno-miR-423-3p 0.5628 0.0031 
rno-miR-103-3p 0.6446 0.0054 
rno-miR-30b-3p 2 0.006 
rno-miR-146b-5p 1.6 0.0068 
rno-miR-130b-3p Inf 0.0157 
rno-miR-326-3p 0.4319 0.0157 
rno-miR-27a-3p 1.5 0.0162 
rno-miR-199a-5p 1.66 0.0171 
rno-miR-31a-5p 0.7084 0.0185 
rno-miR-28-3p 1.35 0.0217 
rno-miR-351-5p 1.43 0.0217 
miRNA ID FC P Adj 
rno-miR-98-3p Inf 0.0305 
rno-miR-195-5p 1.42 0.0367 
rno-miR-204-5p 1.41 0.0367 
rno-miR-26a-5p 1.26 0.0439 
rno-miR-31a-3p 0.6028 0.0527 
rno-miR-7a-1-3p 2.59 0.0631 
rno-miR-132-3p 2.96 0.0649 
rno-miR-101a-3p 0.7949 0.0649 
rno-miR-221-5p 0.7418 0.0682 
rno-miR-24-3p 1.38 0.072 
rno-miR-19a-3p 0.5638 0.072 
rno-miR-425-5p 1.46 0.0812 
rno-miR-802-5p 1.27 0.0812 
rno-miR-181b-5p 0.6625 0.0812 
rno-miR-374-3p 2.28 0.0812 
rno-miR-125b-5p 1.33 0.0812 
rno-miR-101b-3p 0.8072 0.0848 
rno-miR-181a-5p 0.7454 0.0854 
rno-miR-322-3p 0.5814 0.0896 
rno-miR-331-3p 0.6312 0.0906 
rno-miR-1839-3p 0.538 0.1035 
rno-miR-21-5p 0.8335 0.1035 
rno-miR-872-3p 0.6791 0.105 
rno-miR-26b-3p 0.5862 0.1058 
rno-miR-375-3p 0.7144 0.1058 
rno-let-7b-5p 0.7413 0.109 
rno-miR-30b-5p 0.7679 0.112 
rno-miR-3068-3p 0.6025 0.1316 
rno-miR-191a-3p 2 0.1316 
rno-miR-221-3p 0.7296 0.1316 
rno-miR-181a-1-... 0.6614 0.1316 
rno-miR-6215 0.7763 0.1342 
rno-miR-3577 0.5336 0.1366 
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miRNA ID FC P Adj 
rno-miR-22-5p 0.7473 0.1505 
rno-miR-150-5p 0.6874 0.1603 
rno-miR-18a-5p 2.56 0.1634 
rno-miR-29a-5p 0.2497 0.1784 
rno-miR-338-3p 1.58 0.1844 
rno-miR-92a-3p 1.16 0.1844 
rno-miR-144-5p 0.7093 0.1844 
rno-miR-210-3p 0.7485 0.1844 
rno-miR-320-3p 0.7523 0.1867 
rno-miR-181c-5p 0.7793 0.1867 
rno-miR-186-5p 1.22 0.2087 
rno-miR-184 2.04 0.2135 
rno-miR-374-5p 1.44 0.2155 
rno-let-7c-5p 0.799 0.2156 
rno-miR-322-5p 1.29 0.2156 
rno-miR-27b-3p 1.17 0.2329 
rno-let-7f-1-3p 1.46 0.2395 
rno-miR-293-5p 0.3593 0.2475 
rno-mir-322* 0.4956 0.2791 
rno-miR-1843-5p 0.753 0.2794 
rno-miR-301a-3p 0.7615 0.2953 
rno-miR-342-3p 1.41 0.3033 
rno-miR-29c-5p 0.5105 0.3317 
rno-miR-122-3p 0.8084 0.3317 
rno-miR-107-3p 0.8297 0.3317 
rno-miR-16-5p 1.2 0.3319 
rno-miR-532-3p 0.6259 0.3372 
rno-miR-92b-3p 2 0.341 
rno-miR-340-5p 0.8142 0.3714 
rno-miR-879-5p 0.00E+00 0.387 
rno-miR-142-3p 0.8315 0.387 
rno-miR-363-3p 2.22 0.387 
rno-miR-130a-3p 1.2 0.387 
rno-miR-674-5p 0.4959 0.387 
rno-miR-30c-1-3... 1.3 0.387 
rno-miR-542-5p 3.2 0.388 
rno-let-7i-3p 1.01 0.388 
rno-miR-223-3p 1.41 0.3959 
rno-miR-125a-5p 1.15 0.3959 
rno-miR-3559-3p 0.7365 0.3976 
rno-miR-100-5p 1.26 0.3976 
rno-miR-203a-3p 0.8399 0.405 
rno-miR-194-5p 1.15 0.405 
rno-miR-29a-3p 1.19 0.405 
rno-miR-455-3p 0.7777 0.405 
miRNA ID FC P Adj 
rno-miR-30a-5p 1.13 0.405 
rno-miR-3585-5p 0.6896 0.405 
rno-miR-222-3p 1.47 0.405 
rno-miR-365-3p 1.25 0.405 
rno-miR-152-3p 1.23 0.4272 
rno-miR-139-5p 0.816 0.4272 
rno-miR-423-5p 0.7869 0.4272 
rno-miR-200a-5p 0.3538 0.4272 
rno-miR-500-3p 2.8 0.4272 
rno-miR-582-3p 0.5245 0.4276 
rno-miR-99a-3p 0.8046 0.4276 
rno-let-7d-5p 0.8549 0.4276 
rno-miR-144-3p 1.35 0.4276 
rno-miR-3557-3p 0.00E+00 0.4276 
rno-miR-152-5p 0.7496 0.4381 
rno-miR-338-5p 0.00E+00 0.4381 
rno-miR-429 1.34 0.4381 
rno-miR-15b-3p 3.07 0.4471 
rno-miR-33-5p 0.8629 0.4472 
rno-miR-20a-5p 0.8234 0.4503 
rno-miR-29b-3p 0.8649 0.4547 
rno-mir-126* 1.48 0.4705 
rno-miR-128-3p 1.38 0.4705 
rno-miR-23a-3p 1.17 0.4705 
rno-miR-455-5p 0.9407 0.4705 
rno-let-7a-5p 0.8762 0.4769 
rno-miR-195-3p 0.819 0.4903 
rno-miR-32-5p 1.4 0.5051 
rno-miR-200b-3p 1.17 0.507 
rno-miR-30c-2-3... 0.8304 0.514 
rno-miR-6329 0.8088 0.5172 
rno-miR-872-5p 1.16 0.5172 
rno-miR-652-3p 1.22 0.5203 
rno-miR-434-3p 0.451 0.5246 
rno-miR-125b-2-... 1.16 0.5312 
rno-miR-378a-5p 0.8009 0.5377 
rno-miR-411-5p 1.66 0.542 
rno-miR-381-3p 0.4255 0.542 
rno-miR-28-5p 1.13 0.542 
rno-miR-27a-5p 0.7841 0.542 
rno-miR-143-3p 1.13 0.542 
rno-miR-466c-5p 1.43 0.542 
rno-miR-1839-5p 0.805 0.542 
rno-mir-425* 1.9 0.542 
rno-miR-140-5p 0.7815 0.542 
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miRNA ID FC P Adj 
rno-miR-3559-5p 0.8804 0.542 
rno-let-7i-5p 0.8991 0.542 
rno-miR-93-5p 0.8592 0.542 
rno-let-7f-5p 0.8998 0.542 
rno-miR-671 1.16 0.542 
rno-miR-17-5p 0.8811 0.5593 
rno-miR-200c-3p 0.7956 0.5893 
rno-miR-3473 0.5117 0.5893 
rno-miR-148b-5p 1.24 0.6061 
rno-miR-181a-2-... 0.8144 0.6176 
rno-miR-339-3p 1.13 0.6202 
rno-miR-143-5p 1.66 0.6217 
rno-miR-24-2-5p 1.18 0.6217 
rno-miR-34c-5p 0.8515 0.6217 
rno-miR-29c-3p 1.17 0.6217 
rno-miR-96-5p 1.77 0.6257 
rno-miR-328a-3p 0.826 0.6257 
rno-miR-345-5p 0.8556 0.6257 
rno-miR-133a-3p 0.00E+00 0.6257 
rno-miR-185-5p 0.6318 0.6331 
rno-let-7a-1-3p... 1.13 0.6501 
rno-let-7b-3p 0.863 0.6607 
rno-miR-378a-3p 0.8812 0.6646 
rno-miR-218a-5p 1.04 0.694 
rno-miR-26b-5p 0.9177 0.7171 
rno-miR-219-5p 3.53 0.7192 
rno-miR-203b-3p 1.15 0.7268 
rno-miR-30d-3p 1.06 0.7404 
rno-miR-126a-3p 0.9364 0.7577 
rno-miR-499-5p 0.8821 0.7759 
rno-miR-1843-3p 1.06 0.7773 
rno-miR-26a-3p 0.8698 0.7773 
rno-miR-7a-5p 0.7865 0.7953 
rno-miR-27b-5p 1.07 0.798 
rno-miR-92a-1-5... 1.07 0.798 
rno-miR-532-5p 0.9161 0.8043 
rno-miR-1249 0.8101 0.8332 
rno-miR-664-3p 1.12 0.8437 
rno-miR-339-5p 1.11 0.8608 
rno-miR-664-2-5... 1.99 0.8617 
rno-miR-361-3p 1.17 0.8617 
rno-let-7e-5p 0.9367 0.8623 
rno-miR-106b-5p 1.11 0.8631 
rno-miR-136-3p 2.85 0.8631 
rno-miR-30c-5p 0.9261 0.8891 
miRNA ID FC P Adj 
rno-miR-505-3p 0.9915 0.8907 
rno-miR-542-3p 1.13 0.9038 
rno-miR-30e-3p 0.9101 0.9154 
rno-miR-30d-5p 0.92 0.9481 
rno-miR-30e-5p 0.9623 0.9481 
rno-miR-330-5p 1.31 0.9567 
rno-miR-25-3p 1.03 0.9602 
rno-miR-484 1.14 0.9602 
rno-miR-101a-5p 1.28 0.9689 
rno-miR-199a-3p 0.9986 0.9739 
rno-miR-15b-5p 1.1 0.9753 
rno-miR-350 0.8901 0.9767 
rno-miR-106b-3p 1.04 0.9816 
rno-miR-33-3p 1.2 0.9816 
rno-miR-34a-5p 1.05 0.9941 
rno-miR-215 1.34 0.9941 
rno-miR-182 0.9143 0.9941 
rno-miR-190a-5p 1.08 1 
rno-miR-672-5p Inf 1 
rno-miR-192-3p 1.04 1 
rno-miR-9a-5p Inf 1 
rno-miR-345-3p 0.9245 1 
rno-miR-181d-5p 0.9634 1 
rno-miR-421-3p 0.8405 1 
rno-miR-490-3p 1.13 1 
rno-miR-210-5p Inf 1 
rno-let-7e-3p Inf 1 
rno-miR-497-5p 1.02 1 
rno-miR-6324 Inf 1 
rno-miR-335 1.06 1 
rno-miR-138-5p 1.12 1 
rno-miR-410-3p Inf 1 
rno-miR-22-3p 1.01 1 
rno-miR-98-5p 1.04 1 
rno-miR-340-3p 0.7923 1 
rno-miR-425-3p Inf 1 
rno-miR-125b-1-... Inf 1 
rno-miR-10b-5p Inf 1 
rno-miR-122-5p 0.9779 1 
rno-miR-24-1-5p Inf 1 
rno-miR-324-5p 2.45 1 
rno-miR-140-3p 0.9945 1 
rno-let-7d-3p 0.9885 1 
rno-miR-451-5p 1.04 1 
rno-mir-350* 0.904 1 
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miRNA ID FC P Adj 
rno-miR-874-3p Inf 1 
rno-miR-188-5p 0.9363 1 
rno-miR-449a-5p Inf 1 
rno-miR-466b-2-... 1.03 1 
rno-miR-802-3p 0.9504 1 
rno-miR-201-5p Inf 1 
rno-miR-674-3p 1.02 1 
rno-miR-378b Inf 1 
rno-miR-193-5p Inf 1 
rno-miR-23b-3p 1.01 1 
rno-miR-582-5p Inf 1 
rno-miR-200a-3p 1.06 1 
rno-miR-181c-3p 0.9386 1 
rno-miR-10a-3p 1.07 1 
rno-miR-30a-3p 0.9987 1 
rno-miR-17-1-3p Inf 1 
miRNA ID FC P Adj 
rno-miR-362-3p 0.9956 1 
rno-mir-421* Inf 1 
rno-miR-194-3p 1.07 1 
rno-miR-214-3p 1.04 1 
rno-miR-3558-3p Inf 1 
rno-miR-190b-5p 0.9724 1 
rno-miR-153-3p Inf 1 
rno-let-7f-2-3p 0.9779 1 
rno-miR-511-5p Inf 1 
rno-miR-93-3p Inf 1 
rno-mir-28* Inf 1 
rno-miR-136-5p Inf 1 
rno-miR-190a-3p Inf 1 
rno-miR-147 Inf 1 
rno-miR-501-3p Inf 1 
rno-miR-511-3p 1.03 1 
SYN 500 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-484 0.2815 3.31E-05 
rno-miR-21-3p 2.37 0.0003 
rno-miR-191a-5p 1.58 0.0027 
rno-miR-99a-5p 1.73 0.0067 
rno-miR-126a-5p 1.51 0.0145 
rno-miR-184 3.18 0.0266 
rno-miR-145-5p 0.5374 0.0575 
rno-miR-192-5p 1.27 0.0694 
rno-miR-151-3p 1.44 0.1633 
rno-miR-146a-5p 1.74 0.1638 
rno-miR-92a-3p 1.27 0.1638 
rno-miR-146b-5p 0.723 0.1638 
rno-miR-99b-5p 1.36 0.1638 
rno-miR-183-5p 1.82 0.1638 
rno-miR-151-5p 1.4 0.2119 
rno-miR-204-5p 1.62 0.2223 
rno-miR-28-3p 1.31 0.2372 
rno-miR-142-5p 1.48 0.2967 
rno-miR-142-3p 0.6409 0.301 
rno-miR-326-3p 0.4069 0.3209 
rno-miR-30b-3p 1.99 0.3606 
rno-miR-193-3p 0.6852 0.3662 
rno-miR-19b-3p 0.6399 0.4094 
miRNA ID FC P Adj 
rno-mir-126* 0.2966 0.4104 
rno-miR-221-5p 2.12 0.4104 
rno-miR-1839-3p 1.11 0.4104 
rno-miR-6215 1.35 0.4104 
rno-miR-125b-5p 1.26 0.4104 
rno-miR-671 1.56 0.4104 
rno-miR-31a-3p 0.634 0.4658 
rno-miR-29a-3p 1.28 0.4658 
rno-miR-802-5p 1.27 0.4658 
rno-miR-10a-5p 0.852 0.4686 
rno-miR-542-3p 0.6461 0.4888 
rno-miR-127-3p 0.6843 0.5506 
rno-miR-29c-5p 0.1824 0.5744 
rno-miR-191a-3p 2.24 0.5902 
rno-miR-19a-3p 0.5162 0.5902 
rno-miR-203b-3p 1.34 0.683 
rno-miR-350 0.1859 0.6958 
rno-miR-322-3p 0.6499 0.6958 
rno-miR-466b-1-... 0.00E+00 0.6958 
rno-miR-674-5p 0.2467 0.6958 
rno-miR-181b-5p 0.7393 0.6958 
rno-miR-25-3p 1.21 0.6958 
rno-miR-181c-5p 0.7751 0.6958 
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miRNA ID FC P Adj 
rno-miR-148b-3p 1.26 0.6958 
rno-miR-339-5p 1.29 0.7373 
rno-miR-218a-5p 0.5212 0.7457 
rno-let-7f-5p 1.11 0.7457 
rno-miR-181a-5p 0.8206 0.8233 
rno-miR-141-3p 0.8805 0.8233 
rno-miR-200c-3p 0.5481 0.8233 
rno-miR-3585-5p 0.4776 0.8233 
rno-miR-429 1.28 0.8233 
rno-miR-100-5p 1.19 0.8233 
rno-miR-126a-3p 0.8575 0.8508 
rno-miR-331-3p 0.663 0.8717 
rno-miR-31a-5p 0.8507 0.9187 
rno-miR-7a-5p 0.5911 0.9187 
rno-miR-215 0.518 0.9187 
rno-miR-27b-3p 1.12 0.9187 
rno-miR-181d-5p 0.7133 0.9187 
rno-miR-421-3p 0.503 0.9187 
rno-miR-194-5p 1.14 0.9187 
rno-miR-22-5p 0.8285 0.9187 
rno-miR-139-5p 0.8402 0.9187 
rno-miR-219-5p 2.91 0.9187 
rno-miR-301a-3p 0.7757 0.9187 
rno-miR-30e-5p 0.8743 0.9187 
rno-miR-195-3p 0.747 0.9187 
rno-miR-450a-5p 1.25 0.9187 
rno-miR-339-3p 1.18 0.9187 
rno-miR-3577 0.6626 0.9187 
rno-miR-181a-2-... 0.67 0.9187 
rno-let-7b-5p 0.8386 0.9187 
rno-miR-324-5p 2.54 0.9187 
rno-miR-15b-3p 2.4 0.9187 
rno-miR-1249 0.5339 0.9187 
rno-miR-140-5p 0.7045 0.9187 
rno-miR-378a-3p 1.03 0.9187 
rno-miR-802-3p 1.12 0.9187 
rno-miR-328a-3p 0.6842 0.9187 
rno-miR-144-5p 0.7527 0.9187 
rno-let-7a-5p 1.07 0.9187 
rno-miR-499-5p 0.5638 0.9187 
rno-miR-125b-2-... 1.2 0.9187 
rno-miR-652-3p 1.31 0.9187 
rno-miR-107-3p 1.15 0.9187 
rno-miR-362-3p 0.484 0.9187 
rno-miR-3557-3p 3.11 0.9187 
miRNA ID FC P Adj 
rno-miR-26b-3p 0.6997 0.9187 
rno-miR-26b-5p 0.8912 0.9187 
rno-miR-30c-1-3... 1.34 0.9187 
rno-miR-879-5p 0.00E+00 0.9188 
rno-miR-203a-3p 0.9006 0.9188 
rno-miR-30d-5p 0.9099 0.9188 
rno-miR-223-3p 0.8307 0.9188 
rno-miR-152-5p 0.7412 0.9188 
rno-miR-20a-5p 0.8464 0.9188 
rno-miR-425-5p 1.2 0.9188 
rno-miR-22-3p 1.06 0.9188 
rno-miR-143-3p 0.985 0.9188 
rno-miR-363-3p 1.48 0.9188 
rno-miR-505-3p 1.21 0.9188 
rno-miR-185-5p 0.26 0.9188 
rno-miR-199a-3p 0.9224 0.9188 
rno-miR-18a-5p 0.2787 0.9188 
rno-miR-122-5p 0.9229 0.9188 
rno-miR-27b-5p 1.24 0.9188 
rno-miR-451-5p 1.17 0.9188 
rno-miR-101a-5p 0.5943 0.9188 
rno-miR-466b-2-... 0.8007 0.9188 
rno-miR-361-5p 1.27 0.9188 
rno-miR-200a-3p 0.879 0.9188 
rno-miR-181c-3p 0.45 0.9188 
rno-miR-222-3p 0.5926 0.9188 
rno-miR-3559-3p 0.7566 0.9188 
rno-miR-30a-3p 1.13 0.9188 
rno-miR-374-3p 1.62 0.9188 
rno-miR-423-3p 0.7908 0.9188 
rno-miR-194-3p 0.8614 0.9188 
rno-miR-365-3p 1.22 0.9188 
rno-miR-181a-1-... 0.7394 0.9188 
rno-miR-136-3p 0.00E+00 0.9188 
rno-miR-322-5p 0.8716 0.9188 
rno-miR-34c-5p 0.692 0.9188 
rno-miR-32-5p 1.29 0.9188 
rno-let-7i-3p 0.00E+00 0.9188 
rno-miR-375-3p 1.07 0.9188 
rno-miR-338-5p 0.00E+00 0.9413 
rno-miR-497-5p 1.09 0.9426 
rno-miR-293-5p 0.9836 0.9666 
rno-miR-34a-5p 0.827 0.9722 
rno-miR-664-3p 0.934 0.9722 
rno-miR-101b-3p 1.04 0.9722 
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miRNA ID FC P Adj 
rno-miR-27a-3p 1.12 0.9722 
rno-miR-345-3p 0.3888 0.9722 
rno-miR-490-3p 0.6765 0.9722 
rno-let-7c-5p 1 0.9722 
rno-miR-92b-3p 0.5432 0.9722 
rno-miR-6329 0.8911 0.9722 
rno-miR-122-3p 0.9113 0.9722 
rno-miR-30b-5p 0.9123 0.9722 
rno-miR-1843-5p 0.8973 0.9722 
rno-miR-128-3p 1.31 0.9722 
rno-miR-872-5p 1.1 0.9722 
rno-miR-664-2-5... 2.18 0.9722 
rno-miR-466c-5p 0.8562 0.9722 
rno-miR-140-3p 1.06 0.9722 
rno-miR-340-5p 1.01 0.9722 
rno-miR-330-5p 0.5154 0.9722 
rno-mir-425* 0.7952 0.9722 
rno-let-7b-3p 0.872 0.9722 
rno-miR-582-3p 0.9698 0.9722 
rno-miR-221-3p 0.8423 0.9722 
rno-miR-23a-3p 0.9309 0.9722 
rno-miR-3559-5p 1.05 0.9722 
rno-miR-106b-3p 1.26 0.9722 
rno-miR-674-3p 1.11 0.9722 
rno-miR-374-5p 1.15 0.9722 
rno-miR-143-5p 0.288 0.9722 
rno-miR-10a-3p 0.907 0.9722 
rno-miR-106b-5p 1.12 0.9722 
rno-miR-144-3p 1.25 0.9722 
rno-miR-361-3p 1.03 0.9722 
rno-miR-210-3p 1 0.9722 
rno-miR-214-3p 0.8454 0.9722 
rno-miR-24-2-5p 0.918 0.9722 
rno-miR-148b-5p 0.7713 0.9722 
rno-miR-26a-3p 1.17 0.9722 
rno-miR-532-3p 0.7738 0.9722 
rno-miR-351-5p 0.9175 0.9722 
rno-miR-15b-5p 1.09 0.9722 
rno-miR-33-3p 1.08 0.9722 
rno-miR-29c-3p 1.13 0.9722 
rno-miR-92a-1-5... 0.9417 0.9722 
rno-miR-434-3p 0.5999 0.9731 
rno-miR-200b-3p 0.9598 0.9731 
rno-miR-190b-5p 0.7 0.9731 
rno-miR-342-3p 0.9188 0.9731 
miRNA ID FC P Adj 
rno-mir-350* 1 0.9787 
rno-miR-335 0.862 0.9797 
rno-miR-30e-3p 1.02 0.9797 
rno-miR-200a-5p 0.6132 0.9797 
rno-miR-30a-5p 1.04 0.9797 
rno-miR-101a-3p 0.9639 0.9858 
rno-miR-24-3p 1 0.9923 
rno-miR-190a-5p 0.85 1 
rno-miR-103-3p 0.9125 1 
rno-miR-3068-3p 0.9085 1 
rno-miR-199a-5p 1.02 1 
rno-miR-411-5p 0.6293 1 
rno-miR-29a-5p 0.00E+00 1 
rno-miR-872-3p 0.9217 1 
rno-miR-381-3p 0.00E+00 1 
rno-miR-192-3p 0.9586 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-152-3p 1.01 1 
rno-miR-28-5p 1.05 1 
rno-miR-138-5p 0.9351 1 
rno-let-7f-1-3p 1.04 1 
rno-miR-27a-5p 0.00E+00 1 
rno-miR-320-3p 1.01 1 
rno-let-7a-1-3p... 0.9069 1 
rno-miR-423-5p 0.9081 1 
rno-miR-98-5p 1.03 1 
rno-miR-132-3p 0.00E+00 1 
rno-miR-145-3p 1 1 
rno-mir-322* 0.00E+00 1 
rno-miR-340-3p 0.5575 1 
rno-miR-17-5p 0.9449 1 
rno-miR-130a-3p 1 1 
rno-miR-150-5p 0.9064 1 
rno-miR-195-5p 1.02 1 
rno-miR-98-3p Inf 1 
rno-miR-21-5p 0.9899 1 
rno-miR-338-3p 1.04 1 
rno-miR-1843-3p 0.00E+00 1 
rno-miR-30c-5p 0.9468 1 
rno-miR-30d-3p 1.02 1 
rno-miR-182 0.9237 1 
rno-let-7d-3p 1.03 1 
rno-miR-1839-5p 1.02 1 
rno-miR-16-5p 1.02 1 
rno-miR-96-5p 1.13 1 
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miRNA ID FC P Adj 
rno-miR-188-5p 0.9983 1 
rno-miR-455-3p 0.9838 1 
rno-miR-186-5p 0.9819 1 
rno-let-7i-5p 1 1 
rno-miR-23b-3p 1.03 1 
rno-miR-500-3p 1.15 1 
rno-miR-3473 0.00E+00 1 
rno-miR-455-5p 1.03 1 
rno-miR-99a-3p 1.02 1 
rno-miR-378a-5p 0.9602 1 
rno-let-7d-5p 0.9588 1 
rno-miR-29b-3p 0.9733 1 
rno-miR-17-1-3p Inf 1 
miRNA ID FC P Adj 
rno-miR-93-5p 0.9327 1 
rno-miR-33-5p 0.9527 1 
rno-miR-30c-2-3... 0.9755 1 
rno-let-7f-2-3p 0.9119 1 
rno-let-7e-5p 0.9676 1 
rno-miR-345-5p 0.9779 1 
rno-miR-26a-5p 1.02 1 
rno-miR-501-3p Inf 1 
rno-miR-133a-3p 0.00E+00 1 
rno-miR-7a-1-3p 0.6471 1 
rno-miR-532-5p 0.9855 1 
rno-miR-125a-5p 0.994 1 
rno-miR-511-3p 0.9882 1 
SYN 3000 ppm____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-127-3p 3.06 4.02E-07 
rno-miR-21-3p 2.11 6.52E-05 
rno-miR-484 0.3261 0.0041 
rno-miR-378a-3p 1.35 0.0047 
rno-miR-28-3p 1.58 0.006 
rno-miR-145-3p 0.4923 0.0077 
rno-miR-100-5p 0.5845 0.0119 
rno-miR-92a-3p 1.39 0.0158 
rno-miR-126a-3p 0.6817 0.025 
rno-miR-146a-5p 0.7105 0.0267 
rno-miR-802-5p 1.45 0.0285 
rno-miR-671 2.04 0.0296 
rno-miR-6215 0.6317 0.0543 
rno-miR-30b-3p 1.94 0.0771 
rno-miR-16-5p 0.7656 0.0771 
rno-miR-151-5p 0.7086 0.0771 
rno-miR-200c-3p 1.83 0.0774 
rno-miR-25-3p 1.36 0.1417 
rno-miR-15b-5p 0.7098 0.1417 
rno-miR-125b-5p 0.7248 0.1455 
rno-miR-125a-5p 0.7159 0.1455 
rno-miR-411-5p 2.89 0.146 
rno-let-7f-1-3p 1.82 0.146 
rno-miR-451-5p 1.39 0.146 
rno-miR-107-3p 1.47 0.146 
rno-miR-423-3p 0.6532 0.146 
miRNA ID FC P Adj 
rno-miR-17-1-3p Inf 0.1556 
rno-miR-10a-5p 0.8351 0.1617 
rno-miR-15b-3p 1.19 0.1617 
rno-miR-138-5p 2.12 0.1764 
rno-miR-99b-5p 0.7938 0.1808 
rno-miR-1843-3p 0.7093 0.1816 
rno-miR-103-3p 1.3 0.1827 
rno-miR-122-5p 0.8094 0.1827 
rno-miR-101a-3p 1.3 0.1851 
rno-miR-3559-5p 1.51 0.1862 
rno-miR-26a-5p 0.8439 0.2096 
rno-miR-151-3p 1.29 0.2154 
rno-miR-27b-5p 1.66 0.2435 
rno-miR-497-5p 1.25 0.2552 
rno-miR-192-5p 1.2 0.2552 
rno-miR-338-3p 0.7348 0.2552 
rno-miR-24-3p 0.774 0.2552 
rno-miR-146b-5p 0.8701 0.2577 
rno-miR-872-3p 1.27 0.258 
rno-miR-381-3p 4.31 0.2717 
rno-miR-29a-3p 0.822 0.2916 
rno-miR-122-3p 0.76 0.2916 
rno-miR-1843-5p 1.38 0.2916 
rno-miR-340-5p 1.34 0.2916 
rno-miR-27a-3p 0.7711 0.3112 
rno-miR-335 0.7195 0.3127 
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miRNA ID FC P Adj 
rno-miR-140-3p 1.26 0.3127 
rno-miR-434-3p 2.22 0.3136 
rno-miR-19a-3p 0.5982 0.3136 
rno-miR-320-3p 1.35 0.3289 
rno-miR-222-3p 1.73 0.3366 
rno-miR-136-3p 7.02 0.3442 
rno-miR-188-5p 1.69 0.3525 
rno-miR-195-5p 0.791 0.3529 
rno-let-7f-5p 1.17 0.3633 
rno-miR-183-5p 1.41 0.369 
rno-miR-342-3p 0.5563 0.3731 
rno-miR-34a-5p 0.626 0.3887 
rno-miR-98-5p 1.33 0.3887 
rno-miR-30c-2-3... 1.41 0.3887 
rno-miR-532-5p 1.27 0.3887 
rno-miR-191a-5p 1.19 0.4302 
rno-miR-30e-5p 0.8837 0.4443 
rno-miR-21-5p 1.16 0.4443 
rno-miR-362-3p 0.3916 0.4443 
rno-miR-322-3p 0.6985 0.4761 
rno-miR-142-3p 0.7537 0.4868 
rno-miR-182 1.14 0.4868 
rno-miR-33-5p 0.7265 0.4868 
rno-miR-374-5p 0.7218 0.5075 
rno-miR-1839-5p 1.35 0.5151 
rno-miR-200a-5p 2.04 0.5184 
rno-miR-101b-3p 1.17 0.5197 
rno-miR-223-3p 0.6788 0.5197 
rno-miR-148b-3p 1.21 0.5197 
rno-miR-466b-2-... 0.6697 0.5222 
rno-miR-802-3p 1.18 0.534 
rno-miR-130a-3p 0.8135 0.5436 
rno-miR-203a-3p 0.8763 0.5527 
rno-miR-194-5p 1.12 0.5527 
rno-miR-106b-5p 0.7182 0.5527 
rno-miR-92a-1-5... 0.7686 0.5527 
rno-miR-106b-3p 1.73 0.565 
rno-miR-144-3p 0.8446 0.5663 
rno-miR-490-3p 0.2178 0.5686 
rno-miR-28-5p 0.8117 0.5686 
rno-miR-30d-3p 1.2 0.5686 
rno-miR-181c-3p 1.52 0.5686 
rno-miR-361-3p 1.35 0.5686 
rno-miR-322-5p 0.8239 0.5686 
rno-miR-26a-3p 1.28 0.5686 
miRNA ID FC P Adj 
rno-miR-133a-3p 3.28 0.5686 
rno-miR-511-3p 0.6561 0.5686 
rno-let-7a-5p 1.1 0.5928 
rno-miR-466b-1-... 0.2539 0.5954 
rno-miR-195-3p 1.56 0.5962 
rno-miR-879-5p 0.00E+00 0.5996 
rno-miR-542-5p 0.64 0.5996 
rno-miR-421-3p 0.4863 0.5996 
rno-miR-6329 1.28 0.5996 
rno-miR-150-5p 1.02 0.5996 
rno-miR-326-3p 0.657 0.5996 
rno-miR-181b-5p 1.17 0.5996 
rno-miR-378a-5p 1.11 0.5996 
rno-miR-29b-3p 1.25 0.5996 
rno-miR-194-3p 1.28 0.5996 
rno-miR-365-3p 0.8527 0.5996 
rno-miR-190b-5p 1.45 0.5996 
rno-miR-221-5p 0.00E+00 0.6087 
rno-miR-93-5p 1.16 0.6087 
rno-let-7b-5p 0.836 0.6742 
rno-miR-674-3p 0.7594 0.6742 
rno-let-7d-5p 0.8426 0.6742 
rno-miR-27a-5p 0.5034 0.6922 
rno-miR-1839-3p 0.00E+00 0.6922 
rno-miR-99a-5p 0.9055 0.6922 
rno-miR-3557-3p 0.00E+00 0.6922 
rno-let-7f-2-3p 1.18 0.6922 
rno-let-7i-3p 0.00E+00 0.6922 
rno-miR-219-5p 2.39 0.702 
rno-miR-181a-1-... 1.18 0.702 
rno-miR-499-5p 0.7704 0.7023 
rno-miR-324-5p 2.56 0.7072 
rno-miR-338-5p 0.00E+00 0.7076 
rno-miR-126a-5p 1.1 0.7291 
rno-miR-181c-5p 1.12 0.7313 
rno-miR-3473 0.3115 0.7352 
rno-miR-144-5p 1.15 0.7352 
rno-miR-7a-5p 0.8501 0.7419 
rno-mir-126* 0.495 0.7419 
rno-miR-148b-5p 0.6709 0.7419 
rno-miR-351-5p 0.8684 0.7419 
rno-miR-203b-3p 1.22 0.7488 
rno-miR-31a-5p 0.9096 0.7671 
rno-miR-3068-3p 0.8582 0.7671 
rno-miR-350 0.6801 0.7671 
 Appendix –3 
  [ 211 ] 
miRNA ID FC P Adj 
rno-miR-27b-3p 1.09 0.7671 
rno-miR-218a-5p 0.8388 0.7671 
rno-miR-425-5p 0.8852 0.7671 
rno-miR-301a-3p 1.11 0.7671 
rno-mir-322* 0.00E+00 0.7671 
rno-miR-181a-5p 1.07 0.7671 
rno-miR-30e-3p 1.11 0.7671 
rno-miR-141-3p 1.18 0.7671 
rno-miR-30c-5p 1.03 0.7671 
rno-miR-23a-3p 0.8888 0.7671 
rno-miR-30a-5p 1.1 0.7671 
rno-miR-361-5p 0.8715 0.7671 
rno-miR-455-5p 1.21 0.7671 
rno-miR-99a-3p 1.26 0.7671 
rno-miR-3585-5p 1.2 0.7671 
rno-miR-214-3p 0.6834 0.7671 
rno-miR-24-2-5p 0.8592 0.7671 
rno-miR-34c-5p 1.19 0.7671 
rno-miR-221-3p 0.9073 0.768 
rno-miR-33-3p 1.2 0.768 
rno-miR-7a-1-3p 0.5139 0.7734 
rno-miR-199a-5p 0.865 0.7793 
rno-miR-664-3p 0.7526 0.7793 
rno-miR-20a-5p 0.8566 0.7793 
rno-miR-339-3p 1.08 0.7793 
rno-miR-872-5p 0.895 0.7888 
rno-miR-505-3p 1.14 0.8017 
rno-miR-18a-5p 0.5587 0.8017 
rno-miR-29a-5p 1.55 0.8064 
rno-let-7d-3p 1.07 0.8086 
rno-miR-19b-3p 0.92 0.8086 
rno-let-7b-3p 1.06 0.8263 
rno-miR-125b-2-... 0.9189 0.8283 
rno-miR-32-5p 0.9446 0.8335 
rno-miR-181d-5p 1.08 0.8637 
rno-miR-17-5p 0.923 0.8637 
rno-miR-145-5p 0.8611 0.8637 
rno-miR-674-5p 0.6219 0.8637 
rno-miR-26b-3p 0.7936 0.8849 
rno-miR-152-5p 1.13 0.8854 
rno-miR-191a-3p 0.8167 0.8928 
rno-miR-339-5p 0.9363 0.8928 
rno-miR-450a-5p 0.9509 0.8954 
rno-miR-142-5p 0.9265 0.8982 
rno-miR-200b-3p 0.9903 0.8982 
miRNA ID FC P Adj 
rno-miR-30c-1-3... 1.06 0.8982 
rno-miR-152-3p 0.9575 0.9014 
rno-miR-186-5p 0.9617 0.9014 
rno-miR-139-5p 0.8969 0.9415 
rno-miR-423-5p 1.07 0.9415 
rno-miR-652-3p 1.05 0.9415 
rno-miR-345-5p 1.12 0.9415 
rno-miR-31a-3p 0.8643 0.944 
rno-miR-92b-3p 0.6293 0.944 
rno-miR-22-3p 0.9811 0.944 
rno-miR-184 0.8834 0.944 
rno-miR-101a-5p 0.7747 0.944 
rno-miR-1249 1.05 0.944 
rno-let-7i-5p 1.04 0.944 
rno-miR-10a-3p 1.01 0.944 
rno-miR-429 1.05 0.944 
rno-miR-192-3p 1.04 0.9465 
rno-miR-340-3p 0.6768 0.9465 
rno-miR-3577 0.814 0.9465 
rno-mir-425* 0.7103 0.9465 
rno-miR-500-3p 1.46 0.9465 
rno-miR-30a-3p 1.05 0.9465 
rno-miR-363-3p 0.3949 0.9473 
rno-miR-190a-5p 1.07 0.9485 
rno-miR-26b-5p 0.9753 0.9485 
rno-miR-29c-3p 1.06 0.9485 
rno-miR-455-3p 0.882 0.9536 
rno-miR-193-3p 0.8899 0.9536 
rno-miR-532-3p 0.8091 0.9536 
rno-mir-350* 0.6437 0.9564 
rno-miR-293-5p 0.8383 0.9669 
rno-let-7c-5p 0.9831 0.9717 
rno-miR-374-3p 1.02 0.9717 
rno-miR-215 1.16 0.9723 
rno-miR-345-3p 0.88 0.9723 
rno-let-7a-1-3p... 1 0.9723 
rno-miR-30b-5p 0.9395 0.9723 
rno-miR-3559-3p 1.01 0.9723 
rno-miR-375-3p 1.03 0.9723 
rno-miR-30d-5p 1.01 0.9774 
rno-miR-200a-3p 1.02 0.981 
rno-miR-199a-3p 0.9979 0.9885 
rno-miR-330-5p 0.896 0.9885 
rno-miR-140-5p 0.9155 0.9885 
rno-miR-204-5p 0.8371 0.9885 
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miRNA ID FC P Adj 
rno-miR-210-3p 1.01 0.9885 
rno-let-7e-5p 0.9719 0.9885 
rno-miR-29c-5p 0.7159 1 
rno-miR-9a-5p Inf 1 
rno-miR-210-5p Inf 1 
rno-miR-22-5p 0.9373 1 
rno-miR-542-3p 1.07 1 
rno-miR-410-3p Inf 1 
rno-miR-143-3p 1.07 1 
rno-miR-132-3p 0.8616 1 
rno-miR-128-3p 1.16 1 
rno-miR-181a-2-... 1.02 1 
rno-miR-185-5p 0.8359 1 
rno-miR-98-3p Inf 1 
rno-miR-664-2-5... 1.1 1 
rno-miR-466c-5p 1.07 1 
rno-miR-96-5p 0.00E+00 1 
rno-miR-582-3p 0.7387 1 
rno-miR-328a-3p 0.9332 1 
rno-miR-23b-3p 0.9901 1 
rno-miR-143-5p 0.9312 1 
rno-mir-455* Inf 1 
rno-miR-136-5p Inf 1 
rno-miR-331-3p 0.9255 1 
  
Appendix-4.  Day-28 known miRNAs 
 
List of all known miRNAs detected at the 28th day of treatment by miRanalyzer.  miRNAs listed 
are ordered by treatment and ranked by P Adj values. 
 
PB 50 ppm________________________________________________________ 
miRNA ID FC P Adj 
rno-miR-6215 3.58 3.05E-12 
rno-miR-3068-3p 3.19 0.0019 
rno-miR-92b-3p 1.24 0.6084 
rno-miR-200b-3p 1.75 0.6084 
rno-miR-345-5p 1.27 0.6084 
rno-miR-31a-5p 0.8626 1 
rno-miR-34a-5p 0.00E+00 1 
rno-miR-29c-5p 0.00E+00 1 
rno-miR-190a-5p 0.4114 1 
rno-miR-103-3p 0.9899 1 
rno-miR-199a-5p 1.93 1 
rno-miR-21* 0.00E+00 1 
rno-miR-872-3p 0.8949 1 
rno-miR-29a-5p 0.00E+00 1 
rno-miR-664-3p 1.72 1 
rno-miR-101b-3p 0.9479 1 
rno-miR-191a-5p 1.06 1 
rno-miR-203a-3p 0.8854 1 
rno-miR-28-3p 0.9192 1 
rno-miR-203b-3p 0.5651 1 
rno-miR-192-3p 1.15 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-215 1.44 1 
rno-miR-27a-3p 1.2 1 
rno-miR-345-3p 0.00E+00 1 
rno-miR-9a-5p 0.00E+00 1 
rno-miR-27b-3p 1.04 1 
rno-miR-30d-5p 1.03 1 
miRNA ID FC P Adj 
rno-miR-152-3p 1.12 1 
rno-miR-142-5p 1.31 1 
rno-miR-181d-5p 0.7366 1 
rno-miR-421-3p 0.6309 1 
rno-miR-490-3p 0.00E+00 1 
rno-let-7c-5p 0.9939 1 
rno-miR-31a-3p 0.5615 1 
rno-miR-146a-5p 1.14 1 
rno-let-7e-3p 0.00E+00 1 
rno-miR-194-5p 0.9824 1 
rno-miR-22-5p 0.8638 1 
rno-miR-497-5p 1.12 1 
rno-miR-434-3p 0.8791 1 
rno-miR-542-3p 0.7387 1 
rno-miR-335 2.32 1 
rno-miR-223-3p 1.29 1 
rno-miR-28-5p 0.9523 1 
rno-miR-6329 0.9256 1 
rno-miR-139-5p 0.9509 1 
rno-miR-138-5p 0.7617 1 
rno-let-7f-1-3p 0.9855 1 
rno-miR-29a-3p 0.9033 1 
rno-miR-322-3p 1.13 1 
rno-miR-152-5p 0.5843 1 
rno-miR-142-3p 1.17 1 
rno-miR-192-5p 0.9212 1 
rno-miR-320-3p 0.8202 1 
rno-miR-126a-5p 1.13 1 
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miRNA ID FC P Adj 
rno-miR-219-5p Inf 1 
rno-miR-20a-5p 1.18 1 
rno-let-7a-1-3p... 1.03 1 
rno-mir-126* 0.00E+00 1 
rno-miR-423-5p 0.7725 1 
rno-mir-21* 0.00E+00 1 
rno-miR-425-5p 1.05 1 
rno-miR-30e-5p 0.9773 1 
rno-miR-10a-5p 1.03 1 
rno-miR-301a-3p 1.16 1 
rno-miR-22-3p 0.9281 1 
rno-miR-98-5p 0.8974 1 
rno-miR-143-3p 1.16 1 
rno-miR-195-3p 1 1 
rno-miR-122-3p 0.9001 1 
rno-miR-30b-5p 1 1 
rno-miR-145-3p 0.6488 1 
rno-mir-322* 0.6209 1 
rno-miR-340-3p 0.8903 1 
rno-miR-450a-5p 1.08 1 
rno-miR-363-3p 0.00E+00 1 
rno-miR-339-3p 1.09 1 
rno-miR-1843-5p 0.7239 1 
rno-miR-126a-3p 0.9718 1 
rno-miR-3577 0.9153 1 
rno-miR-17-5p 1.17 1 
rno-miR-128-3p 1.08 1 
rno-miR-802-5p 1.22 1 
rno-miR-505-3p 0.6953 1 
rno-miR-181a-2-... 1.05 1 
rno-miR-181a-5p 0.9892 1 
rno-miR-199a-3p 1.37 1 
rno-miR-30e-3p 1.05 1 
rno-let-7b-5p 0.8783 1 
rno-miR-872-5p 1.01 1 
rno-miR-130a-3p 1.09 1 
rno-miR-150-5p 0.8932 1 
rno-miR-195-5p 1.25 1 
rno-miR-101a-3p 0.9562 1 
rno-miR-98-3p 0.9802 1 
rno-miR-664-2-5... 1.05 1 
rno-miR-145-5p 1.39 1 
rno-miR-122-5p 0.926 1 
rno-miR-466c-5p 0.2378 1 
rno-miR-21-5p 0.9667 1 
miRNA ID FC P Adj 
rno-miR-191a-3p 0.6771 1 
rno-miR-140-3p 0.9521 1 
rno-miR-30b-3p 0.7981 1 
rno-miR-340-5p 0.888 1 
rno-miR-141-3p 0.6275 1 
rno-miR-338-3p 0.6835 1 
rno-miR-1843-3p 0.2722 1 
rno-miR-330-5p 0.00E+00 1 
rno-miR-27b-5p 1.04 1 
rno-miR-24-3p 1.28 1 
rno-miR-30d-3p 1.21 1 
rno-miR-30c-5p 0.9422 1 
rno-miR-182 1 1 
rno-miR-451-5p 1.1 1 
rno-let-7d-3p 0.8411 1 
rno-miR-1839-5p 0.911 1 
rno-miR-92a-3p 0.9439 1 
rno-miR-16-5p 0.9956 1 
rno-let-7b-3p 1.06 1 
rno-miR-96-5p 2.14 1 
rno-mir-350* 0.00E+00 1 
rno-miR-188-5p 0.275 1 
rno-miR-1249 0.4192 1 
rno-miR-326-3p 0.00E+00 1 
rno-miR-455-3p 1.87 1 
rno-miR-582-3p 0.00E+00 1 
rno-miR-140-5p 0.8421 1 
rno-miR-378a-3p 0.9031 1 
rno-miR-186-5p 1.06 1 
rno-miR-221-3p 1.05 1 
rno-miR-466b-2-... 1.2 1 
rno-miR-293-5p 0.00E+00 1 
rno-miR-23a-3p 1.33 1 
rno-miR-3559-5p 1.2 1 
rno-miR-181b-5p 1.03 1 
rno-miR-802-3p 1.08 1 
rno-miR-106b-3p 1.09 1 
rno-miR-21-3p 1.64 1 
rno-miR-674-3p 1.4 1 
rno-miR-374-5p 1.28 1 
rno-miR-328a-3p 0.7632 1 
rno-miR-30a-5p 0.9966 1 
rno-let-7i-5p 0.979 1 
rno-miR-23b-3p 1.39 1 
rno-miR-143-5p 0.7803 1 
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miRNA ID FC P Adj 
rno-miR-361-5p 0.9866 1 
rno-miR-19a-3p 0.9165 1 
rno-miR-204-5p 1.06 1 
rno-miR-3473 8.95 1 
rno-miR-144-5p 0.6894 1 
rno-miR-455-5p 0.7207 1 
rno-miR-181c-3p 0.00E+00 1 
rno-miR-200a-3p 2.43 1 
rno-miR-99a-3p 1.08 1 
rno-let-7a-5p 0.9188 1 
rno-miR-25-3p 1.03 1 
rno-miR-378a-5p 0.7157 1 
rno-miR-499-5p 0.337 1 
rno-let-7d-5p 1 1 
rno-miR-3585-5p 3.47 1 
rno-miR-339-5p 0.5928 1 
rno-miR-10a-3p 0.7957 1 
rno-miR-181c-5p 0.8786 1 
rno-miR-222-3p 0.8269 1 
rno-miR-125b-2-... 0.9709 1 
rno-miR-29b-3p 1.23 1 
rno-miR-3559-3p 0.00E+00 1 
rno-miR-652-3p 2.77 1 
rno-miR-106b-5p 1.12 1 
rno-miR-107-3p 0.9274 1 
rno-miR-30a-3p 0.9894 1 
rno-miR-429 1.18 1 
rno-miR-374-3p 1.65 1 
rno-miR-423-3p 0.8422 1 
rno-miR-93-5p 0.9845 1 
rno-miR-144-3p 0.9016 1 
rno-miR-33-5p 0.7795 1 
rno-miR-361-3p 0.7799 1 
rno-miR-210-3p 1.11 1 
rno-miR-127-3p 0.5135 1 
rno-miR-151-5p 0.9585 1 
rno-miR-193-3p 0.8344 1 
rno-miR-194-3p 0.7839 1 
rno-miR-365-3p 0.9746 1 
   
miRNA ID FC P Adj 
rno-miR-214-3p 4.54 1 
rno-miR-99a-5p 0.9014 1 
rno-miR-181a-1-... 1.26 1 
rno-miR-322-5p 1.22 1 
rno-miR-24-2-5p 1.12 1 
rno-miR-26b-3p 0.7684 1 
rno-miR-30c-2-3... 0.9924 1 
rno-let-7f-2-3p 0.9371 1 
rno-miR-148b-5p 1.28 1 
rno-miR-26a-3p 0.2148 1 
rno-miR-26b-5p 0.9951 1 
rno-miR-511-5p Inf 1 
rno-miR-532-3p 0.00E+00 1 
rno-let-7f-5p 0.8756 1 
rno-miR-351-5p 1.1 1 
rno-miR-34c-5p 1.38 1 
rno-miR-484 0.2954 1 
rno-miR-151-3p 0.9206 1 
rno-miR-15b-5p 0.8644 1 
rno-miR-33-3p 0.9035 1 
rno-miR-32-5p 0.9785 1 
rno-miR-29c-3p 0.9468 1 
rno-miR-342-3p 0.9436 1 
rno-miR-100-5p 0.5334 1 
rno-let-7e-5p 0.8587 1 
rno-miR-125b-5p 0.7738 1 
rno-miR-331-3p 0.00E+00 1 
rno-miR-92a-1-5... 1.28 1 
rno-miR-146b-5p 1.44 1 
rno-miR-19b-3p 1.18 1 
rno-miR-30c-1-3... 0.5681 1 
rno-miR-26a-5p 1.04 1 
rno-miR-99b-5p 1.14 1 
rno-miR-148b-3p 1.11 1 
rno-miR-183-5p 1.56 1 
rno-miR-375-3p 1.1 1 
rno-miR-125a-5p 0.8867 1 
rno-miR-532-5p 1 1 
rno-miR-671 0.7642 1 
rno-miR-511-3p 0.5953 1 
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PB 1000 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-200b-3p 4 1.00E-13 
rno-miR-182 2.4 2.96E-13 
rno-miR-429 2.78 0.0373 
rno-miR-200a-3p 4.44 0.0855 
rno-miR-122-5p 0.7839 0.4508 
rno-miR-3068-3p 1.79 0.5525 
rno-miR-802-5p 1.47 0.5525 
rno-miR-96-5p 7.34 0.5525 
rno-miR-33-5p 0.1163 0.5525 
rno-miR-99b-5p 0.7144 0.5525 
rno-miR-183-5p 3.57 0.5525 
rno-miR-92b-3p 2 0.6036 
rno-miR-338-3p 0.0788 0.7352 
rno-miR-802-3p 1.59 0.7352 
rno-miR-3473 1.6 0.7352 
rno-miR-125a-5p 0.7297 0.7352 
rno-miR-674-3p 0.3224 0.8216 
rno-miR-31a-5p 0.9718 1 
rno-miR-34a-5p 0.6632 1 
rno-miR-29c-5p 0.00E+00 1 
rno-miR-190a-5p 0.00E+00 1 
rno-miR-103-3p 1.05 1 
rno-miR-199a-5p 0.6922 1 
rno-miR-21* 0.00E+00 1 
rno-miR-872-3p 0.9215 1 
rno-miR-29a-5p 0.00E+00 1 
rno-miR-664-3p 0.7833 1 
rno-miR-101b-3p 1.03 1 
rno-miR-191a-5p 0.8309 1 
rno-miR-203a-3p 1.06 1 
rno-miR-28-3p 1.14 1 
rno-miR-203b-3p 0.5774 1 
rno-miR-192-3p 0.4086 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-215 1.94 1 
rno-miR-27a-3p 0.8508 1 
rno-miR-345-3p 0.00E+00 1 
rno-miR-9a-5p 0.00E+00 1 
rno-miR-27b-3p 1.03 1 
rno-miR-30d-5p 1.06 1 
rno-miR-152-3p 0.946 1 
rno-miR-142-5p 0.7994 1 
miRNA ID FC P Adj 
rno-miR-181d-5p 0.1749 1 
rno-miR-421-3p 0.00E+00 1 
rno-miR-490-3p 0.00E+00 1 
rno-let-7c-5p 1.11 1 
rno-miR-31a-3p 0.00E+00 1 
rno-miR-146a-5p 0.8848 1 
rno-let-7e-3p 0.00E+00 1 
rno-miR-194-5p 0.9165 1 
rno-miR-22-5p 0.6887 1 
rno-miR-497-5p 0.9409 1 
rno-miR-434-3p 0.4767 1 
rno-miR-542-3p 0.6981 1 
rno-miR-335 0.7808 1 
rno-miR-223-3p 0.4995 1 
rno-miR-28-5p 0.9914 1 
rno-miR-6329 1.3 1 
rno-miR-139-5p 0.567 1 
rno-miR-138-5p 0.6523 1 
rno-let-7f-1-3p 0.00E+00 1 
rno-miR-29a-3p 0.8194 1 
rno-miR-322-3p 0.9247 1 
rno-miR-152-5p 0.8071 1 
rno-miR-142-3p 1.04 1 
rno-miR-192-5p 0.9327 1 
rno-miR-320-3p 1.1 1 
rno-miR-126a-5p 0.8685 1 
rno-miR-20a-5p 1.19 1 
rno-let-7a-1-3p... 0.8939 1 
rno-mir-126* 0.00E+00 1 
rno-miR-423-5p 0.9447 1 
rno-mir-21* 0.00E+00 1 
rno-miR-425-5p 0.8957 1 
rno-miR-30e-5p 0.9831 1 
rno-miR-10a-5p 0.9442 1 
rno-miR-301a-3p 0.999 1 
rno-miR-22-3p 0.9479 1 
rno-miR-98-5p 1.09 1 
rno-miR-143-3p 1.02 1 
rno-miR-195-3p 0.3896 1 
rno-miR-122-3p 0.9734 1 
rno-miR-30b-5p 0.8935 1 
rno-miR-145-3p 0.3327 1 
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miRNA ID FC P Adj 
rno-mir-322* 0.00E+00 1 
rno-miR-340-3p 0.3097 1 
rno-miR-450a-5p 0.9245 1 
rno-miR-363-3p 0.00E+00 1 
rno-miR-339-3p 1.11 1 
rno-miR-1843-5p 1.07 1 
rno-miR-126a-3p 1.01 1 
rno-miR-3577 0.7422 1 
rno-miR-17-5p 0.8222 1 
rno-miR-128-3p 1.13 1 
rno-miR-505-3p 0.6074 1 
rno-miR-181a-2-... 0.8174 1 
rno-miR-181a-5p 1.05 1 
rno-miR-199a-3p 0.9132 1 
rno-miR-30e-3p 0.8908 1 
rno-let-7b-5p 1.03 1 
rno-miR-872-5p 0.9771 1 
rno-miR-130a-3p 1.1 1 
rno-miR-150-5p 0.7406 1 
rno-miR-195-5p 0.9495 1 
rno-miR-101a-3p 1.2 1 
rno-miR-98-3p 0.6343 1 
rno-miR-664-2-5... 0.5778 1 
rno-miR-145-5p 0.9444 1 
rno-miR-466c-5p 0.00E+00 1 
rno-miR-21-5p 0.9123 1 
rno-miR-191a-3p 0.00E+00 1 
rno-miR-140-3p 1.07 1 
rno-miR-30b-3p 0.6484 1 
rno-miR-340-5p 1.05 1 
rno-miR-141-3p 0.5181 1 
rno-miR-1843-3p 0.5176 1 
rno-miR-330-5p 1.46 1 
rno-miR-27b-5p 1.29 1 
rno-miR-24-3p 0.5572 1 
rno-miR-30d-3p 0.9585 1 
rno-miR-30c-5p 0.9251 1 
rno-miR-451-5p 1.25 1 
rno-let-7d-3p 1.37 1 
rno-miR-1839-5p 1.39 1 
rno-miR-92a-3p 0.8817 1 
rno-miR-16-5p 0.865 1 
rno-miR-101a-5p Inf 1 
rno-let-7b-3p 1.07 1 
rno-mir-350* 0.00E+00 1 
miRNA ID FC P Adj 
rno-miR-188-5p 0.8212 1 
rno-miR-1249 2.06 1 
rno-miR-326-3p 0.00E+00 1 
rno-miR-455-3p 3.19 1 
rno-miR-582-3p 0.00E+00 1 
rno-miR-140-5p 0.8391 1 
rno-miR-378a-3p 1.09 1 
rno-miR-186-5p 0.9395 1 
rno-miR-200a-5p Inf 1 
rno-miR-221-3p 1.46 1 
rno-miR-466b-2-... 0.6721 1 
rno-miR-293-5p 0.00E+00 1 
rno-miR-23a-3p 0.9377 1 
rno-miR-3559-5p 1.02 1 
rno-miR-181b-5p 1.03 1 
rno-miR-106b-3p 0.00E+00 1 
rno-miR-21-3p 0.9283 1 
rno-miR-374-5p 0.6076 1 
rno-miR-328a-3p 1.07 1 
rno-miR-30a-5p 0.9876 1 
rno-let-7i-5p 1.06 1 
rno-miR-23b-3p 1.17 1 
rno-miR-143-5p 0.00E+00 1 
rno-miR-361-5p 0.4524 1 
rno-miR-19a-3p 0.28 1 
rno-miR-204-5p 1.04 1 
rno-miR-144-5p 0.7621 1 
rno-miR-455-5p 0.4239 1 
rno-miR-181c-3p 0.00E+00 1 
rno-miR-99a-3p 0.8795 1 
rno-let-7a-5p 1.11 1 
rno-miR-25-3p 1.06 1 
rno-miR-378a-5p 0.983 1 
rno-miR-499-5p 0.00E+00 1 
rno-let-7d-5p 1.14 1 
rno-miR-3585-5p 0.00E+00 1 
rno-miR-339-5p 0.8092 1 
rno-miR-10a-3p 0.00E+00 1 
rno-miR-181c-5p 0.7702 1 
rno-miR-222-3p 1.08 1 
rno-miR-125b-2-... 0.6582 1 
rno-miR-29b-3p 0.6525 1 
rno-miR-3559-3p 0.8595 1 
rno-miR-652-3p 3.22 1 
rno-miR-106b-5p 0.9906 1 
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miRNA ID FC P Adj 
rno-miR-107-3p 0.8466 1 
rno-miR-30a-3p 0.8426 1 
rno-miR-6215 0.9073 1 
rno-miR-374-3p 0.00E+00 1 
rno-miR-423-3p 0.9486 1 
rno-miR-93-5p 0.9742 1 
rno-miR-144-3p 1.1 1 
rno-miR-361-3p 1.35 1 
rno-miR-210-3p 0.9941 1 
rno-miR-127-3p 0.7658 1 
rno-miR-151-5p 0.9666 1 
rno-miR-193-3p 0.9828 1 
rno-miR-194-3p 0.639 1 
rno-miR-365-3p 1.01 1 
rno-miR-214-3p 0.7347 1 
rno-miR-99a-5p 0.8387 1 
rno-miR-181a-1-... 1.34 1 
rno-miR-322-5p 0.947 1 
rno-miR-24-2-5p 0.7953 1 
rno-miR-26b-3p 0.5111 1 
rno-miR-30c-2-3... 1.25 1 
rno-let-7f-2-3p 1.12 1 
rno-miR-148b-5p 1.09 1 
rno-miR-26a-3p 1.52 1 
rno-miR-26b-5p 0.9575 1 
   
miRNA ID FC P Adj 
rno-miR-532-3p 0.00E+00 1 
rno-let-7f-5p 1.22 1 
rno-miR-351-5p 1.06 1 
rno-miR-34c-5p 0.7766 1 
rno-miR-484 0.00E+00 1 
rno-miR-151-3p 1.03 1 
rno-miR-15b-5p 0.7843 1 
rno-miR-33-3p 1.28 1 
rno-miR-32-5p 0.00E+00 1 
rno-miR-29c-3p 0.8125 1 
rno-miR-342-3p 0.00E+00 1 
rno-miR-100-5p 0.629 1 
rno-let-7e-5p 1.14 1 
rno-miR-125b-5p 0.7915 1 
rno-miR-331-3p 0.00E+00 1 
rno-miR-92a-1-5... 0.5959 1 
rno-miR-345-5p 0.00E+00 1 
rno-miR-146b-5p 1.32 1 
rno-miR-19b-3p 0.7935 1 
rno-miR-30c-1-3... 0.7518 1 
rno-miR-26a-5p 0.8721 1 
rno-miR-148b-3p 1.19 1 
rno-miR-375-3p 0.7133 1 
rno-miR-532-5p 0.9358 1 
rno-miR-671 1.07 1 
rno-miR-511-3p 1.63 1 
SYN 50 ppm______________________________________________________ 
miRNA ID FC  P Adj 
rno-miR-31a-5p 0.9495 1 
rno-miR-34a-5p 1.03 1 
rno-miR-29c-5p 0.674 1 
rno-miR-190a-5p 0.5442 1 
rno-miR-103-3p 0.9871 1 
rno-miR-199a-5p 0.6698 1 
rno-miR-3068-3p 0.8884 1 
rno-miR-21* 0.00E+00 1 
rno-miR-872-3p 0.8565 1 
rno-miR-29a-5p 0.00E+00 1 
rno-miR-664-3p 1.24 1 
rno-miR-101b-3p 1.03 1 
rno-miR-191a-5p 1.07 1 
rno-miR-203a-3p 1.05 1 
miRNA ID FC  P Adj 
rno-miR-28-3p 1.02 1 
rno-miR-203b-3p 1.03 1 
rno-miR-192-3p 0.8488 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-215 1.38 1 
rno-miR-27a-3p 0.9401 1 
rno-miR-345-3p 1.69 1 
rno-miR-9a-5p 0.00E+00 1 
rno-miR-27b-3p 1.11 1 
rno-miR-30d-5p 1.09 1 
rno-miR-152-3p 1.24 1 
rno-miR-142-5p 0.9971 1 
rno-miR-181d-5p 0.7878 1 
rno-miR-421-3p 1.03 1 
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miRNA ID FC  P Adj 
rno-miR-490-3p 0.00E+00 1 
rno-let-7c-5p 1.1 1 
rno-miR-31a-3p 0.00E+00 1 
rno-miR-146a-5p 0.8657 1 
rno-miR-92b-3p 0.00E+00 1 
rno-let-7e-3p 0.00E+00 1 
rno-miR-194-5p 1.08 1 
rno-miR-22-5p 1.08 1 
rno-miR-497-5p 0.8681 1 
rno-miR-434-3p 1.53 1 
rno-miR-542-3p 0.26 1 
rno-miR-335 0.6609 1 
rno-miR-223-3p 1.38 1 
rno-miR-28-5p 0.9574 1 
rno-miR-6329 0.6637 1 
rno-miR-139-5p 0.7039 1 
rno-miR-138-5p 0.9781 1 
rno-let-7f-1-3p 1.17 1 
rno-miR-29a-3p 0.9431 1 
rno-miR-322-3p 1.04 1 
rno-miR-152-5p 0.2631 1 
rno-miR-142-3p 0.779 1 
rno-miR-192-5p 1.03 1 
rno-miR-320-3p 0.6353 1 
rno-miR-126a-5p 1.03 1 
rno-miR-219-5p Inf 1 
rno-miR-20a-5p 0.9901 1 
rno-let-7a-1-3p... 0.7648 1 
rno-mir-126* 0.00E+00 1 
rno-miR-423-5p 1.06 1 
rno-mir-21* 0.00E+00 1 
rno-miR-425-5p 0.9845 1 
rno-miR-30e-5p 1 1 
rno-miR-10a-5p 1.03 1 
rno-miR-301a-3p 0.7775 1 
rno-miR-22-3p 1.01 1 
rno-miR-98-5p 0.9633 1 
rno-miR-143-3p 0.9831 1 
rno-miR-195-3p 1.05 1 
rno-miR-122-3p 1.08 1 
rno-miR-30b-5p 0.9737 1 
rno-miR-145-3p 0.655 1 
rno-mir-322* 0.00E+00 1 
rno-miR-340-3p 0.8161 1 
rno-miR-450a-5p 0.8725 1 
miRNA ID FC  P Adj 
rno-miR-363-3p 0.00E+00 1 
rno-miR-339-3p 1.15 1 
rno-miR-1843-5p 0.7263 1 
rno-miR-126a-3p 0.9948 1 
rno-miR-3577 0.6167 1 
rno-miR-17-5p 0.8126 1 
rno-miR-128-3p 1.67 1 
rno-miR-802-5p 1.1 1 
rno-miR-505-3p 0.3453 1 
rno-miR-181a-2-... 0.9717 1 
rno-miR-181a-5p 0.9554 1 
rno-miR-199a-3p 0.7906 1 
rno-miR-30e-3p 1.08 1 
rno-let-7b-5p 1.11 1 
rno-miR-872-5p 0.9737 1 
rno-miR-130a-3p 0.9476 1 
rno-miR-150-5p 0.7088 1 
rno-miR-195-5p 0.9645 1 
rno-miR-101a-3p 1.02 1 
rno-miR-98-3p 0.8246 1 
rno-miR-664-2-5... 0.761 1 
rno-miR-145-5p 0.8267 1 
rno-miR-122-5p 1.06 1 
rno-miR-466c-5p 0.2766 1 
rno-miR-21-5p 0.9989 1 
rno-miR-191a-3p 0.5618 1 
rno-miR-140-3p 1 1 
rno-miR-30b-3p 0.4439 1 
rno-miR-340-5p 1 1 
rno-miR-141-3p 0.5527 1 
rno-miR-338-3p 0.8104 1 
rno-miR-1843-3p 0.3957 1 
rno-miR-330-5p 0.00E+00 1 
rno-miR-27b-5p 1.26 1 
rno-miR-24-3p 0.885 1 
rno-miR-30d-3p 0.8209 1 
rno-miR-30c-5p 1 1 
rno-miR-182 1.06 1 
rno-miR-451-5p 1.31 1 
rno-let-7d-3p 1.16 1 
rno-miR-1839-5p 0.8533 1 
rno-miR-92a-3p 1.08 1 
rno-miR-16-5p 1.01 1 
rno-miR-101a-5p Inf 1 
rno-let-7b-3p 1.03 1 
 Appendix –4 
  [ 220 ] 
miRNA ID FC  P Adj 
rno-miR-96-5p 0.8622 1 
rno-mir-350* 0.5933 1 
rno-miR-188-5p 0.3499 1 
rno-miR-1249 1.04 1 
rno-miR-326-3p 0.00E+00 1 
rno-miR-455-3p 2.29 1 
rno-miR-582-3p 0.5453 1 
rno-miR-140-5p 1.24 1 
rno-miR-378a-3p 1.11 1 
rno-miR-186-5p 0.9602 1 
rno-miR-200b-3p 1.09 1 
rno-miR-221-3p 1.23 1 
rno-miR-466b-2-... 0.6065 1 
rno-miR-293-5p 0.00E+00 1 
rno-miR-23a-3p 0.7648 1 
rno-miR-3559-5p 1.04 1 
rno-miR-181b-5p 0.8258 1 
rno-miR-802-3p 1.18 1 
rno-miR-106b-3p 0.4276 1 
rno-miR-21-3p 1.26 1 
rno-miR-674-3p 0.7162 1 
rno-miR-378b Inf 1 
rno-miR-374-5p 1.06 1 
rno-miR-328a-3p 0.9377 1 
rno-miR-30a-5p 0.9718 1 
rno-let-7i-5p 1.01 1 
rno-miR-23b-3p 1.11 1 
rno-miR-143-5p 0.9364 1 
rno-miR-361-5p 0.8097 1 
rno-miR-19a-3p 0.7656 1 
rno-miR-204-5p 0.7659 1 
rno-miR-3473 0.00E+00 1 
rno-miR-144-5p 0.898 1 
rno-miR-455-5p 0.6932 1 
rno-miR-181c-3p 0.00E+00 1 
rno-miR-200a-3p 1.36 1 
rno-miR-99a-3p 0.8128 1 
rno-let-7a-5p 1.06 1 
rno-miR-25-3p 0.9774 1 
rno-miR-378a-5p 0.7121 1 
rno-miR-499-5p 0.5886 1 
rno-let-7d-5p 1.05 1 
rno-miR-3585-5p 0.00E+00 1 
rno-miR-339-5p 0.9062 1 
rno-miR-10a-3p 0.486 1 
miRNA ID FC  P Adj 
rno-miR-181c-5p 0.7331 1 
rno-miR-222-3p 0.9734 1 
rno-miR-125b-2-... 0.7036 1 
rno-miR-29b-3p 0.9594 1 
rno-miR-3559-3p 0.00E+00 1 
rno-miR-652-3p 1.48 1 
rno-miR-106b-5p 0.7521 1 
rno-miR-107-3p 1.03 1 
rno-miR-30a-3p 0.9055 1 
rno-miR-429 0.8378 1 
rno-miR-6215 0.3793 1 
rno-miR-374-3p 1.84 1 
rno-miR-423-3p 1.01 1 
rno-miR-93-5p 0.8181 1 
rno-miR-144-3p 1.07 1 
rno-miR-33-5p 0.7883 1 
rno-miR-361-3p 0.5628 1 
rno-miR-210-3p 1.17 1 
rno-miR-127-3p 1.23 1 
rno-miR-151-5p 1.15 1 
rno-miR-193-3p 0.9147 1 
rno-miR-194-3p 0.7873 1 
rno-miR-365-3p 0.8551 1 
rno-miR-214-3p 0.00E+00 1 
rno-miR-99a-5p 1.15 1 
rno-miR-181a-1-... 0.8501 1 
rno-miR-322-5p 0.9424 1 
rno-miR-24-2-5p 0.973 1 
rno-miR-26b-3p 0.6786 1 
rno-miR-30c-2-3... 1.1 1 
rno-let-7f-2-3p 0.5795 1 
rno-miR-148b-5p 0.7117 1 
rno-miR-26a-3p 1.03 1 
rno-miR-26b-5p 1.05 1 
rno-miR-532-3p 0.00E+00 1 
rno-let-7f-5p 1.09 1 
rno-miR-351-5p 0.979 1 
rno-miR-34c-5p 0.9999 1 
rno-miR-484 2.06 1 
rno-miR-151-3p 0.9447 1 
rno-miR-15b-5p 0.8695 1 
rno-miR-33-3p 1.69 1 
rno-miR-32-5p 2.93 1 
rno-miR-29c-3p 0.7976 1 
rno-miR-342-3p 1.61 1 
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miRNA ID FC  P Adj 
rno-miR-100-5p 0.7132 1 
rno-let-7e-5p 1.05 1 
rno-miR-125b-5p 1.1 1 
rno-miR-331-3p 0.00E+00 1 
rno-miR-92a-1-5... 0.7901 1 
rno-miR-345-5p 0.00E+00 1 
rno-miR-146b-5p 1.18 1 
rno-miR-19b-3p 0.9525 1 
rno-miR-30c-1-3... 0.4466 1 
miRNA ID FC  P Adj 
rno-miR-26a-5p 1.02 1 
rno-miR-99b-5p 1.21 1 
rno-miR-148b-3p 1.1 1 
rno-miR-183-5p 0.9238 1 
rno-miR-375-3p 0.8841 1 
rno-miR-125a-5p 1 1 
rno-miR-532-5p 1.01 1 
rno-miR-671 0.7513 1 
rno-miR-511-3p 0.943 1 
SYN 500 ppm_____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-6215 2.24 0.0006 
rno-miR-3068-3p 2.45 0.3169 
rno-miR-31a-5p 0.9678 1 
rno-miR-34a-5p 0.6215 1 
rno-miR-29c-5p 0.6745 1 
rno-miR-190a-5p 0.00E+00 1 
rno-miR-103-3p 1.03 1 
rno-miR-199a-5p 0.3664 1 
rno-miR-21* 0.00E+00 1 
rno-miR-872-3p 0.9187 1 
rno-miR-29a-5p 0.00E+00 1 
rno-miR-664-3p 1.73 1 
rno-miR-101b-3p 1.03 1 
rno-miR-191a-5p 0.9708 1 
rno-miR-203a-3p 1.09 1 
rno-miR-28-3p 1.04 1 
rno-miR-203b-3p 0.5281 1 
rno-miR-192-3p 0.6116 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-215 3.31 1 
rno-miR-27a-3p 1.09 1 
rno-miR-345-3p 0.7281 1 
rno-miR-9a-5p 0.00E+00 1 
rno-miR-27b-3p 1.05 1 
rno-miR-30d-5p 1.11 1 
rno-miR-152-3p 1.01 1 
rno-miR-142-5p 0.9351 1 
rno-miR-181d-5p 0.5303 1 
rno-miR-421-3p 0.3702 1 
rno-miR-490-3p 0.00E+00 1 
rno-miR-210-5p Inf 1 
miRNA ID FC P Adj 
rno-let-7c-5p 1.18 1 
rno-miR-31a-3p 0.00E+00 1 
rno-miR-146a-5p 0.9913 1 
rno-miR-92b-3p 2.05 1 
rno-let-7e-3p 0.00E+00 1 
rno-miR-194-5p 1.02 1 
rno-miR-22-5p 1.23 1 
rno-miR-497-5p 0.9234 1 
rno-miR-434-3p 1.45 1 
rno-miR-542-3p 0.5468 1 
rno-miR-335 0.8627 1 
rno-miR-223-3p 1.25 1 
rno-miR-28-5p 1 1 
rno-miR-6329 0.3926 1 
rno-miR-139-5p 0.2507 1 
rno-miR-138-5p 0.00E+00 1 
rno-let-7f-1-3p 0.5158 1 
rno-miR-29a-3p 0.9131 1 
rno-miR-322-3p 0.9807 1 
rno-miR-152-5p 0.1744 1 
rno-miR-142-3p 0.8997 1 
rno-miR-192-5p 0.9224 1 
rno-miR-320-3p 0.9667 1 
rno-miR-126a-5p 0.9328 1 
rno-miR-20a-5p 0.946 1 
rno-let-7a-1-3p... 0.901 1 
rno-mir-126* 0.00E+00 1 
rno-miR-423-5p 0.9965 1 
rno-mir-21* 0.00E+00 1 
rno-miR-425-5p 0.9396 1 
rno-miR-30e-5p 0.9539 1 
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miRNA ID FC P Adj 
rno-miR-10a-5p 0.8921 1 
rno-miR-301a-3p 0.9045 1 
rno-miR-22-3p 0.9791 1 
rno-miR-98-5p 0.9947 1 
rno-miR-143-3p 1.04 1 
rno-miR-195-3p 1.28 1 
rno-miR-122-3p 1.16 1 
rno-miR-30b-5p 1.02 1 
rno-miR-145-3p 0.4783 1 
rno-mir-322* 0.00E+00 1 
rno-miR-340-3p 1.03 1 
rno-miR-450a-5p 0.887 1 
rno-miR-363-3p 0.00E+00 1 
rno-miR-339-3p 0.8966 1 
rno-miR-1843-5p 0.9528 1 
rno-miR-126a-3p 1.02 1 
rno-miR-3577 0.5385 1 
rno-miR-17-5p 0.8408 1 
rno-miR-128-3p 1.38 1 
rno-miR-802-5p 1.29 1 
rno-miR-505-3p 0.6908 1 
rno-miR-181a-2-... 0.7489 1 
rno-miR-181a-5p 0.9509 1 
rno-miR-199a-3p 1.02 1 
rno-miR-30e-3p 0.9464 1 
rno-let-7b-5p 1.08 1 
rno-miR-872-5p 0.8752 1 
rno-miR-130a-3p 1.09 1 
rno-miR-150-5p 0.7912 1 
rno-miR-195-5p 1.01 1 
rno-miR-101a-3p 1.07 1 
rno-miR-98-3p 0.00E+00 1 
rno-miR-664-2-5... 0.4002 1 
rno-miR-145-5p 1.01 1 
rno-miR-122-5p 0.9353 1 
rno-miR-466c-5p 0.00E+00 1 
rno-miR-21-5p 1.03 1 
rno-miR-191a-3p 0.00E+00 1 
rno-miR-140-3p 0.9891 1 
rno-miR-30b-3p 0.3829 1 
rno-miR-340-5p 0.9717 1 
rno-miR-141-3p 0.8664 1 
rno-miR-338-3p 0.2857 1 
rno-miR-1843-3p 0.932 1 
rno-miR-330-5p 0.00E+00 1 
miRNA ID FC P Adj 
rno-miR-27b-5p 1.07 1 
rno-miR-24-3p 0.8792 1 
rno-miR-30d-3p 0.7871 1 
rno-miR-30c-5p 0.9926 1 
rno-miR-182 1.06 1 
rno-miR-451-5p 0.7626 1 
rno-let-7d-3p 1.41 1 
rno-miR-1839-5p 0.8412 1 
rno-miR-92a-3p 0.9107 1 
rno-miR-16-5p 0.9488 1 
rno-let-7b-3p 0.7938 1 
rno-miR-96-5p 0.00E+00 1 
rno-mir-350* 0.00E+00 1 
rno-miR-188-5p 0.3894 1 
rno-miR-1249 1.45 1 
rno-miR-326-3p 0.00E+00 1 
rno-miR-455-3p 2.61 1 
rno-miR-582-3p 0.00E+00 1 
rno-miR-140-5p 0.4759 1 
rno-miR-378a-3p 1.07 1 
rno-miR-186-5p 0.9351 1 
rno-miR-200b-3p 1.49 1 
rno-miR-221-3p 2.07 1 
rno-miR-466b-2-... 0.7706 1 
rno-miR-293-5p 0.00E+00 1 
rno-miR-23a-3p 0.9833 1 
rno-miR-3559-5p 0.8573 1 
rno-miR-181b-5p 0.9248 1 
rno-miR-802-3p 1.36 1 
rno-miR-106b-3p 0.7385 1 
rno-miR-21-3p 1.28 1 
rno-miR-674-3p 1 1 
rno-miR-374-5p 0.7512 1 
rno-miR-328a-3p 1.19 1 
rno-miR-30a-5p 0.9287 1 
rno-let-7i-5p 1.02 1 
rno-miR-23b-3p 1.14 1 
rno-miR-143-5p 0.00E+00 1 
rno-miR-361-5p 0.5305 1 
rno-miR-19a-3p 0.514 1 
rno-miR-204-5p 0.9915 1 
rno-miR-3473 5.17 1 
rno-miR-144-5p 0.6187 1 
rno-miR-455-5p 0.8526 1 
rno-miR-181c-3p 0.00E+00 1 
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miRNA ID FC P Adj 
rno-miR-200a-3p 0.751 1 
rno-miR-99a-3p 0.8745 1 
rno-let-7a-5p 1.13 1 
rno-miR-25-3p 1.04 1 
rno-miR-378a-5p 0.8099 1 
rno-miR-499-5p 0.00E+00 1 
rno-let-7d-5p 1.19 1 
rno-miR-3585-5p 0.00E+00 1 
rno-miR-339-5p 0.7417 1 
rno-miR-10a-3p 0.4289 1 
rno-miR-181c-5p 0.8693 1 
rno-miR-222-3p 1.12 1 
rno-miR-125b-2-... 0.7578 1 
rno-miR-29b-3p 0.6454 1 
rno-miR-3559-3p 0.6265 1 
rno-miR-652-3p 1.43 1 
rno-miR-106b-5p 0.8248 1 
rno-miR-107-3p 1.05 1 
rno-miR-30a-3p 0.9393 1 
rno-miR-429 1.51 1 
rno-miR-374-3p 0.6624 1 
rno-miR-423-3p 1.03 1 
rno-miR-93-5p 0.9226 1 
rno-miR-144-3p 0.8621 1 
rno-miR-33-5p 0.5289 1 
rno-miR-361-3p 0.9677 1 
rno-miR-210-3p 0.7493 1 
rno-miR-127-3p 1.48 1 
rno-miR-151-5p 1.02 1 
rno-miR-193-3p 0.9251 1 
rno-miR-194-3p 0.624 1 
rno-miR-365-3p 0.9229 1 
rno-miR-214-3p 0.8034 1 
rno-miR-99a-5p 0.8584 1 
rno-miR-181a-1-... 0.5615 1 
rno-miR-322-5p 1.06 1 
miRNA ID FC P Adj 
rno-miR-24-2-5p 0.9341 1 
rno-miR-26b-3p 0.5588 1 
rno-miR-30c-2-3... 1.02 1 
rno-let-7f-2-3p 0.8217 1 
rno-miR-148b-5p 0.4627 1 
rno-miR-26a-3p 0.4446 1 
rno-miR-26b-5p 1.04 1 
rno-miR-532-3p 0.00E+00 1 
rno-let-7f-5p 1.26 1 
rno-miR-351-5p 0.8842 1 
rno-miR-34c-5p 0.6808 1 
rno-miR-484 2.43 1 
rno-miR-151-3p 1 1 
rno-miR-15b-5p 0.8763 1 
rno-miR-33-3p 0.7757 1 
rno-miR-32-5p 0.9901 1 
rno-miR-29c-3p 0.8382 1 
rno-miR-342-3p 0.5264 1 
rno-miR-100-5p 0.8522 1 
rno-let-7e-5p 1.33 1 
rno-miR-125b-5p 0.9216 1 
rno-miR-331-3p 0.00E+00 1 
rno-miR-92a-1-5... 0.6407 1 
rno-miR-345-5p 0.00E+00 1 
rno-miR-146b-5p 1.56 1 
rno-miR-19b-3p 0.7194 1 
rno-miR-30c-1-3... 0.5865 1 
rno-miR-26a-5p 0.9447 1 
rno-miR-99b-5p 0.8745 1 
rno-miR-148b-3p 1.08 1 
rno-miR-183-5p 0.4183 1 
rno-miR-375-3p 0.7309 1 
rno-miR-125a-5p 0.8897 1 
rno-miR-532-5p 1.04 1 
rno-miR-671 0.865 1 
rno-miR-511-3p 0.7336 1 
SYN 3000 ppm____________________________________________________ 
miRNA ID FC P Adj 
rno-miR-182 3.26 1.12E-21 
rno-miR-200b-3p 3.53 3.95E-16 
rno-miR-6215 3.31 3.69E-11 
rno-miR-375-3p 0.3404 4.83E-10 
miRNA ID FC P Adj 
rno-miR-92a-3p 0.6636 0.0002 
rno-miR-200a-3p 4.18 0.0059 
rno-miR-192-5p 0.7904 0.013 
rno-miR-429 2.42 0.0479 
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miRNA ID FC P Adj 
rno-miR-183-5p 5.02 0.0479 
rno-miR-125b-5p 0.59 0.1095 
rno-miR-3068-3p 1.91 0.1095 
rno-miR-802-5p 1.45 0.1095 
rno-miR-122-5p 0.8331 0.1302 
rno-miR-200a-5p Inf 0.1743 
rno-miR-331-3p 1.29 0.3501 
rno-miR-455-3p 5.57 0.3501 
rno-miR-99b-5p 0.6443 0.4221 
rno-miR-150-5p 0.799 0.4465 
rno-miR-125b-2-... 0.5993 0.4839 
rno-miR-802-3p 1.44 0.4862 
rno-miR-92b-3p 1.19 0.5331 
rno-miR-3473 1.02 0.5437 
rno-miR-99a-5p 0.6416 0.5437 
rno-miR-96-5p 4.3 0.5815 
rno-miR-484 3.08 0.5815 
rno-miR-125a-5p 0.7866 0.6289 
rno-miR-21-3p 1.64 0.6333 
rno-miR-19b-3p 0.5647 0.6803 
rno-miR-10a-5p 0.8831 0.695 
rno-miR-215 1.93 0.695 
rno-miR-195-5p 0.7072 0.7333 
rno-miR-497-5p 0.7504 0.7364 
rno-miR-100-5p 0.3147 0.9303 
rno-miR-30a-3p 0.9443 1 
rno-miR-128-3p 1.24 1 
rno-miR-30d-5p 1.11 1 
rno-miR-30a-5p 0.9537 1 
rno-miR-142-5p 0.7627 1 
rno-miR-191a-3p 0.9728 1 
rno-miR-19a-3p 0.112 1 
rno-let-7f-5p 1.14 1 
rno-miR-203b-3p 0.4531 1 
rno-miR-26a-5p 0.8685 1 
rno-miR-335 1.18 1 
rno-miR-92a-1-5... 0.4585 1 
rno-miR-146a-5p 0.9103 1 
rno-miR-143-5p 0.5704 1 
rno-miR-29c-3p 1.09 1 
rno-miR-664-3p 2.05 1 
rno-miR-30b-5p 1.05 1 
rno-miR-29a-3p 1.05 1 
rno-miR-21-5p 1.18 1 
rno-miR-33-3p 1.7 1 
miRNA ID FC P Adj 
rno-miR-145-3p 0.4219 1 
rno-miR-31a-5p 0.8173 1 
rno-miR-181a-5p 0.9737 1 
rno-miR-203a-3p 0.728 1 
rno-miR-195-3p 0.5866 1 
rno-let-7d-5p 1.14 1 
rno-miR-22-5p 1.45 1 
rno-miR-101b-3p 0.9493 1 
rno-miR-21* 1.72 1 
rno-mir-21* 1.72 1 
rno-miR-130a-3p 1.11 1 
rno-miR-127-3p 0.237 1 
rno-miR-29c-5p 0.5523 1 
rno-miR-30e-3p 0.9848 1 
rno-miR-29a-5p 0.3936 1 
rno-miR-181c-5p 0.8494 1 
rno-miR-423-5p 0.8979 1 
rno-miR-374-5p 0.2314 1 
rno-miR-152-3p 1.19 1 
rno-miR-148b-3p 1.15 1 
rno-let-7c-5p 1.01 1 
rno-miR-143-3p 0.9784 1 
rno-miR-181b-5p 0.913 1 
rno-miR-30c-5p 1.03 1 
rno-let-7d-3p 1.15 1 
rno-miR-374-3p 0.7999 1 
rno-miR-455-5p 0.5768 1 
rno-let-7e-5p 0.9032 1 
rno-miR-499-5p 0.7805 1 
rno-miR-142-3p 0.623 1 
rno-miR-144-3p 1.19 1 
rno-miR-29b-3p 1.33 1 
rno-miR-351-5p 0.9017 1 
rno-miR-26b-3p 0.6386 1 
rno-miR-140-3p 1.14 1 
rno-miR-32-5p 0.7967 1 
rno-miR-345-3p 0.7786 1 
rno-miR-652-3p 0.9843 1 
rno-miR-146b-5p 1.13 1 
rno-miR-181d-5p 0.4461 1 
rno-miR-1843-3p 0.9454 1 
rno-miR-1839-5p 1.4 1 
rno-miR-26a-3p 0.4145 1 
rno-miR-26b-5p 0.9737 1 
rno-miR-664-2-5... 0.9768 1 
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miRNA ID FC P Adj 
rno-miR-190a-5p 0.669 1 
rno-miR-23b-3p 1.15 1 
rno-miR-24-3p 0.9905 1 
rno-miR-20a-5p 0.5315 1 
rno-miR-223-3p 0.4453 1 
rno-miR-425-5p 1.08 1 
rno-let-7a-5p 1 1 
rno-miR-27b-5p 1.48 1 
rno-miR-421-3p 0.6101 1 
rno-miR-466b-2-... 0.3544 1 
rno-miR-200c-3p Inf 1 
rno-miR-210-3p 0.8723 1 
rno-miR-122-3p 0.8727 1 
rno-miR-361-5p 0.8635 1 
rno-miR-98-3p 0.3409 1 
rno-miR-320-3p 0.8451 1 
rno-miR-3585-5p 1.2 1 
rno-miR-28-3p 1.04 1 
rno-miR-1843-5p 1.09 1 
rno-miR-103-3p 1.17 1 
rno-miR-191a-5p 0.983 1 
rno-miR-23a-3p 0.9035 1 
rno-miR-365-3p 0.6441 1 
rno-miR-22-3p 1.01 1 
rno-miR-194-3p 0.5018 1 
rno-miR-872-3p 0.9391 1 
rno-miR-466c-5p 0.2898 1 
rno-miR-423-3p 0.9557 1 
rno-miR-340-3p 0.3199 1 
rno-miR-93-5p 1.04 1 
rno-miR-322-3p 1.02 1 
rno-miR-15b-5p 0.8588 1 
rno-miR-99a-3p 0.8141 1 
rno-miR-322-5p 0.9971 1 
rno-miR-126a-3p 0.9674 1 
rno-let-7b-5p 1.02 1 
rno-miR-30c-2-3... 1.05 1 
rno-miR-339-3p 1.09 1 
rno-miR-222-3p 0.9899 1 
rno-miR-33-5p 0.5044 1 
rno-miR-671 1.08 1 
rno-miR-140-5p 0.9515 1 
rno-miR-199a-3p 0.9184 1 
rno-miR-340-5p 1.12 1 
rno-miR-27a-3p 0.895 1 
miRNA ID FC P Adj 
rno-miR-138-5p 0.2362 1 
rno-miR-328a-3p 0.8735 1 
rno-miR-204-5p 0.772 1 
rno-miR-674-3p 0.9113 1 
rno-miR-181a-1-... 0.7576 1 
rno-miR-24-2-5p 0.7285 1 
rno-miR-451-5p 1.01 1 
rno-miR-30c-1-3... 0.5606 1 
rno-miR-542-3p 0.9955 1 
rno-miR-199a-5p 0.5553 1 
rno-miR-434-3p 1.05 1 
rno-miR-30b-3p 0.5794 1 
rno-miR-151-5p 0.9343 1 
rno-miR-186-5p 1 1 
rno-miR-532-5p 0.9847 1 
rno-mir-350* 0.147 1 
rno-miR-101a-3p 1.07 1 
rno-miR-148b-5p 0.9519 1 
rno-miR-27b-3p 1.01 1 
rno-miR-3577 0.6889 1 
rno-miR-144-5p 0.8264 1 
rno-miR-16-5p 0.9471 1 
rno-miR-98-5p 1.05 1 
rno-miR-301a-3p 0.9617 1 
rno-let-7f-1-3p 0.7262 1 
rno-miR-139-5p 0.7351 1 
rno-miR-145-5p 1.16 1 
rno-miR-151-3p 1.07 1 
rno-miR-872-5p 0.9449 1 
rno-let-7f-2-3p 0.9571 1 
rno-miR-378a-3p 1.06 1 
rno-miR-1249 1.02 1 
rno-miR-361-3p 0.8011 1 
rno-miR-141-3p 0.686 1 
rno-miR-221-3p 1.16 1 
rno-miR-30d-3p 0.9896 1 
rno-miR-450a-5p 0.8463 1 
rno-miR-505-3p 0.6445 1 
rno-miR-126a-5p 0.9596 1 
rno-let-7a-1-3p... 0.7479 1 
rno-miR-17-5p 0.7446 1 
rno-miR-107-3p 1.04 1 
rno-miR-30e-5p 0.9563 1 
rno-miR-10a-3p 0.5458 1 
rno-miR-25-3p 1.06 1 
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miRNA ID FC P Adj 
rno-miR-339-5p 1.12 1 
rno-miR-28-5p 0.9224 1 
rno-miR-6329 0.8421 1 
rno-miR-34c-5p 0.832 1 
rno-miR-192-3p 0.8559 1 
rno-miR-106b-5p 0.746 1 
rno-miR-3559-5p 1.12 1 
rno-let-7b-3p 0.7833 1 
rno-miR-193-3p 0.9574 1 
rno-miR-152-5p 0.6426 1 
rno-miR-378a-5p 0.7237 1 
rno-miR-194-5p 0.8922 1 
rno-let-7i-5p 1.01 1 
rno-miR-511-3p 0.8612 1 
rno-miR-34a-5p 0.00E+00 1 
rno-miR-542-5p 0.00E+00 1 
rno-miR-9a-5p 0.00E+00 1 
rno-miR-490-3p 0.00E+00 1 
rno-miR-31a-3p 0.00E+00 1 
rno-let-7e-3p 0.00E+00 1 
rno-mir-126* 0.00E+00 1 
rno-mir-322* 0.00E+00 1 
rno-miR-363-3p 0.00E+00 1 
rno-miR-181a-2-... 0.5886 1 
rno-miR-338-3p 0.9439 1 
rno-miR-330-5p 0.00E+00 1 
rno-miR-188-5p 0.7686 1 
rno-miR-326-3p 0.00E+00 1 
rno-miR-582-3p 0.00E+00 1 
rno-miR-293-5p 0.00E+00 1 
rno-miR-106b-3p 0.6133 1 
rno-miR-181c-3p 0.00E+00 1 
rno-miR-3559-3p 0.00E+00 1 
rno-miR-214-3p 0.00E+00 1 
rno-miR-532-3p 0.00E+00 1 
rno-miR-342-3p 0.00E+00 1 
rno-miR-345-5p 0.00E+00 1 
  
Appendix-5. Putative novel miRNAs 
 
Table A5.1  Homologous miRNAs and putative homologous sequences. 
Name Homologous miRNA Homologous Sequence 
Candidate-28 rno-miR-6215 (MIMAT0024854) UUUAGGGUUGCAGAGCCAGG 
Candidate-10 
has-miR-4488 (MIMAT0019022) # 
ggo-miR-4488 (MIMAT0024152) 
AGGGGGCGGGCUCCGGCG # 
UAGGGGGCGGGCUCCGGCG 
Candidate-64 
has-miR-4488 (MIMAT0019022) # 
ggo-miR-4488 (MIMAT0024152) 
AGGGGGCGGGCUCCGGCG # 
UAGGGGGCGGGCUCCGGCG 
Candidate-40 
has-miR-4488 (MIMAT0019022) # 
ggo-miR-4488 (MIMAT0024152) 
AGGGGGCGGGCUCCGGCG # 
UAGGGGGCGGGCUCCGGCG 
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Table A5.2  Mature sequences and genomic location of non-significant (P Adj > 0.05) putative miRNA homologous to miR-4488 
Treatment Name Mature sequence Chr Start- End Strand P Adj 
SYN3000-D1 Candidate_21 CGTGGGTCGGGCGCCGGCGGCT chrUn 
23403911-
23404017 
+ 0.818 
PB50-D3 Candidate_60 CGTGGGTCGGGCGCCGGCGGCT chrUn 
23403914-
23404014 
+ 0.990 
SYN500-D3 Candidate_61 CGGGGGTCGGGCGCCGGCG chrUn 
438269-
438374 
+ 0.114 
SYN3000-D3 Candidate_55 CGTGGGTCGGGCGCCGGCGGCTTTGG chrUn 
23403911-
23404017 
+ 0.663 
PB50-D28 Candidate_35 CGTGGGTCGGGCGCCGGCGGCTTTGG chrUn 
23403914-
23404014 
+ 0.801 
PB1000-D28 Candidate_26 GGGTCGGGCGCCGGCGGCT chrUn 
438273-
438377 
+ 0.982 
SYN50-D28 Candidate_29 CGTGGGTCGGGCGCCGGCGGCTT chrUn 
23403914-
23404014 
+ 0.882 
SYN500-D28 Candidate_22 GGGTCGGGCGCCGGCGGCT chrUn 
438273-
438377 
+ 0.739 
SYN3000-D28 Candidate_24 GGGTCGGGCGCCGGCGGCT chrUn 
438270-
438377 
+ 0.537 
SYN3000-D28 Candidate_34 CGTGGGTCGGGCGCCGGCGGCTT chrUn 
23403914-
23404014 
+ 0.677 
NOTE:  chrUn refers to those sequences that cannot be related to a specific chromosome
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Table A5.3  Precursor sequences of non-significant (P Adj > 0.05)                                                     
putative miRNA homologous to miR-4488. 
Name Precursor Sequence 
Candidate_21 
GGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCC
GGCCGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGG 
Candidate_60 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTC 
Candidate_61 
GGGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCT
CCGGCCGGGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCG 
Candidate_55 
GGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCC
GGCCGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGG 
Candidate_35 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTC 
Candidate_26 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGGGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGGC 
Candidate_29 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTC 
Candidate_22 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGGGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGGC 
Candidate_24 
GGGGGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCC
GGCCGGGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTCGGGC 
Candidate_34 
GGGACGCGTGCATTTATCAGATCAAAACCAACCCGGTCAGCCCCCTCCCGGCTCCGGC
CGTGGGTCGGGCGCCGGCGGCTTTGGTGACTCTAGATAACCTC 
NOTE:  Mature putative miRNA sequences are marked in bold and underlined font. 
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